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PLUME ET SCALPEL
Current Management of 
Choledocholithiasis
Roger G. Keith, MD, FACS, FRCSC, FRCS
Chairman, Department o f  Surgery, Royal University Hospital, Saskatoon, Sask. Coeditor, 
Canadian Journal of Surgery
A bdominal surgeons have been the recognized experts in man­
agement of disease of the biliary 
tract, but technologic advances 
have now opened a welcome door 
for radiologists and gastroenterolo­
gists to participate in the manage­
ment of stone disease. Currently, 
interventional endoscopists see far 
more bile duct disease than a sur­
geon would have seen during a 
comparable period of the “operative 
era.” In Europe and especially in 
the United States, the interventional 
endoscopist is rarely a surgeon. 
Such is not the case in Canada. A 
substantial number of general sur­
geons in Canadian medical centres 
have expertise in endoscopic biliary 
intervention. The working relation­
ship between surgeons, gastroen­
terologists and interventional radi­
ologists has developed favourably in 
most teaching centres in this coun­
try.
During the decades before the 
advent of laparoscopic cholecystec­
tomy, exploration of the common 
bile duct was frequently performed 
in association with cholecystecto­
my. This was standard treatment 
for common bile duct stones. With 
the introduction of endoscopic ret­
rograde cholangiopancreatography 
(ERCP) in the early 1970s and the 
subsequent development of inter­
ventional techniques, preoperative 
endoscopic stone removal became
popular. Experienced surgical and 
medical endoscopists were able to 
remove the majority of common 
duct stones with ever-decreasing 
morbidity and mortality. Neverthe­
less, during the early 1980s, the 
majority of general surgeons still 
favoured open exploration of the 
common bile duct, and this became 
the accepted choice for patients 
with the gallbladder in situ and with 
documented common bile duct cal­
culi. In the mid-1980s, authorita­
tive “ERCPists”1'2 recommended 
clearance of the common bile duct 
by endoscopic sphincterotomy (ES) 
before cholecystectomy and limiting 
the open operation to cholecystec­
tomy with operative cholangiogra­
phy to confirm a stone-free biliary 
tract. In the hands of such experts, 
this protocol reduced overall mor­
bidity and mortality compared with 
those reported in surgical series.3-5 
Endoscopists noted that the com­
mon bile duct remained cleared of 
stones after ES, and occasionally 
stones cleared from the gallbladder 
as well. Inconsistency of gallbladder 
clearance, disturbance of function 
and stasis all preclude ES as total 
treatment for cholelithiasis and 
choledocholithiasis.6
Interventional endoscopy for the 
management of retained common 
bile duct stones after cholecystecto­
my had the same effect on reopera­
tive biliary surgery as H2 receptor
blockers have had on peptic ulcer 
surgery. Residents training in gen­
eral surgery have limited exposure 
to reoperative biliary procedures. 
Trainees will require increasing ex­
perience with endoscopic interven­
tional procedures.
In this issue (pages 75 to 80), 
Girard and Morin from the Univer­
sity de Montreal report a Canadian 
experience with open cholecystecto­
my, which will serve as a cited 
publication by virtue of case num­
bers and the excellence of outcome 
immediately predating the shift to 
laparoscopic cholecystectomy. Pur­
suant to management strategy for 
choledocholithiasis, Girard and 
Morin documented a death rate for 
open duct exploration of 1.6%. This 
is superior to the rate reported in 
most other large surgical series and 
is comparable to the 1% death rate 
recognized for ERCP with ES. Simi­
larly, the death rate of 0.3% for 
open cholecystectomy alone in Gi­
rard and Morin’s series will likely be 
comparable to that from laparo­
scopic cholecystectomy after accru­
al of data from single centres to 
more than 9000 cases. In Girard 
and Morin’s series, only 24 bile 
duct injuries were reported in the 
cholecystectomy group, of which 7 
were considered major — an inci­
dence of 0.07%. This represents a 
high-water mark for safe open cho­
lecystectomy.
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Except for the incidence of bile 
duct injury, laparoscopic cholecys­
tectomy dramatically reduces peri­
operative morbidity, shortens hospi­
tal stay and hastens return to work. 
Early reports of bile duct injury 
during laparoscopic cholecystecto­
my by well-trained surgeons was 
0.2%.7 Recent data and longer term 
follow-up suggest that the inci­
dence may be 10- to 20-fold great­
er. The time of recognition and the 
site of injury associated with laparo­
scopic cholecystectomy render the 
consequences more threatening 
than injuries associated with open 
cholecystectomy.
Additional manipulations of the 
bile duct for stone extraction dur­
ing laparoscopic cholecystectomy 
include transcystic duct retrieval or 
lithotripsy, cystic duct or direct 
laparoscopic choledochoscopy, and 
laparoscopic choledochotomy and 
exploration. As biliary surgical 
techniques, these are not new meth­
ods; however, recent advances are 
through the minimal access ap­
proach. These methods are in the 
development stage and must be crit­
ically evaluated over the longer 
term for the incidence of retained 
common duct stones and increase in 
the frequency of bile duct injury.
Roy, McAlister and Passi (pages 
81 to 84) from London, Ont., pres­
ent their preliminary experience 
with perioperative ERCP in associa­
tion with laparoscopic cholecystec­
tomy. Endoscopists have achieved 
ERCP success rates of 85% to 95%. 
Therefore, the London group fa­
vours selective laparoscopic cholan­
giography. This approach demands 
that the following be recognized: (a) 
liberal use preoperatively of ERCP 
and possible ES, based on indica­
tions outlined by Roy, McAlister
and Passi in their Table II; (b) safe 
and effective laparoscopic clearance 
of common duct stones after posi­
tive laparoscopic cholangiography; 
and (c) effective postoperative clear­
ance of common duct stones by 
ERCP and ES. Postoperative diag­
nostic ERCP will be indicated for all 
suspected biliary complications of 
laparoscopic cholecystectomy.
Deaths recorded after ERCP have 
been due to pancreatitis or sepsis. 
There is virtually no evidence of 
iatrogenic bile duct stricture or 
transection after ERCP. Clearance 
rates of common duct stones ap­
proaching 100% will be achieved by 
experienced endoscopists through 
ERCP and ES. Recently, Carr- 
Locke8 reported a 1.5% incidence of 
residual stones utilizing selective 
preoperative ERCP and intraopera­
tive cholangiography in 600 con­
secutive cases. None of these pa­
tients had indications for preopera­
tive ERCP or intraoperative cholan­
giography. All presented within 6 
months of laparoscopic cholecystec­
tomy with non-life-threatening 
symptoms.
Laparoscopic cholecystectomy is 
now accepted as the treatment of 
choice for cholelithiasis. To pre­
clude a moratorium on this tech­
nique, surgeons must reduce the 
incidence of bile duct injury close to 
that reported for open cholecystec­
tomy by Girard and Morin. Choledo- 
cholithiasis suspected preoperative­
ly should be diagnosed and treated 
by ERCP before laparoscopic chole­
cystectomy is carried out. Current 
data indicate that this combination 
would achieve the lowest mortality, 
morbidity, length of hospital stay 
and “sick time.” Common bile duct 
stones that are demonstrated by 
selective laparoscopic cholangiogra­
phy should be considered for post­
operative ERCP and stone extrac­
tion, until laparoscopic bile duct 
surgery proves to be as effective as 
postoperative ERCP and to create 
no iatrogenic bile duct injury. The 
natural history of residual common 
duct stones will select postcholecys­
tectomy patients for efficacious 
stone extraction by ERCP with 
morbidity and mortality far lower 
than those reported for primary or 
secondary open exploration of the 
common bile duct.
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QUILL ON SCALPEL
Transurethral Resection of the Prostate: 
Still the Gold Standard?
Ernest W. Ramsey, MB, ChB, FRCS, FRCSC
Member, Editorial Board, Canadian Journal of Surgery. Professor, University o f  Manitoba,
Section o f  Urology, Health Sciences Centre, Winnipeg, Man.
I n this issue of the Journal (pages 37 to 40), Estey, Mador and 
McPhee report on a 3-year experi­
ence with transurethral resection of 
the prostate (TURP) in a teaching 
hospital where 75% of the primary 
resectionists were senior residents. 
Their results confirm those of other 
reports that TURP for most pa­
tients is a fairly safe procedure with 
a low death rate and a relatively low 
complication rate.1 Mortality was 
related to age, impaired renal func­
tion and higher American Society of 
Anaesthesiologists class. The article 
does not address the success of the 
procedure in relation to improve­
ment in symptoms or long-term 
complications such as urethral 
strictures and the reoperation rate. 
TURP has been used to treat benign 
prostatic hyperplasia (BPH) for over 
50 years and has largely replaced 
open prostatectomy, which is re­
served for large glands. Microscopic 
BPH seems to be an inevitable 
consequence of aging.2 It is more 
difficult to determine the incidence 
of clinical BPH because not all men 
with symptoms seek or undergo 
treatment. The incidence of clinical 
BPH appears to range from about 
10% of men in the 40- to 50-year 
age group to about 40% of men 
over 70 years of age.3 The probabil­
ity of a 40-year-old man undergoing 
TURP in the United States during 
his lifetime is 29%. This translates 
into over 400 000 such procedures 
each year.4 In Canada in 1991, over 
38 000 such resections were per­
formed.
Despite the frequency with which 
TURP is performed, it is only re­
cently that efforts have been made 
to assess the short- and long-term 
outcomes.5 At the same time, the 
management of patients with BPH 
has been thrown into turmoil by 
recent advances, which have seen 
the successful use of medication to 
treat this disease as well as the 
introduction of a variety of new 
techniques that may permit treat­
ment with less morbidity. A recent 
editorial in the New England Jour­
nal o f Medicine was entitled “ Is the 
prostate pill finally here?”6 This 
editorial was in reaction to publica­
tion of the results of a study of 
finasteride, a 5a-reductase inhibi­
tor. Finasteride prevents the con­
version of testosterone to dihy­
drotestosterone, the active andro­
gen in the prostate, causing a de­
crease in the size of the prostate 
and improving symptoms and urine 
flow rates. This drug is now ap­
proved for use in Canada. Alpha- 
adrenergic blocking agents have 
also been studied in BPH. These do 
not decrease prostate size but cause 
relaxation of the smooth muscle in 
the gland, again improving symp­
toms and voiding. Terazosin, an 
a-l-adrenergic blocking agent cur­
rently approved in Canada for the 
treatment of hypertension, is under­
going investigation for use in BPH, 
as are a variety of other treatment 
options. These include transureth­
ral incision of the prostate, balloon 
dilatation, prostatic stenting, tran­
surethral microwave thermotherapy
and the use of lasers to perform 
transurethral prostatectomy.
Although the morbidity associat­
ed with these treatments appears 
lower than that for TURP, the 
effectiveness of some of them, such 
as thermotherapy, requires further 
evaluation before they are offered 
as an alternative treatment. It has 
become obvious that there is a 
major placebo effect in the treat­
ment of this disease. This effect 
must be considered in the assess­
ment of new treatments. Also, not 
all patients with symptoms require 
treatment, and observation (watch­
ful waiting) is an option even with 
the advent of less morbid treat­
ments. Although TURP remains the 
most effective way to relieve ob­
struction, the decreased morbidity 
associated with newer options may 
make them attractive. The relative 
costs of the new treatments also 
need to be assessed.
How is the urologist and the 
patient to choose from this plethora 
of treatments? The decision will 
relate partly to the severity of the 
problem. Medical treatment for ex­
ample, has been assessed for pa­
tients with symptoms of BPH and is 
not currently indicated for the treat­
ment of patients with acute or 
chronic urinary retention. An inter­
esting and possibly helpful ap­
proach is that taken by the Founda­
tion for Informed Medical Decision 
Making, in New Hampshire. This 
group has produced an interactive 
videodisc program that allows the 
patient to review treatment options
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along with their harms and benefits 
and to watch interviews with pa­
tients who have chosen particular 
options. In this way the patient can 
play an active role in decision mak­
ing. However, to be effective, the 
information supplied to the patient 
must be comprehensive and accu­
rate. This will require prospective, 
controlled studies of all new treat­
ment options.
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QUILL ON SCALPEL
Blood Use in Resuscitation After Trauma
James P. Waddell, MD, FRCSC
Department of Surgery, St. Michael’s Hospital, Toronto, Ont. Member, Editorial Board, 
Canadian Journal of Surgery
I n this issue (pages 21 to 27), Hamilton lucidly outlines the use 
and abuse of blood transfusion in 
the trauma patient.
In a comprehensive review of the 
current literature he describes clear­
ly the indications for blood transfu­
sion, the risks associated with such 
transfusion and the alternatives to 
banked blood.
Of particular interest is the em­
phasis on the initial priorities in 
resuscitating the trauma patient, 
the different categories of transfu­
sion (emergency versus urgent) and 
a comprehensive discussion of the 
complications of blood transfusion.
Surgeons involved in the care of 
trauma patients know how essential 
rapid access to a reliable source of 
banked blood is — both in resusci­
tation and during surgical treat­
ment of the patient. Too often 
blood is given at inappropriate 
times, for inappropriate reasons and 
in inappropriate amounts. Careful 
reading of Hamilton’s article will 
help the surgeon rationalize the use
of blood and blood products in the 
trauma patient, ensuring that safe 
transfusion practice complements 
safe surgical practice during resus­
citation and surgical control of on­
going hemorrhage.
All surgeons and residents in­
volved in the care of trauma pa­
tients should be familiar with the 
principles outlined by Hamilton and 
should modify their treatment prior­
ities if necessary to reflect current 
practice in the use of blood in 
resuscitating the trauma patient. ■
QUILL ON SCALPEL
T h e  Journal Expands Its Role
Jonathan L. Meakins, MD, FRCSC;* Roger G. Keith, MD, FRCSCf
*Coeditor, Canadian Journal of Surgery. Chairman, Department o f  Surgery, McGill University, 
Royal Victoria Hospital, Montreal, Que.
fCoeditor, Canadian Journal of Surgery. Chairman, Department o f  Surgery, University o f 
Saskatchewan, Royal University Hospital, Saskatoon, Sask.
The crisis imposed on the Cana­dian Journal o f Surgery (CJS) 
and the previous coeditors by the 
staged withdrawal of financial sup­
port of the Royal College of Physi­
cians and Surgeons of Canada has 
given the Journal an opportunity to 
expand its role and better serve its 
surgical community, now made up 
of the Canadian Society for Vascu­
lar Surgery, the Canadian Ortho­
paedic Association, the Canadian 
Association of General Surgeons, 
the Canadian Society of Cardiovas­
cular and Thoracic Surgeons and 
the Canadian Society of Surgical 
Oncology, with support from the 
Royal College. These sponsoring
societies have begun to publish ab­
stracts and representative portions 
of their annual meetings in the CJS. 
It is the intention of the coeditors 
that the involvement of these socie­
ties shall expand to include many of 
their innovative and key manu­
scripts. It is planned that within the 
next year the journal will carry a 
review article solicited from each 
society, starting in this issue 
(pages 29 to 32) with an overview 
of the Royal College’s Maintenance 
of Competence Program.
With this issue a new section 
“Sponsors’ News” (pages 96 to 99) 
is being initiated. Its purpose is to 
provide a forum of communication
on a bimonthly basis for the Cana­
dian surgical community. This issue 
carries the initial offering, which, in 
time, we expect to expand signifi­
cantly. Although each society’s 
input is focussed on its members, 
there is much information that with 
diffusion will benefit the entire Ca­
nadian surgical community. The 
participating societies incorporate 
Canadian cardiac, general, orthope­
dic, thoracic and vascular surgeons 
together with surgical oncologists. 
Although this represents the major­
ity of Canadian surgery, we look 
forward to the other surgical spe­
cialties participating and publishing 
their work in the CJS. u
SESAP VII Question /  Question SESAP VII
Item 360
Which of the following statements about pulmonary function after nonthoracic operation is TRUE?
(A) The site of incision has only a minor effect on postoperative pulmonary function.
(B) Patients with significant chronic obstructive pulmonary disease (COPD) have a 60% incidence of 
pulmonary complications despite preoperative treatment with bronchodilation, antibiotics, and 
physiotherapy.
(C) The lower limit of FEVi below which a patient should not be given general anesthesia has not been 
clearly defined.
(D) The changes in lung volume seen after an upper abdominal midline incision can be reversed by 
intercostal nerve blockade.
(E) The decrease in vital capacity is directly related to the anesthetic agent used.
For the critique of Item 360 see page 52.
(Reproduced by permission from SESAP '92-’93 Syllabus; Surgical Education and Self-Assessment Program
No. 7. For enrolment in the Surgical Education and Self-Assessment No. 7, please apply to the American College
of Surgeons, 55 E Erie St., Chicago, IL 60611.)
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NON-NARCOTIC NARCOTIC EFFICACY 
WITHOUT NARCOTIC DRAWBACKS
Now, Toradol offers a real alternative to narcotics 
for the management of pain - an analgesic that 
provides the strength of narcotics without the 
associated drawbacks.
CLASSIFICATION
Toradol belongs to the non-steroidal anti­
inflammatory drug (NSAID) family. However, unlike 
conventional NSAIDs, it is a potent analgesic agent 
with minimal anti-inflammatory and antipyretic 
activity. And it’s the only non-narcotic analgesic 
available in both IM injection and tablet form.'2
EFFICACY
One Toradol 30 mg IM injection has been proven to 
be as effective as morphine 12 mg IM and meperidine 
100 mg IM,410 while one Toradol 10 mg tablet has 
been shown to be more effective than 2 tablets of 
acetaminophen + codeine #3*:,7',M2
1 2 3 4 5
HOURS FROM ADMINISTRATION 
Measure of pain relief: 0 = none, 1 = poor, 2 = fair, 3 = good, 4 = very good.
Analgesic efficacy of 
TORADOL 10 mg Tablet 
vs. 2 Tablets of 
acetaminophen + 
codeine #3'7
1 2  3 4 5
HOURS FROM ADMINISTRATION
Measure of pain relief: 0 = none. 1 = poor, 2 = fair, 3 = good, 4 - very good.
D ’ Acefaminophen 600 mg -r 
codeine 60 mg oral
Analgesic efficacy of 
TORADOL 30 mg IM vs. 
morphine 12 mg IM and 
meperidine 100 mg IM.'“
□  TORADOL 30 mg IM
□  Morphinel2 mg IM
□  MeperidinelOO mg IM
□  TORADOL 10 mg oral
COMPARABLE PEAK 
PAIN RELIEF
LONGER DURATION 
OF ANALGESIA
Analgesic efficacy of Toradol 30 mg 
IM administered 24-72 hours 
postsurgery in 5 single dose studies. 
Adapted from reference 10.
EQUIVALENTS SUPERIOR PEAK 
ONSET OF ■  PAIN RELIEF 
ACTION
LONGER DURATION 
OF ANALGESIA
Randomized, double-blind, 
single dose study in patients 
following oral surgery. 
Adapted from reference 17.
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TOLERABILITY
Because Toradol is peripherally- 
acting, its tolerability profile is superior 
to morphine, meperidine, and codeine 
containing analgesics, producing less 
nausea, vomiting, drowsiness171821 and 
constipation.2 Furthermore, Toradol has 
no reported incidence of respiratory 
depression,"12 and no potential for 
narcotic addiction or abuse.3
CLINICAL APPLICATIONS
Toradol has been proven effective in 
managing a wide range of pain following 
general, orthopedic, gynecological4 9 
and oral surgery1718 as well as pain in the 
Emergency Room setting.2922 27
And Toradol is well-suited for the post­
operative pain of day-stay surgery, with 
faster patient recovery,13 and no need for 
monitoring of narcotic-related side-effects 
which can delay discharge.32
COST-EFFECTIVE
Importantly, Toradol’s proven efficacy 
and tolerability help make it cost-effective 
for Canadian hospitals.13 Earlier hospital 
discharge and a lower incidence of 
complications result in considerable cost 
savings - in one well-controlled study, 
Toradol IM and tablets saved an average 
of approximately $75.00 per patient 
compared to meperidine IM followed by 
acetaminophen + codeine #3.13
This study also demonstrated that 
patients on Toradol were easier to care 
for and had greater independence, 
requiring significantly less nursing time 
and effort.13
General Surgery' Orthopedic Surgery'
Gynecological Surgery' Oral Surgery
For a better alternative to narcotics in 
pain management, consider Toradol IM 
and tablets. The non-narcotic analgesic 
that is a step ahead of narcotics.
aT0RAD0L3 |
ketorolac tromethamine 
tablets/comprim6s 
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(KETOROLAC TROMETHAMINE)
CORRESPONDENCE
CORRESPONDANCE
Forearm-Plate Removal
To the editors. I am an orthopedic 
surgeon and practise in a communi­
ty hospital. I read with interest the 
article “Complications of forearm- 
plate removal” by Bednar and 
Grandwilewski in the August 1992 
issue (pages 428 to 431) of the 
Journal. The authors state that an 
incidence of infectious and neuro­
logic complications of approximate­
ly 10% each may be expected with 
elective forearm implant removal. 
Personally, I think that a 10% infec­
tion rate with elective upper ex­
tremity surgery is unacceptable, 
and I would suggest the authors 
review their aseptic technique.
George K. Aitken, MD, FRCSC
Brampton Orthopedic Associates 
Brampton, ON 
L6V 1B4
Dr. Bednar Responds
To the editors. I am happy to 
review Dr. Aitken’s letter and con­
cur with his comment on the sur­
prisingly high infection rate we 
noted in our review of elective fore­
arm-plate removal.
Frankly, we were surprised and 
appalled at the finding, much as we 
would expect any surgeon to be on 
discovering such a high complica­
tion rate in his own case review. 
Nevertheless, we stand by the im­
portance of the review and encour­
age all practising orthopedic sur­
geons to pay thorough attention to 
aseptic techniques in all of the 
surgeries they undertake.
The clinical review of this series 
was most aggressively directed to 
the definition of complications and
probably identified minor, early 
postoperative cellulitis that might 
otherwise go unreported. To my 
knowledge, in the 5 years I have 
been practising on the Orthopedic 
and Trauma Service of the Hamil­
ton General Hospital there has been 
no problem with infection rates 
generally reported on the service; 
this close attention to infectious 
complications may define part of 
our elevated incidence. Although 
these minor acute cellulitides are 
generally not a major clinical prob­
lem, their appearance does increase 
the reported frequency of complica­
tions, although perhaps they do not 
carry any great clinical significance.
Drew A. Bednar, MD, FRCSC, FAAOS
Assistant clinical professor 
Department of Orthopedic Surgery 
McMaster University 
Hamilton. Ont.
Retroperitoneal
Lymphadenectomy
To the editors. I read with interest 
the report by Morin and colleagues 
regarding vascular injury and repair 
associated with retroperitoneal 
lymph node dissection (RPLND) in 
patients with testicular cancer (Can 
J Surg 1992; 35: 253-256). In 78 
patients who underwent RPLND, 
17 (22%) required vascular repair 
intraoperatively. Of particular inter­
est were five renal artery injuries, 
three of which resulted in nephrec­
tomy. The 6.4% renal injury rate 
and 3.8% nephrectomy rate are 
noteworthy.
In a review of complications of 
testicular cancer therapy, we noted
six lost renal units in 148 patients 
who underwent RPLND, for a renal 
loss rate of 4.1%.1 In our series, 
only one nephrectomy was per­
formed at the time of RPLND be­
cause of inadvertent injury. Howev­
er, three patients required nephrec­
tomy within 1 year of operation 
because of nonfunction or hydrone­
phrosis, and two patients required 
nephrectomy because of renovascu­
lar hypertension. We have now doc­
umented five cases of renovascular 
hypertension after RPLND (unpub­
lished data). Hypertension in three 
of the cases was due to renal artery 
injury, in one to cortical necrosis 
and in one to hydronephrosis from 
utereral injury. Interestingly, in 
three of the five cases, hypertension 
did not develop until more than 10 
years after the testicular cancer 
surgery.
We emphasize the importance of 
monitoring these patients on a 
long-term basis for the possibility of 
delayed renovascular hypertension, 
which could have resulted from 
unrecognized surgical insult. In ad­
dition, because of the possibility of 
hypertension as a result of vascular 
toxicity from cisplatin-based chemo­
therapy also commonly used to 
treat this patient population, blood 
pressure screening takes on added 
importance.2 The two patients re­
ported by Morin and colleagues 
who had renovascular repair and 
did not require immediate nephrec­
tomy would be interesting to study 
in the long term for the possibility 
of renovascular hypertension. Long­
term follow-up of their entire co­
hort with respect to hypertension 
may also lead to delayed morbidity 
as our experience has shown.1-2 We 
agree with Morin and colleagues
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that surgery for the patient with 
advanced retroperitoneal testicular 
cancer should encompass a multi­
specialty approach.
Despite these precautions, mor­
bidity does occur, and the patients 
require long-term follow-up.
Judd W. Moul, MD
Attending urologic-oncologist 
Walter Reed Army Medical Center 
Washington, DC.
Assistant professor of surgery 
Uniformed Services University of the Health 
Sciences 
Bethesda, Md
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The Need for General 
Surgeons
To the editors. The article by 
Blanchard (Can J Surg 1992; 35: 
531-535) and the editorials by Duff 
(page 466) and Taylor (pages 467 
and 468) are of interest to me and 
to all rural general surgeons, active 
or retired.
Time, the Golden Hour — is it 
forgotten? Weather and its com­
plexities — are they not a factor? 
Economics — are the patient and 
his or her loved ones considered? It 
appears that the tertiary centres 
supported by the surgeon-scientist 
will be valid by the 21st century.
Is this the way to go? Personally 
I, and active and retired rural sur­
geons, disagree that all patients 
should go to a tertiary centre and 
be supervised by surgeon-scientists.
Each rural medical centre has its 
own particular problems. For this 
reason, regionalization is not the 
answer.
The seaport of Prince Rupert, 
BC, is an excellent example, yet 
there are active surgeons who feel 
that Terrace, BC, should be a re­
gional centre. Personally, I do not 
agree. Each year half a million 
people use the “Inside Passage” 
or are off shore, whether they 
are on cruise ships, American or 
Canadian ferries, commercial fish­
ing or pleasure boats and local or 
off-shore freighters. Medically and 
surgically the Prince Rupert Re­
gional Hospital supports five native 
villages, Oona River and the Queen 
Charlotte Islands.
In the second paragraph I men­
tioned time, weather and econom­
ics. It takes time to bring a patient 
to hospital whether for trauma, 
abdominal surgery, heart attack or 
pregnancy. The weather and its 
complexities at times make it diffi­
cult to get the patient to a tertiary 
hospital. Economically it is cheaper 
for the British Columbia govern­
ment, since an air ambulance is 
costly, for a patient to be looked 
after in his or her own area whenev­
er possible. The loved ones cannot 
afford the air fare, $600 to go to 
Vancouver, the nearest tertiary fa­
cility.
Trainee surgeons should have an 
opportunity early in their training 
to practise under the supervision of 
a general surgeon in a rural com­
munity hospital. The provincial 
government should provide an ade­
quate allowance for new surgeons 
until they can support themselves 
financially. All physicians should 
take the Advanced Trauma Life 
Support course. General surgeons 
will have to make decisions, wheth­
er to operate now or later, or to 
transfer. If they can read, there are 
books. If they are in doubt, they 
can phone the resident on call at
the tertiary hospital for the specific 
specialty.
There is an absolute need for true 
general surgeons now and into the 
21st century.
J.E. Schinbein, BA, MD, FRCSC, FACS
1137 Prince Rupert Blvd.
Prince Rupert, BC 
V8J 2Y8
To the editors. The recent article 
by Blanchard in the October 1992 
issue (pages 531 to 535) and the 
editorials from Drs. Duff (page 
466), Taylor (pages 467 and 468) 
and Deschenes (page 469) point out 
the need for general surgical train­
ing programs to be responsive to 
the changing needs of society.
However, we must also recognize 
the present constraints on our pro­
grams and the resources available 
for training and be realistic as to 
what newly trained general sur­
geons may be willing to undertake. 
Above all, we must not compromise 
the quality of our programs or the 
care of patients in the interests of 
cost containment, ease of access or 
short-term political gains.
General surgery training current­
ly takes 5 years. The increase from 
4 years was introduced for two 
reasons. The first reason was to add 
flexibility to training to allow for 
the production of community sur­
geons, academic teachers or surgi­
cal scientists and to form a basis for 
the training of subspecialists in vas­
cular, thoracic and colorectal sur­
gery and in critical care. The second 
reason was to recognize the in­
creasing scope of general surgery, 
which has grown to include the 
technical skills of endoscopy, head 
and neck surgery and laparoscopic 
surgery, the cognitive areas of criti-
Training the General 
Surgeon
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cal appraisal, research methodology 
and medical ethics and jurispru­
dence, and the treatment of the old, 
the sick and immune deficient. Pro­
grams also need to inculcate atti­
tudes of humanity, communication 
skills, cost consciousness and the 
need for maintenance of compe­
tence.
All of these added requirements 
make for a very crowded 5-year 
program. If we are proposing to add 
extra exposure to plastics, urology, 
obstetrics and gynecology and or­
thopedics, what should we drop 
from the present training?
My nonsurgical colleagues in 
community hospitals claim that any 
“well-trained general surgeon” 
should be able to repair an extensor 
tendon, do a cesarean section or pin 
a hip. Will newly trained general 
surgeons be willing to offer these 
services, mainly at night and on 
weekends? Will they still wish to 
offer them if “capping” dictates 
that such services are offered with­
out pay? What will lawyers and 
judges have to say if things go 
wrong? Finally, and most impor­
tantly, would it not be wise to seek 
the views of the relevant specialty
BOOK REVIEWS 
CRITIQUES DE LIVRES
The following books are also re­
viewed in this issue: Sabiston Re­
view of Surgery (page 32); Surgi­
cal Revascularization of the Heart: 
the Internal Thoracic Arteries 
(page 71); The Principles of Trau­
ma Surgery (page 71).
HISTORY OF ORTHOPAEDICS. 
David LeVay. 693 pp. Illust. The Par­
thenon Publishing Group, Park Ridge, 
NJ. 1990. $125. ISBN 0-85070-145- 
8
The hard, mineral nature of bone has 
preserved evidence of human bone and 
joint disease since the New Stone Age. 
Dinosaur fossils have also shown how 
long vertebrates have suffered from 
degenerative arthritis.
In this book, David LeVay reviews 
the history of human musculoskeletal 
disorders and their treatment from the 
time of the building of the Pyramids of 
Giza in the 5th dynasty to the present. 
The great antiquity of what is now 
orthopedic surgery was established by a
drawing on the wall of the 12th century 
BC Tomb of Ipuy. In that drawing, a 
dislocated shoulder is seen being re­
duced using a method exactly like 
Kocher’s, 3000 years before he de­
scribed it. The Egyptian Orthopaedic 
Association, with understandable pride, 
uses the same drawing as its logo.
LeVay presents a massive amount of 
historical information in a clever and 
readable way. He reviews first the peri­
od from the Stone Age to the end of the 
16th century, ranging with an eclectic 
pen through the lore of ancient Egypt, 
India, China, Japan and the well-record­
ed Hellenic and Roman periods. The 
section ends in early medieval Europe. 
It is a fascinating story of pragmatism 
and of intelligent innovation. The text 
is both well illustrated and well refer­
enced.
The second and largest section of the 
book concerns development of the arts 
and science used in the management of 
musculoskeletal disorders. A good ac­
count is given of finding the term under 
which the many aspects of this field of 
interest could be collected. Nicolas
committees on what areas general 
surgeons could undertake safely 
without 6 or 7 years of training?
The old-fashioned surgeon who 
did everything is a popular cult-fig­
ure. However, the scope and com­
plexity of modern surgery has made 
him (few, if any, were women) a 
virtual anachronism. Let us be care­
ful not to turn the clock back 30 
years in the name of progress.
Christopher Heughan, MB, BChir, FRCSC
Division of Surgery
Memorial University of Newfoundland
St. John’s, NF
A1B3V6
Andry (1658-1747), Dean of the Facul­
ty of Physics at the University of Paris, 
combined the Greek words “orthos” 
(straight) and “paidion” (a child) into 
“orthopedie.” Other, current and older 
terms, like Andry’s, were used original­
ly as book titles. The Paedotrophia of 
Scevole de Sainte-Marthe and Callipa- 
edia of the Abbe Claude Quillet were 
soon dropped. Nineteenth century ef­
forts — “orthomorphy” , “orthosomat- 
ics” and “orthopraxy” thankfully also 
lost out to “orthopaedic surgery.”
Major developments in orthopedic 
surgery and traumatology are described 
in 18 separate chapters, each devoted to 
the contributions of a nation. To create 
a text that is a pleasure to read and not 
a catalogue, the author has described 
the work of great surgical pioneers in 
the form of brief biographical sketches 
and the diseases, such as poliomyelitis 
that have had a significant effect on 
orthopedic practice. Landmark papers 
are referred to and in some instances, 
their face pages are reproduced. Indeed, 
the whole of this section is a treasure-
continued on page 32
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People who buy a Mercedes-Benz 
expect to keep it longer than other 
cars. And for good reason.
Galvanized steel is used for body 
parts that are prone to corrosion. 
Ten kilograms of weather-resistant 
sealant and as many as eight 
coatings and finishes protect the
car’s underbody and exterior.
Little wonder that 97% of all 
Mercedes-Benz cars registered over 
the last 15 years are still in 
operation* (that’s more than any 
luxury car make sold throughout 
that time period).
So buy your budding young
driver a new Mercedes, and drive it 
yourself until he’s ready.
For additional information on 
Mercedes-Benz call 1-800-387-4632.
'Based on registration data for cars sold continuously for years 1977-1991. ©1992 Mercedes-Benz Canada Inc., Toronto, Ont., Member o f the Daimler-Benz Group.
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T he Use of Blood in Resuscitation 
of the Trauma Patient
Stewart M. Hamilton, MD, FRCSC, FACS
The ability to transfuse blood (a form of tissue transplantation) with relatively few 
immediate and long-term complications has led to increased survival in victims of 
injury who require massive amounts of blood. The primary deficit in hypovolemic 
shock secondary to trauma is in oxygen transport to the hypoperfused tissues; 
therefore, blood transfusion has an essential role in therapy during resuscitation 
and definitive treatment. The major immediate complications to be avoided are 
hypothermia and acidosis, which are the main causes of the coagulopathy associated 
with massive transfusion. The most worrisome long-term complication is the 
transmission of disease, of which hepatitis C is the most frequent. With improved 
screening techniques and heightened donor awareness, the risk of disease 
transmission is less than 2%. Until synthetic oxygen-carrying solutions are 
available, the transfusion of red blood cells, when appropriately indicated, will 
remain an important component in the resuscitation of the trauma patient.
La capacite a transfuser du sang (une forme de greffe tissulaire) avec relativement 
peu de complications immediates ou retardees, a contribue a l’augmentation de la 
survie des blesses qui necessitent des quantites massives de sang. Le deficit primaire 
en cas de choc hypovolemique consecutif a un traumatisme, est relie au transport 
d’oxygene vers les tissus hypoperfuses; en consequence, la transfusion sanguine 
joue un role therapeutique essentiel durant la reanimation et au cours du traitement 
definitif. Les complications majeures immediates qui doivent etre evitees sont 
l’hypothermie et l’acidose, les principales causes de la coagulopathie reliee aux 
transfusions massives. La complication tardive la plus inquietante est la 
transmission de maladies, l’hepatite C etant la plus frequente. Avec les techniques de 
depistages ameliorees et des donneurs mieux informes, le risque de transmission est 
inferieur a 2 %. En attendant la venue des solutions de transporteurs d’oxygene de 
synthese, la transfusion d’hematies pour les indications appropriees va demeurer 
une composante importante de la reanimation des patients traumatises.
Throughout history blood has been synonymous with life. In 
ancient times it was considered to 
be the basis of the soul and to carry 
with it the physical and mental
qualities of its owner. The Romans 
drank the blood of recently slain 
gladiators to acquire their strength. 
These attitudes toward blood con­
tinued well into the Renaissance,
when in 1492, Pope Innocent VIII 
received blood from three young 
boys in an unsuccessful attempt to 
rejuvenate him. Following Harvey’s 
description of the circulation, oth­
ers, among them Sir Christopher 
Wren, began to work on the intra­
venous injection of fluids into the 
circulation. In 1667, the first re­
corded transfusion of an animal’s 
blood into a human was made by 
Jean Baptiste Denis. His work met 
with some success and led to the 
first description of a transfusion 
reaction, including diaphoresis, 
tachycardia, pain at the injection 
site and black urine. The patient 
survived but 2 months later re­
ceived another transfusion and died 
the next day. This led to a charge 
of murder against Denis, of which 
he was acquitted, and to a ban on 
all transfusions by the Faculty of 
Medicine in Paris.1’2 
It was not until early in the 19th 
century that man-to-man transfu­
sion was initiated by an obstetri­
cian, James Blundell, for acute he­
morrhage. He performed 10 such 
transfusions, of which 4 were suc­
cessful.1 The success rate of trans­
fusion therapy did not improve sig­
nificantly until the major blood 
groups (ABO) were described in 
1901 by Landsteiner. During the 
late 1930s progress was made to 
develop blood banking, and during 
the Spanish Civil War, mobile trans­
fusion services came into being 
largely because of work by Be- 
thune. The Barcelona Blood Trans­
fusion Service used more than 9000 
L of blood during its existence. In
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1939 the Rhesus factor system was 
described, further facilitating blood 
transfusion and lowering the inci­
dence of transfusion reactions.2-3
Blood transfusion is a form of 
tissue transplantation, with atten­
dant risks that must be weighed 
against the perceived benefits. Our 
ability to store blood in large quan­
tities for immediate use has permit­
ted tremendous advances in the 
fields of surgery and critical care, 
particularly cardiac, transplant and 
trauma surgery.
Twenty years ago, survival after 
transfusion of more than 20 units 
of blood was reported to be 7%.4 
With improved triage, retrieval, re­
suscitation techniques, surgical 
care, anesthetic care and postopera­
tive intensive care, the survival in 
one series today is over 50%. Addi­
tionally, the majority of these survi­
vors returned to gainful employ­
ment.5 Clearly, the ability to trans­
fuse blood, a solution that for the 
most part remains in the vascular 
compartment as a volume expander, 
that carries oxygen and has some 
buffering capacity, is an important 
weapon in the management of the 
injury victim. In fact, if we could be 
certain that there were no risks of 
disease transmission, allergic reac­
tions or transfusion reactions, it 
would be the ideal fluid.
Initial Priorities
The initial treatment of the trau­
matized patient is challenging and 
in most cases rewarding. Primary 
objectives are to ensure an adequate 
airway, oxygenation and ventila­
tion, with spinal control. Assess­
ment of the circulatory status re­
quires an estimate of the blood- 
volume deficit and of ongoing loss­
es. This will determine the rapidity 
with which blood will be used. The 
response or lack of it, to the initial 
fluid bolus of 2000 mL of crystal-
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loid, aids in this assessment. Imme­
diate surgical control of ongoing 
losses must be considered in all 
hypotensive patients. It is essential 
to remember that most complica­
tions of hemostasis are related to 
the length of time that the patient 
is in hypovolemic shock and to the 
degree of hypothermia present.6-8 
Reversing hypotension and hypo­
thermia are the top priorities of 
management once oxygenation and 
ventilation are assured.
In the trauma patient with hypo­
volemia who does not require imme­
diate surgical control, the options 
for the type of fluid to be adminis­
tered are many. That the initial 
fluid resuscitation should be a bal­
anced electrolyte solution is not 
controversial, although the adminis­
tration of hypertonic saline solu­
tions, particularly in the prehospital 
setting, has its proponents. Intrave­
nous access should be through two 
large-bore (12 to 14 gauge) short 
catheters inserted into an uninjured 
upper extremity. A second option is 
to access the femoral vein percuta- 
neously using a large-bore line (8.5 
French). A third option would be by 
a saphenous vein cutdown at the 
medial malleolus. Resistance to flow 
is proportional to diameter and to 
length; therefore, for rapid large- 
volume resuscitation, short, large 
lines must be placed.
Hemorrhagic shock can be classi­
fied into four categories. Loss of up 
to 1000 mL (15% of blood volume) 
(class 1) results in minimal clinical 
symptoms. In uncomplicated cases 
tachycardia develops, but blood 
pressure, respiratory rate, capillary 
refill and pulse pressure are un­
changed. In class 2 hemorrhagic 
shock (a loss of 15% to 30% of 
blood volume [1001 to 1500 mL]), 
symptoms include tachycardia 
(more than 100 beats/min), tachyp­
nea, a decrease in pulse pressure 
(mainly due to a rise in the diastolic 
pressure secondary to catechola­
mine stimulation), anxiety and de­
layed capillary refill. In class 3 
hemorrhagic shock (a loss of 30% 
to 40% of blood volume [1501 to 
2000 mL]), the signs are more 
dramatic and consist of cold clam­
my skin, diaphoresis, marked tachy­
cardia and tachypnea, significant 
changes in mental status and a 
measurable fall in systolic blood 
pressure. With this degree of blood 
loss transfusion is required. In class 
4 shock (loss of more than 40% of 
blood volume [more than 2000 
mL]), there is an immediate threat 
to life. Marked tachypnea and 
tachycardia and a very narrow pulse 
pressure, or unrecordable diastolic 
pressure, indicate this magnitude of 
bleeding. End-organ function is 
markedly impaired as manifested 
mainly by oliguria progressing to 
anuria. Patients in this situation 
require immediate blood therapy 
and surgical intervention.3
Oxygen Transport
By definition a patient who is in 
shock suffers from a generalized 
state of circulatory inadequacy. 
Specifically, in hemorrhagic shock, 
cellular hypoperfusion exists be­
cause of a primary deficit in circu­
lating blood volume resulting in 
inadequate oxygen delivery. It fol­
lows that the major objective of 
treatment is to restore cellular per­
fusion. This requires the restoration 
of oxygen delivery which can be 
defined by the equation: oxygen 
delivery = oxygen content X cardi­
ac output, which equals percent 
oxygen saturation X (hemoglobin X 
1.34) X cardiac output.
Oxygen saturation can be opti­
mized by ensuring that an adequate 
airway and an adequate minute ven­
tilation exist, either spontaneously 
or with intervention. Cardiac output 
is determined by preload, contractil­
ity and afterload. It is unusual for
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intrinsic cardiac disease to exist in 
the majority of injury victims. How­
ever, with increasing numbers of 
elderly people involved in motor 
vehicle accidents, intrinsic cardiac 
disease must be considered. In the 
younger patient population, the 
component most commonly in­
volved in causing a decrease in 
cardiac output is inadequate pre­
load. This is corrected by the ad­
ministration of fluids or blood, or 
both. Obstructive causes of shock 
in the form of pericardial tampon­
ade or tension pneumothorax, must 
be diagnosed and treated. It is rare 
for increased afterload to be of 
concern, and if it is, it can be 
rectified by volume infusion and 
augmented cardiac performance.
The ability of the blood to oxy­
genate tissues is determined by the 
intrinsic ability of the hemoglobin 
molecule to carry oxygen. This rela­
tionship between oxygen and hemo­
globin is further defined by the 
hemoglobin-oxygen dissociation 
curve. The association of hemoglo­
bin and oxygen is influenced by 
many factors, but with respect to 
the quantity of oxygen carried and 
in a young patient without intrinsic 
lung or cardiac disease, the hemo­
globin concentration is the major 
determinant of oxygen delivery.
Hemoglobin-Oxygen Dissociation
The primary function of the red 
cell is to carry oxygen to the tissues 
and to carry carbon dioxide away 
from them, both functions being 
performed by the hemoglobin mole­
cule. In the terminal vascular bed, 
the ability of the hemoglobin to 
unload oxygen is modified by three 
intracellular factors: the hydrogen 
ion concentration, the carbon diox­
ide tension and the level of 
2,3-diphosphoglycerate (2,3-DPG). 
An increase in concentration of 
each or any of these substances 
allows oxygen to dissociate more
easily from hemoglobin, a “shift to 
the right” of the hemoglobin-oxy­
gen dissociation curve, resulting in 
improved oxygen delivery. Other 
conditions that assist oxygen deliv­
ery are not commonly found in the 
acute situation of hemorrhagic 
shock associated with trauma.9
Manipulation of the hemo­
globin-oxygen dissociation curve 
can be valuable in assisting oxygen 
delivery when resuscitating a pa­
tient with extensive blood loss (Fig. 
1). Most importantly, a “shift to the 
left,” in which an increased affinity 
of hemoglobin for oxygen occurs, 
must be prevented. All stored red 
cells become depleted in 2,3-DPG, 
although functionally this reverses 
with transfusion. In the traumatized 
patient it is treatment of the associ­
ated hypothermia and avoidance of 
an alkalotic state, by overadminis­
tration of sodium bicarbonate, that 
can prevent this leftward shift. Mild 
elevation of temperature is prefera­
ble to hypothermia, and a moderate 
acidosis with pH ranging between
7.25 and 7.35 is preferable to alka­
losis.3 In summary, although ade­
quate preload to maximize cardiac 
output and restoration of hemoglo­
bin to maintain oxygen-carrying ca­
pacity are the first goals of resusci­
tation, attention to the effects on 
the hemoglobin-oxygen dissociation 
curve, particularly with respect to 
hypothermia, will assist in achiev­
ing the overall objective: restoring 
cellular perfusion.
Indications for Blood 
Transfusion
Emerqency Transfusion
In certain situations, consider­
ation must be given to immediate 
transfusion. This decision is made 
on clinical grounds after a rapid 
initial assessment reveals a patient 
in a state of profound hypoperfu­
sion, unresponsive to volume load­
ing. As venous access is being es­
tablished, blood must be sent for
Oxygen unloading
FIG. 1. Hemoglobin-oxygen dissociation curve. Relationship of hemoglobin to 
oxygen as function of saturation versus partial pressure of oxygen. Increased 
acidosis, decreased 2,3-diphosphoglycerate (DPG) and decreased temperature all 
shift curve to left, interfering with the unloading of oxygen in terminal vascular 
bed.
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typing and crossmatching. It is im­
perative that this be done before the 
administration of blood products. 
After the blood has been typed and 
crossmatched, the trauma team has 
three options: (a) use of type-specif­
ic blood, (b) use of type 0, Rh-nega- 
tive blood and (c) autotransfusion.
In most situations, the time taken 
to establish lines and infuse a 
2000-mL bolus of crystalloid is 
long enough for type-specific blood 
to be made available. It is axiomatic 
that the typing of the patient be 
done by the blood bank giving the 
blood. This process should take no 
longer than 5 minutes, so the need 
for “universal donor” blood is mini­
mal, and if it is used, it should be 
used only until type-specific blood 
is available.10 That this is possible is 
borne out by military experience: 
even in situations of mass casual­
ties, the number of units of type 0, 
Rh-negative blood transfused is less 
than 5%.n
If type 0, Rh-negative blood is to 
be transfused, it should be as 
packed cells and not as whole 
blood. Because of the presence of 
anti-A and anti-B antibodies in the 
plasma of universal donor whole 
blood, the risk of a subsequent 
transfusion reaction is greatly en­
hanced. The lack of available low 
titre anti-A and anti-B whole blood 
precludes it as a solution whose 
supply can be relied upon. It should 
be necessary to transfuse only 1 or 
2 units of type 0, Rh-negative 
packed red cells before type-specific 
blood is ready. By switching to 
type-specific blood early in the 
transfusion, reactions can be mini­
mized.10 If the situation dictates 
that a large volume of universal 
donor blood be used, then type 0, 
Rh-negative blood should continue 
to be given, to prevent a reaction, 
until the patient is stable and can 
manufacture red blood cells.
Potentially, autologous blood 
transfusion is the safest alternative
to type-specific blood in emergency 
situations. There is no risk of a 
transfusion reaction or of the trans­
mission of disease. The ability to 
predict the potential benefit of 
using an autotransfusion device is 
difficult and very subjective. Age, 
presence of shock and mechanism 
of injury are not predictors of auto­
transfusion efficacy. Some very gen­
eral indicators that may assist in 
determining that autotransfusion 
could be beneficial are an initial 
hematocrit of less than 35% and the 
requirement for more than 2000 
mL of crystalloid solution for resus­
citation.12
Blood that is confined to the 
thorax is usually clean, as is blood 
from the abdominal cavity, provided 
the gastrointestinal tract is not 
open. Devices for collection and 
subsequent administration of blood 
from the chest are readily available 
and are not expensive. Red blood 
cell-saver techniques used intraop- 
eratively for retrieval of in- 
traperitoneal blood require more 
set-up in equipment, personnel and 
disposal costs. They require a larger 
priming volume and have slower, 
less powerful suction. To be of 
benefit at least 3.5 units of packed 
cells should be transfused.13 The 
major drawbacks to autotransfused 
blood are the potential for contami­
nation, microemboli from platelet 
plugs and fractured red blood cells, 
and anticoagulant administration to 
a bleeding patient. However, it must 
be remembered that the patient’s 
own blood comes closest to the 
“ideal fluid” in all trauma situations 
and therefore it is perhaps best to 
err on the side of having liberal 
indications for setting up the auto­
transfusion system.
Urgent Blood Transfusion
The decision to transfuse a pa­
tient who is responding to resusci­
tation must be based on a complete
assessment of the clinical situation. 
Blood is a scarce resource, and its 
administration is not without com­
plications. Young adults without 
cardiac disease can tolerate hemato­
crit levels of 25%, and it is appropri­
ate in many situations to allow the 
patient’s own bone marrow to re­
solve the anemia. However, the de­
cision to withold blood must be 
based on which organ systems are 
injured and the trend in the pa­
tient’s hemodynamic status. If there 
are signs of circulatory inadequacy 
such as a persistent tachycardia, 
ongoing lactic acidosis, a fall in 
blood pressure of more than 20% 
that is refractory to crystalloid ther­
apy and an estimated blood loss of 
greater than 20% with some ongo­
ing losses, blood should be trans­
fused to correct the primary prob­
lem or to stabilize the situation 
until surgical control is obtained. 
Associated injury to the brain de­
mands close attention to maintain­
ing oxygen delivery and an ade­
quate cerebral perfusion pressure. 
In acute lung injury, the manage­
ment of ventilation to minimize ba­
rotrauma may necessitate lower ox­
ygen saturations. In these situa­
tions oxygen transport must be 
maintained by optimizing the hemo­
globin concentration.14
Complications of Blood 
T ransfusion
The complications of blood trans­
fusion can be broadly classified into 
the general complications of all 
fluid resuscitation and complica­
tions that are specific to blood 
transfusion. The most important of 
the general complications are hypo­
thermia and coagulopathy. The spe­
cific complications pertaining to 
blood transfusion that can occur 
immediately include an allergic 
reaction (4% of recipients), a febrile 
reaction (2% of recipients), bacterial 
sepsis (0.01% of recipients) and he-
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molytic transfusion reaction (0.03% 
of recipients).3 The long-term risks 
of transfusion are most often asso­
ciated with the complications of 
transmissible disease and im­
munosuppression.
Hypothermia
Hypothermia is defined as a core 
body temperature of less than 
35°C. With progression to moder­
ate hypothermia (32°C to 28°C) 
and then severe hypothermia (less 
than 28 °C) the metabolic abnormal­
ities progressively worsen to a state 
of coma and cardiac standstill. In 
most, if not all, victims of injury, it 
can be assumed that they are or will 
become hypothermic during their 
resuscitation. This condition leads 
to a number of physiologic derange­
ments that will hinder the return to 
a well-perfused state. Among these 
derangements are depressed hepatic 
metabolism (i.e., synthesis of acute- 
phase reactants, metabolism of ci­
trate), a worsening of metabolic 
acidosis (due to hypoperfusion of 
cold extremities and increased ener­
gy consumption due to shivering), 
impaired platelet function (de­
creased aggregation caused by di­
minished production of thrombox­
ane B2) and a shift of the oxygen- 
hemoglobin dissociation curve to 
the left (increasing its affinity for 
oxygen). The management of hypo­
thermia is first preventive and sec­
ond therapeutic, by warming fluids 
and inspired gases and by using 
external heating devices. The spe­
cific heat-transfer problem that 
needs to be addressed in resuscitat­
ing with blood is how to rapidly 
infuse at temperatures of 35 °C a 
solution that is stored at 4°C and 
has a high viscosity. Whether 
packed red blood cells or additive 
red cells are used, the temperature 
gradient to be overcome is the 
same. An ideal fluid warmer is one 
that has a minimum flow rate of
150 mL/min, has a low priming 
volume and low pressure drop, is 
compatible with blood and is safe, 
compact and inexpensive.
There are a number of fluid- 
warming devices on the market, and 
new technology has facilitated the 
development of the ideal fluid 
warmer. In a comparison of avail­
able devices, the single-channel 
counter-current heat exchanger was 
found to have the most optimal 
flow characteristics, although the 
multichannel counter-current heat 
exchanger also worked well.15 With 
these systems now readily available 
at moderate cost, the prevention 
and treatment of hypothermia in 
the injury victim has been greatly 
facilitated.
In certain patients who undergo 
massive transfusion after traumatic 
injury, diffuse pathologic bleeding 
develops. There is now abundant 
evidence that this “medical” bleed­
ing develops because of the pa­
tient’s generalized state of hypoper­
fusion, usually associated with hy­
pothermia and acidosis. This is im­
portant to recognize, because the 
treatment of this problem is to 
warm the patient and to reverse the 
state of circulatory inadequacy not 
to administer massive volumes of 
blood components for their clotting 
factors.
Coagulopathy
The coagulopathy of massive 
transfusion has been attributed to 
the “washout” of platelets and clot­
ting factors, and to their deteriora­
tion in stored blood. Clinical hemo­
stasis requires about one-third nor­
mal levels of clotting factors, most 
notably the labile Factors V and 
VIII. Even after one blood volume 
exchange this amount is retained, 
and although levels are depressed, 
stored blood also preserves some of 
these factors. Factor VIII is an 
acute-phase reactant that is rapidly
produced in response to injury. 
Studies done on patients undergo­
ing multiple plasma exchange indi­
cate that the factor most danger­
ously depleted is fibrinogen, which 
can affect coagulation. However, 
fibrinogen does not deteriorate in 
stored packed red cells, so unless 
many units of washed cells are 
used, depletion of fibrinogen should 
not occur. Based on these data, 
there is little evidence to support 
the prophylactic use of plasma or 
cryoprecipitate, which are rich in 
clotting factors.616 These compo­
nents should be used only when the 
patient’s state of hypothermia and 
hypoperfusion has been reversed (as 
measured by end organ function) 
and there are documented abnor­
malities in the coagulation profile.17
Platelets are the other major 
component that deteriorate in stor­
age and have been implicated in 
non-surgical bleeding problems. 
The thrombocytopenia associated 
with massive transfusion reaches its 
nadir 2 days after injury and usually 
returns to normal by day 4.18 In 
studies comparing groups of pa­
tients who received platelet transfu­
sion with those who did not, no 
difference was found in platelet 
count or in bleeding problems.19 In 
a patient with normal bone marrow 
function it is very difficult to push 
the platelet count to a level below 
50 X 109/L . Platelet function is an 
important aspect of thrombocyto­
penia-induced coagulopathy and 
must be taken into consideration 
with respect to platelet transfusion. 
As has been discussed, hypothermia 
induces changes in platelet aggre­
gation, as do a multitude of medica­
tions. In the situation of a non­
bleeding patient with normally func­
tioning platelets, platelet transfu­
sion need not be given prophylacti- 
cally unless the count falls below 
20 X 109/L . In the bleeding patient 
with normal function, platelet trans­
fusion is generally indicated for a
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count below 50 X 109/L . In both 
situations aggressive steps must be 
taken to rewarm and reperfuse the 
patient.
Transmission o f Disease
Potentially the most frightening 
complication of blood transfusion is 
the transmission of disease that 
manifests itself weeks to years later. 
As the number of persons infected 
with the human immunodeficiency 
virus (HIV) increases, the need for 
vigilant screening of the donor pool 
also increases. Although HIV trans­
mission through blood transfusion 
has declined, cases are still reported 
to occur when screening programs 
are in place. The development of 
more sensitive screening and aware­
ness among donors should help to 
diminish the risk of HIV in blood 
recipients.20 Despite the public’s 
preoccupation with HIV transmis­
sion, the most commonly transmit­
ted viral disease remains non-A, 
non-B hepatitis, now known as hep­
atitis C.
This disease, recognized as 
non-A, non-B hepatitis since 1974, 
has now been studied thoroughly 
and its clinical course well estab­
lished. It is now understood that it 
has an even greater tendency than 
hepatitis B to produce chronic liver 
disease. Persistent alanine amino­
transferase (ALT) elevation develops 
in more than 50% of cases, and in 
up to half of these an indolent form 
of chronic active hepatitis will de­
velop subsequently with an in­
creased risk of cirrhosis and prima­
ry hepatocellular carcinoma.21
Identification of the complete 
hepatitis C virus (HCV) nucleic acid 
sequence has permitted the develop­
ment of an HCV antibody im­
munoassay. The prevalence of anti­
bodies to the virus varies world­
wide. The ability to screen for the 
virus and surrogate testing for ALT 
and the antibody to hepatitis B core
antigen since 1986, have dropped 
the risk of hepatitis C transmission 
from 10% to 5% at a cost of about 
5% of the donor population. Addi­
tional donor awareness about HIV 
and the ability to screen for anti­
body to HIV have resulted in a 
further drop, so that the risk today 
of post-transfusion HCV is less than 
2%.21
Immunosuppression
In recent years increased atten­
tion has been given to the possibi­
lity of a persistent form of im­
munosuppression in blood transfu­
sion recipients. Initial evidence sug­
gests that this effect might be dose 
related. This has potentially impor­
tant ramifications for the trauma 
patient who receives massive trans­
fusions, particularly because sepsis 
is the major non-neurologic cause 
of death associated with trauma and 
thermal injury, carrying with it an 
overall mortality of more than 
60%.15'22 Much of the evidence sug­
gesting this immunosuppressive ef­
fect in humans comes from patients 
with cancer and renal transplant 
recipients.623-25 It is difficult to 
study this phenomenon in the trau­
ma patient because of the im­
munosuppressive effects of soft tis­
sue trauma and hemorrhage, both 
of which are usually present.
Most of the laboratory evidence 
for suppression of the immune sys­
tem after blood loss comes from 
small-animal models. Within this 
context, hemorrhage has been 
found to depress the proliferation of 
blood lymphocytes and to reduce 
the production of certain cytokines 
(interleukin-2). These effects persist 
despite resuscitation and can last up 
to 3 days.26-28 Within the humoral 
immune system, hemorrhage has 
been found to depress the ability of 
the B cell to react to known anti­
gens.29-30 Additionally, impaired 
phagocytosis may be associated
with the increased production of 
other cytokines (tumour necrosis 
factor and interleukin-1) or the re­
lease of endotoxin by bacteria tran­
slocating from the gastrointestinal 
tract.29 The net result is to leave the 
victim of blood loss more suscepti­
ble to sepsis for an undetermined 
time after injury.29-31-32 
Because of these findings it will 
be very difficult to determine if the 
transfusion of blood into the trau­
matized patient has an immunosup­
pressive effect attributable to the 
blood alone. To date, studies in 
cancer patients and renal transplant 
recipients do provide some circum­
stantial evidence for this.23-25 How­
ever, after hemorrhage and soft 
tissue trauma all efforts should be 
directed toward restoring homeosta­
sis, and if blood transfusion is indi­
cated, it should be given. To deny 
blood therapy because of a sup­
posed depressive effect on the im­
mune system would be incorrect on 
the basis of the evidence that exists 
today.
C onclusions
Work on blood substitutes con­
tinues, but recent medical history is 
littered with hopeful solutions that 
proved to be unsatisfactory. The 
best hope appears to be purified 
polymerized hemoglobin. In a re­
cently published study, sheep toler­
ated a 95% exchange transfusion 
without evidence of clinical distress 
and with stable hemodynamics. The 
final hematocrit in this group was 
24 ± 0.5%.33 Many of the problems 
associated with stroma-free hemo­
globin (i.e., physiologic P50, oncotic 
pressure, depletion of plasma pro­
teins) are gradually being over­
come.34 The prospects for having a 
synthetic oxygen-carrying solution 
that is disease free for use as a 
partial or total substitute for red 
blood cells appears closer now then
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ever before. Until it is available at 
reasonable cost, however, blood re­
mains the closest to being an ideal 
fluid. Although blood must be used 
in selected situations, because it is a 
limited resource and because of the 
potential long-term complications of 
blood transfusion, it remains the 
fluid of choice for resuscitation in 
the critically injured patient with 
signs of tissue hypoperfusion.
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PHARMACOLOGICAL CLASSIFICATION 
Anti-inflammatory, Analgesic Agent
ACTIONS AND CLINICAL PHARMACOLOGY
Non-steroidal anti-inflammatory agent (NSAID) with analgesic and 
antipyretic properties. Mechanism of action not completely known. 
Tenoxicam inhibits prostaglandin biosynthesis both in vitro and in vivo 
(protects mice against arachidonic acid induced toxicity). In vitro tests of 
leucocyte peroxidase also suggest tenoxicam may act as a scavenger for 
active oxygen at site of inflammation. Effects probably explain in part, 
activity in treatment of painful inflammatory and degenerative diseases 
of musculoskeletal system. Does not act by pituitary adrenal stimulation. 
INDICATIONS
Symptomatic treatment of rheumatoid arthritis, osteoarthritis, 
ankylosing spondylitis and extra-articular inflammations eg. tendinitis, 
bursitis, and periarthritis of shoulders or hips.
CONTRAINDICATIONS
Should not be administered to: patients with active peptic ulcer or 
active inflammatory diseases of gastrointestinal tract; patients who have 
shown hypersensitivity to the drug; patients in whom acute asthmatic 
attacks, urticaria, rhinitis or other allergic manifestations are precipi­
tated by ASA or other NSAID’s. Fatal anaphylactoid reactions have 
occured in such individuals.
Before anesthesia or surgery, should not be given to elderly patients, 
those at risk of renal failure, or those with increased risk of bleeding, 
because of increased risk of acute renal failure and possibility of 
impaired hemostasis.
WARNINGS
Peptic ulceration, perforation and gastrointestinal bleeding, 
sometimes severe and occasionally fatal reported during therapy with 
NSAID's including Mobiflex®. Caution should be exercised when a 
NSAID such as Mobiflex® used in patients with history suggestive of pep­
tic ulcer, melena, or any gastrointestinal disease. Physician must weigh 
benefits of treatment against possible hazards.
Patients taking any NSAID including this drug should be instructed to 
contact a physician immediately if they experience symptoms or signs 
suggestive of peptic ulceration or gastrointestinal bleeding which can 
occur without warning symptoms or signs at any time.
Elderly, frail and debilitated patients appear to be at higher risk from a 
variety of adverse reactions from NSAID’s. Mobiflex® should be used 
with special caution in these patients.
Use in Pregnancy and Lactation -  Safety of Mobiflex® during pregnancy 
and lactation not established. Use not recommended.
No teratogenic effects observed in animal reproductive studies. Rats 
receiving tenoxicam during pregnancy showed delayed delivery. 
Tenoxicam readily passes into the milk of lactating rats.
Use in Children -  Not recommended for use in patients under 16 years 
as dose and indications not established.
PRECAUTIONS
Gastro-intestinal system: If peptic ulceration or gastrointestinal 
bleeding occur during treatment drug should be immediately withdrawn.
No definitive evidence that concomitant administration of histamine 
H2-receptor antagonists and/or antacids will either prevent occurrence 
of gastrointestinal side effects or allow continuation of therapy when and 
if these adverse reactions appear.
Renal function: As with other NSAID’s, long-term administration of 
tenoxicam to animals has resulted in renal papillary necrosis and other 
abnormal renal pathology. In humans, acute interstitial nephritis with 
hematuria, proteinuria, and occasionally nephrotic syndrome reported.
A second form of renal toxicity seen in patients with prerenal con­
ditions leading to reduction in renal blood flow or blood volume, where 
renal prostaglandins have supportive role in maintenance of renal per­
fusion. In these patients, administration of a NSAID may cause dose- 
dependent reduction in prostaglandin formation and precipitate overt 
renal decompensation. Those with impaired renal function, heart failure, 
liver dysfunction, those taking diuretics, and the elderly at greatest risk. 
Discontinuation of NSAID therapy usually followed by recovery to pre­
treatment state.
Reversible elevation of BUN and serum creatinine reported with 
Mobiflex®. Thought to result from inhibition of renal prostaglandin 
synthesis resulting in changes in medullary and deep cortical blood flow 
with attendant effect on renal function. Patients with impaired renal func­
tion or on diuretics, elderly patients and those with congestive heart 
failure or liver ascites, more at risk. During long-term therapy, kidney 
function should be monitored periodically.
Hepatic Function -  As with other NSAID's, borderline elevations of one 
or more liver tests may occur. Abnormalities may progress, remain 
essentially unchanged, or be transient with continued therapy. A patient 
with symptoms and/or signs suggesting liver dysfunction, or in whom 
abnormal liver test has occured, should be evaluated for evidence of 
development of more severe hepatic reactions. Severe hepatic reactions 
including jaundice and fatal hepatitis reported with this drug as with 
other NSAID’s. Although rare, if abnormal liver tests persist or worsen, 
if clinical signs and symptoms consistent with liver disease develop, or 
if systemic manifestations occur (e.g. eosinophilia, rash, etc.), discon­
tinue drug.
During long-term therapy, liver function tests should be monitored 
periodically.
Fluid and Electrolyte Balance -  Fluid retention and edema observed in 
patients treated with Mobiflex®. As with many other NSAID’s, possibility 
of precipitating congestive heart-failure in elderly patients or those with
compromised cardiac function should be borne in mind. Use with 
caution in patients with heart failure, hypertension or other conditions 
predisposing to fluid retention.
With NSAID treatment, there is potential risk of hyperkalemia 
particularly in patients with conditions such as diabetes mellitus or renal 
failure; elderly patients; and patients receiving concomitant therapy with 
B-adrenergic blockers, angiotensin converting enzyme inhibitors or 
some diuretics. Serum electrolytes should be monitored periodically 
during long-term therapy, especially in patients at risk.
Hematology -  Drugs inhibiting prostaglandin biosynthesis interfere with 
platelet function to some degree; therefore, patients who may be 
adversely affected by such action should be carefully observed when 
Mobiflex® administered.
Blood dyscrasias associated with use of NSAID’s rare, but could be 
with severe consequences.
Infection -  In common with other NSAID’s Mobiflex® may mask usual 
signs of infection.
Ophthalmology -  Blurred and/or diminished vision reported with use of 
Mobiflex® and other NSAID's. If such symptoms develop drug should be 
discontinued and ophthalmologic examination performed; ophthalmic 
examination should be carried out at periodic intervals in any patient 
receiving drug for extended period.
Hypersensitivity Reactions -  As with other NSAID’s, allergic reactions 
may occur. Manifestations include urticaria, bronchospasm and 
anaphylaxis, and in rare instances, severe skin reactions e.g. Stevens- 
Johnson syndrome and Lyell Syndrome.
Drug Interactions: ASA or Other NSAID’s -  Plasma concentrations of 
tenoxicam reduced to approx. 80% of normal concentrations when 
single doses administered in conjunction with ASA (2,600 to 3,900 
mg/day). At steady state, simultaneous administration of ASA does not 
appear to have significant effect on plasma concentration of tenoxicam. 
Use in conjunction with ASA or another NSAID not recommended since 
data not available demonstrating that combination produces greater 
improvement than that achieved with either drug alone, and potential for 
adverse reactions increased.
Protein-Bound Drugs -  As with other NSAID’s, Mobiflex® is highly 
protein-bound, and therefore, might be expected to displace other 
protein-bound drugs, such as anticoagulants, oral hypoglycemics 
(sulfonylureas), phenytoin, and sulfonamides.
Short term pharmacodynamic studies demonstrated that tenoxicam 
does not potentiate anticoagulant effect of coumarin-type anti­
coagulants nor hypoglycemic effect of sulfonylurea drugs. However, 
when a NSAID such as Mobiflex® administered concomitantly with 
anticoagulants, oral hypoglycemics, or other highly protein bound 
drugs, patients should be monitored and dosage adjustments made, if 
necessary.
Oiuretics/Antihypertensives -  As with other NSAIDs, Mobiflex® can 
attenuate blood pressure lowering effect of hydrocholorathiazide and 
peak excretion rates of NA+ and C1- in patients with hypertension. Close 
monitoring of patients advisable. Excretion of electrolytes not 
significantly affected when tenoxicam (2-day loading dose of 40 mg dai­
ly, followed by 20 mg daily) administered to normotensive patients 
receiving furosemide therapy (40 mg daily). Some NSAID’s reported to 
reduce antihypertensive effects of certain beta-blockers. Interaction 
between Mobiflex® and beta-blockers not studied.
Digoxin -  In elderly patients, with normal plasma creatinine levels, 
plasma digoxin levels not altered by concomitant administration of 
Mobiflex® (30 mg daily).
Antacids -  Administration of 15 ml of aluminum hydroxide or aluminum 
and magnesium hydroxide antacid just prior to single 20 mg oral dose of 
Mobiflex® did not affect bioavailability.
Cholestyramine -  Average half-life of tenoxicam, after single 20 mg 
intravenous dose, reduced from 67.4 hrs. to 31.9 hrs. following 
administration of cholestyramine (4 g in 200 ml water p.o.t.i.d.). 
Apparent drug clearance of tenoxicam increased by 105%.
Lithium -  NSAID’s reported to increase steady state plasma lithium con­
centrations. Recommended these concentrations be monitored when 
initiating, adjusting and discontinuing Mobiflex® treatment.
Methotrexate -  Co-administration of some NSAID’s and methotrexate 
associated with reduced renal tubular secretion of methotrexate, higher 
plasma concentrations, and severe methotrexate toxicity. Therefore, 
caution should be exercised when NSAID’s, such as Mobiflex®, 
administered concurrently with methotrexate. Interaction between 
Mobiflex® and methotrexate not studied.
ADVERSE REACTIONS
Most common adverse reactions encountered with NSAID’s are 
gastrointestinal, of which peptic ulcer, with or without bleeding, is most 
severe. Fatalities have occurred, particularly in the elderly. In approx. 
12,000 patients administered Mobiflex® (tenoxicam) 10-40mg/day, 
(approx, four/fifths receiving 20 mg/day), incidence of peptic ulceration 
and of gastrointestinal bleeding (including hematemesis and melena) 
was 0.1-0.6%.
Approx, incidences of other adverse effects listed by systems are: 
Gastrointestinal: (10.4-23.0%) -  Dyspepsia (0.1-9.7%), nausea 
(2.0-67%), constipation (0.5-2.9%), abdominal pain (07-3.3%), diar­
rhea (0.5-2.3%), flatulence (0.04-1.9%), vomiting (0.2-1.1%), ulcerative 
stomatitis (0.1-07% ), gastritis (0.1-0.8%), esophagitis (0.2%), 
abdominal discomfort (1.4-2.2%), pyrosis (1.3-1.9%), epigastric dis­
comfort (0.2-0.4% ), epigastric pain (1.8-2.5% ), hyperacidity 
(0.02-0.4%), anorexia (0.05-0.4%), indigestion (0.1-0.2%), meteorism 
(0.2-0.4%), gastric pressure (0.5-1.0%), mouth dryness (0.1-0.3%). 
Glossitis, stomatitis, dysphagia, reflux esophagitis each reported in less 
than 0.1%.
Dermatologic: (1.6-39%) -  Rash (0.2-14%), pruritis (0.3-13%),
sweating (0.06-0.3%), exanthema (0.2-0.3%), itching (0.05-0.4%). 
Photosensitivity reaction, seborrhea, urticaria, eczema, nail disorder 
each reported in 0.1% or less of patients. One case of angioedema 
reported.
Central Nervous System: (2.0-9.1%) -  Headache (0.9-4.3%), dizziness 
(0.8-3.3%), malaise (0.04-0.8%), parasthesia (0.02-0.5%), somnolence 
(0.1-07%), vertigo (0.2-0.4%), confusion (0.2%), fatigue (0.1 -0.9%), *
depression (0.6%), insomnia (0.1-0.2%). Leg cramps, nervousness, 
fever, and paresis each reported in 0.1%.
Cardiovascular: Hypertension (0.02-0.3%), palpitations (0.02-0.2%), 
flushing (0.02-0.03%), purpura (0.02-0.2%). Tachycardia reported in 
less than 0.1%.
Hematologic: Anemia (0.04-0.3%), leukopenia (0.04-0.4%). Thrombo­
cytopenia reported in 0.1% or less.
Renal: Haematuria (0.02-0.2%), edema (0.2-1.3%), micturition 
frequency (0.02-0.3%), polyuria (0.03-0.1%). Dysuria, cystitis, 
increased BUN, increased creatinine, and albuminuria each reported in 
less than 0.1% of patients. Isolated cases of abnormal renal function and 
one case of renal failure reported.
Hepatic: (0.06-0.4%) -  Abnormal hepatic function (0.3%). Jaundice, 
increased SG0T, SGPT, gamma GT and bilirubin each reported in less 
than 0.1%. Hepatitis, hepatic coma and hepatic failure each reported 
once.
Respiratory: (0.02-0.65%) -  Dyspnea (0.2%), bronchospasm (0.1%).
Eyes, Ears, Nose, Throat: -  Vision abnormal (0.02-0.3%). Diplopia, I 
conjunctivitis, tinnitus, deafness, epistaxis, abnormal lacrimation each 
reported in 0.1% or less.
SYMPTOMS AND TREATMENT OVERDOSE
Cases of overdoses not reported. In event of overdosage with Mobiflex®, ■
supportive and symptomatic therapy indicated. i
DOSAGE AND ADMINISTRATION
Single daily dose of 20 mg Mobiflex® (tenoxicam) should be taken orally 
at the same time each day. Higher doses should be avoided as they do 1
not usually achieve significantly greater therapeutic effect, but may be 
associated with higher risk of adverse events. I
In some patients a 10 mg (1/2 tablet) daily dose may be sufficient.
Smallest effective dose should be prescribed.
Use In elderly -  Mobiflex® should be used with special caution in elderly ,
patients since they may be less able to tolerate side effects than younger 1
patients. Also more likely to be receiving concomitant medication or \
have impaired hepatic, renal or cardiovascular function.
AVAILABILITY
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T h e Maintenance of Competence 
(MOCOMP) Program: Motivating 
Specialists to Appraise the Quality 
of Their Continuing Medical 
Education Activities
I. John T. Parboosingh, MB, ChB, FRCOG, FRCSC;* S. Tunde Gondocz, MScf
The goal of the Maintenance of Competence (MOCOMP) Pilot Project is to develop a 
comprehensive CME strategy that will motivate specialists to continuously update 
their clinical practice. In its 1st year the pilot program has taken several significant 
steps. A credit system has been implemented to facilitate recognition of CME of the 
highest educational quality and to encourage specialists to compare their CME 
efforts with those of their colleagues. The self-directed CME curriculum currently 
followed by the typical MOCOMP Program member has been described. A diary has 
been implemented for specialists to record CME activities and their potential impact 
on practice. The MOCOMP Program is the first attempt to motivate self-directed 
continuing medical education (CME) through the use of a diary and the first attempt 
to use this instrument to encourage critical appraisal of personal CME habits.
Le but du projet pilote de maintien des competences (MOCOMP) est de developper 
une strategic globale de FMC qui va inciter le specialiste a continuellement remettre 
a jour sa pratique clinique. Dans sa premiere annee d’application, le programme 
pilote a franchi plusieurs etapes importantes. Un systeme de credits a ete instaure 
en vue de faciliter la reconnaissance d’une FMC des plus hauts standards de qualite 
et d’encourager les specialistes a comparer leurs efforts de FMC a ceux de leurs 
collegues. On decrit ici le programme courant de FMC auto-geree suivi par un 
participant type au programme MOCOMP. Un journal a ete develope pour permettre 
aux specialistes de consigner leurs activites de FMC et d’enregistrer Timpact 
qu’elles peuvent avoir sur leur pratique. Le programme MOCOMP constitue la 
premiere tentative pour promouvoir la formation medicale continue (FMC) 
auto-geree par Tutilisation d’un journal; c’est aussi la premiere utilisation de cet 
instrument pour encourager une evaluation critique des habitudes personnelles de 
FMC.
*Associate director, Office o f Fellowship Affairs, Royal College o f  Physicians and Surgeons o f  
Canada, Ottawa, Ont.
fResearch associate, MOCOMP Pilot Project, Royal College o f  Physicians and Surgeons o f 
Canada, Ottawa
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Most programs of maintenance of competence (MOCOMP) op­
erate through legislation, which 
mandates continuing medical educa­
tion (CME) or re-certification by 
examination. Nineteen specialty 
boards in the United States have 
introduced time-limited certifica­
tion, and mandatory CME is in 
place in many states. The Royal 
Australian College of Obstetricians 
and Gynaecologists has linked man­
datory CME to licensure since 
1988.
The MOCOMP Program of the 
Royal College of Physicians and 
Surgeons of Canada will achieve its 
objectives by encouraging special­
ists to apply the principles of total 
quality management to their CME 
efforts. This involves examining the 
resources used, the outcome of 
their CME efforts and the process 
whereby these outcomes are 
achieved.
CME resources are the time com­
mitted and the CME methods used 
(e.g., reading, conferences, rounds). 
Data on the CME resources used by 
members of the MOCOMP Pilot 
Project (MOCOMP Bulletin January 
1993) show that teaching and re­
search (Type III CME activities) 
account for more than 50% of the 
time spent undertaking CME. Al-
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though scholarly activities certainly 
contribute to MOCOMP, the rela­
tionship is not always easily de­
scribed. Furthermore, this CME ac­
tivity is more likely to be driven by 
the needs of students and research 
programs than by the needs of 
patients. The data suggest a need to 
define and record the outcomes of 
CME efforts, namely the clinical 
problems in current practices that 
have been reviewed and updated. 
The model of a self-directed CME 
curriculum (Fig. 1) describes the
process whereby MOCOMP Pro­
gram members use CME resources 
to achieve the outcomes that have 
impact on their clinical practice.
Physicians obtain information on 
a daily basis from a multitude of 
sources. Some professional activi­
ties (e.g., rounds, journal reading) 
are used primarily to scan for new 
information that may enhance clini­
cal practice, whereas others (e.g., 
consultations, teaching, research) 
are undertaken primarily for other 
purposes. Both are rich sources of
new ideas and opportunities to up­
date patient care practices. This 
CME activity, whereby physicians 
scan their professional environment 
for new ideas, is referred to as level
I CME activity in our model. These 
CME activities are too numerous to 
be recorded by busy practitioners. 
As important as they are, level I 
activities rarely motivate specialists 
to initiate a change in practice. 
Some of the information derived by 
scanning the environment, however, 
captures the attention of the spe­
cialist, who perceives an opportuni­
ty to improve on the management 
of a clinical problem.
CME resources (e.g., reading, dis­
cussions, programs, rounds) are 
now used in a more focussed man­
ner to seek answers to the follow­
ing three questions:
•  What is the state-of-the-art 
method of managing this problem?
•  What is my current method of 
managing this problem?
•  What method of management 
are my colleagues using?
This CME activity, termed level II 
CME, differs from level I activity in 
that it focuses on a specific clinical 
problem and requires a more in- 
depth use of CME resources. Level
II CME is goal oriented and always 
comes to one of three possible 
conclusions (or outcomes) regard­
ing the management of the clinical 
problem under review: (a) “ I have 
decided to make a change in my 
management of this clinical problem 
as a consequence of this CME activ­
ity” ; (b) “ I will wait for further 
information before making the deci­
sion to modify my practice” ; or (c) 
“I see no need to change my prac­
tice; I am satisfied with my current 
approach to the management of this 
clinical problem.”
The recording of self-directed 
CME in the MOCOMP diary (Fig. 2) 
has been restricted to level II CME 
activity — those activities that ad­
dress specific topics in sufficient
LEVEL I: General professional activity (e.g., reading, teaching, consultation)
LEVEL II: In-depth review (e.g., in-depth reading, practice audit) 
(All LEVEL II activities should lead to an outcome)
I
c
ti lc
I
I will modify 
my practice
I will wait for information 
before modifying my practice
I see no need to 
modify my practice
FIG. 1. Model of self-directed continuing medical education (CME) curriculum.
SAMPLE: SELF-DIRECTED CME
CLINICAL ISSUE OR PROBLEM under review (print and underline keywords):
Si- FOLiC ZcT
/ V T l )  (  f J e u / Z A - c  T u & g : d t P e c f s )
Circle code for CME method used (as many as appropriate): (  D o t s '
Im TTL
A S  A  RESULT O F  THIS CM E A C TIV ITY  (check  ONLYcne):
W  \ \y31 modify [ ] I will wait for more [ ] I see no need to 
rnY practice Information before modify my practice
modifying my practice
mm yy 
' T o t a l  h o u r ^
/ / ,
FIG. 2. Record of self-directed CME taken from MOCOMP diary.
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depth for specialists to express the 
potential impact on their practice.
MOCOMP Program members will 
receive feedback of their CME activ­
ities in the form of an annual CME 
profile.
The MOCOMP Annual CME 
Profile
A summary of diary entries, in­
cluding attendance at conferences 
registered in the MOCOMP Pro­
gram will be sent to each specialist 
annually along with aggregate data 
computed from submissions by col­
leagues in the same specialty and 
practice setting. The main purpose 
of providing an annual CME profile 
is to assist specialists to appraise, 
critically, the quality of their CME 
activities. It is designed to encour­
age specialists to review their CME 
activities, discuss their results with 
their colleagues and plan their CME 
for the coming year. The profile will 
consist of two sections.
Section A: Group and Type II CME
This section of the annual CME 
profile will give specialists a sum­
mary of the number of MOCOMP 
credits earned, the mean credit rat­
ing and the number of hours spent 
attending rounds and conferences 
as well as aggregate data obtained 
from colleagues in the same special­
ty and practice setting.
Section B: Self-directed CME
This section will provide a sum­
mary of the number of individual 
topics submitted by the specialist in 
the year and the number of hours 
spent in self-directed CME as well 
as data, in aggregate form, submit­
ted by colleagues.
The annual CME profile will in­
clude, for the individual specialist, a 
list of the keywords, the CME
methods used and the outcome des­
ignated to each topic recorded in 
the MOCOMP diary during the year 
(Table I).
A directory of keywords, CME 
methods used and outcomes desig­
nated to topics recorded during the 
year by colleagues will also be in­
cluded with the CME profile. The 
topics entered into the diary should 
be compared with the specialist’s 
practice profile or case mix. All 
specialists should be working to­
ward obtaining data on their case 
mix from computer records and 
using these data to determine the 
direction of their CME efforts.
The topics reviewed by the spe­
cialist in the past year should be 
compared with those reviewed by 
colleagues in the same specialty and 
practice setting. This exercise, 
whereby we are kept informed of 
the CME activities of our colleagues 
(the topics they studied, the CME 
methods used and the outcome des­
ignated to each topic), is intended 
to motivate the individual to keep 
up to date.
A national specialty society may 
use aggregate data obtained from 
the annual CME profiles of its mem­
bers to plan educational programs. 
The data from the CME profiles of 
members of a national specialty 
society may serve as an important 
method of needs assessment for a 
national education program. For in­
stance, the fact that members have 
reviewed a specific topic during the 
year and are waiting for more infor­
mation before changing their prac­
tice may be an indication for a 
national or regional education ses­
sion on that topic. The data from 
the CME profiles will provide a 
society with information on the 
CME methods used by its members. 
This information may be used to 
plan future needs such as computer 
learning programs and audiotapes. 
Also, the data from CME profiles 
may be used to monitor the re­
sponse of society members to new 
information. For instance, a society 
may promote the recommendations 
that result from a multicentred ran­
domized trial. The response to 
these recommendations can be 
monitored by searching for the rele­
vant keywords and identifying the 
potential impact on practice (out­
come codes) recorded in the CME 
profiles of its members.
Summary
The Royal College MOCOMP 
Pilot Project has taken several sig­
nificant steps in its 1st year. A 
credit system has been implemented 
to facilitate recognition of CME of 
the highest educational quality and 
to encourage specialists to compare 
their CME efforts with those of 
their colleagues. The self-directed 
CME curriculum currently followed 
by the typical MOCOMP Program 
member has been described. A diary 
has been implemented for special­
ists to record CME activities and
Table I. Example of an Entry from an Annual Continuing Medical Education (CME) Profile
Item no. CME code Keywords Outcome code
4* 1,2,6 Folate, NTDs 1
5 t 1,2,6 PROM, antibiotics 2
*The role of folate in preventing fetal neural tube defects (NTDs) has been reviewed, using journal 
reading, a literature search and preparing a seminar (CME codes 1, 2 and 6 respectively); the 
outcome code (1) indicates the specialist’s intention to modify current practice as a consequence 
of this review.
fThe role of antibiotics in premature rupture of the membranes (PROM) has been reviewed by the 
same methods as those in item 4 (CME codes 1, 2 and 6); the outcome code (2) indicates the 
specialist's intention to wait for more information before changing practice.
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their potential impact on practice. 
Data will be fed back in the form of 
an annual CME profile.
The MOCOMP Program is the 
first attempt to motivate self-direct­
ed CME through the use of a 
diary and the first attempt to use 
this instrument to encourage criti­
cal appraisal of personal CME ha­
bits. This unique component of
MOCOMP has created much atten­
tion around the world where physi­
cians are concerned about regula­
tion of CME through examination. 
The program is developing stan­
dards for lifelong learning which, 
when evaluated appropriately, 
should be introduced into residency 
training programs. Finally, a credi­
ble program of research is develop­
ing around the MOCOMP project to 
answer questions regarding the re­
lationship between CME and quality 
of care and, in the future, to pro­
vide information concerning the 
relationship between performance in 
residency training programs, CME 
habits in practice and the quality 
of care provided by practising 
specialists. ■
BOOK REVIEWS
continued from page 18
trove of information on a group of 
remarkable people. The illustrations are 
both intriguing and plentiful. They 
show in the faces of both surgeons and 
patients the Zeitgeist of their times.
The third section of the book is 
devoted to a wide variety of special 
subjects and covers the historical as­
pects of almost everything from ampu­
tations to orthopedic implants.
The fourth section is a station stop 
at the turn of the century — a pause to 
reflect on the state of the art at that 
time, what had been achieved and what 
was to come.
The book ends with reference to the 
impetus wars have given to trauma 
surgery, which arose from the sheer 
necessity to keep soldiers alive and 
capable of fighting again, or at least to 
rehabilitate the veterans. Homer’s ob­
servations on war injuries are well re­
corded in the Iliad, and Roman Army 
surgeons 2000 years ago were early 
developers of pylons for immediate fit­
ting to battlefield amputees.
David LeVay was a practising consul­
tant orthopedic surgeon in London, 
England, for over 30 years, after which 
he spent a year working in Africa and 
Australia. He has always been a writer 
and at various times an editor and a 
translator of French and German works. 
He is also a gifted author, having 
completed the monumental task of as­
sembling historical facts and knowledge 
on what is now orthopedic surgery. He 
has chosen a very attractive way of 
presenting his information as a blend of 
history, anecdote and reference. This
book will provide endless pleasure for 
all who have an interest in the human 
frame, its failure and its repair. The 
book will appeal to anyone involved in 
medical care who is curious about its 
origins or who has heard at college or 
university names of the medical pio­
neers. Who knows, you may even find 
out what happened to Virchow!
Charles Sorbie, MB, ChB, FRCS(Edin), 
FRCSC
Professor and head 
Department o f Surgery 
Queen's University 
Kingston, ON 
K7L 3N6
SABISTON REVIEW OF SURGERY. 
David C. Sabiston Jr. 291 pp. Illust. 
W.B. Saunders Company, London; 
Harcourt Brace Jovanovich, Inc., Phil­
adelphia; HBJ-Holt-Saunders Distri­
bution Services, Toronto. 1992. 
$37.95. ISBN 0-7216-3534-2
This paperback book is a companion to 
the 14th edition of Textbook o f Sur­
gery: The Biological Basis of Modern 
Surgical Practice.
According to the preface, medical 
students, surgical residents and practis­
ing surgeons will benefit from reading 
this book; it will be useful for revision 
of basic surgical science in preparation 
for the Board examinations, for ortho­
pedic surgeons, neurosurgeons, otola­
ryngologists, plastic surgeons, maxil­
lofacial surgeons and neurologists.
Moreover, the book claims to be benefi­
cial for residents in colorectal surgery, 
pediatric surgery and vascular surgery.
It comprises a series of questions on 
the content of each chapter of the main 
textbook. Each question is followed by 
a brief critique, and the correct answer 
is given. The number of questions for 
each chapter range from 12 (“The 
management of acute trauma”) to 125 
(“Cardiac surgery”).
The critiques are readable, compact, 
well-written and clear, and the book is 
probably helpful in emphasizing the 
aspects of each chapter that the authors 
feel to be of importance.
I found that the format is not condu­
cive to proper study. Each critique and 
answer is placed immediately after the 
question. The temptation to skip to this 
part before thinking over the question 
and truly testing one’s knowledge is 
almost overwhelming. It would be bet­
ter if the questions were together and 
the critiques were in a separate section, 
similar to the format employed in the 
SESAP syllabus.
It seems inherently improbable that 
one compact volume could be helpful to 
everybody from a medical student to a 
subspecialist in one area of general 
surgery although, clearly, there are 
parts that may be helpful to each 
particular level of training.
Overall, I found this to be an inter­
esting companion for anybody who hap­
pens to be in possession of Sabiston’s 
textbook (14th edition). It is fun to dip
continued on page 70
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Th e Value of Prostate-Specific Antigen 
Levels in Pelvic Lymph Nodes 
for Diagnosing Metastatic Spread 
of Prostate Cancer
Daniel A. Shoskes, MD; John Trachtenberg, MD, FRCSC
Curative radical therapy for prostate cancer depends on accurate diagnosis of 
metastatic spread to pelvic lymph nodes. The authors measured prostate-specific 
antigen (PSA) levels in homogenized pelvic lymph nodes to determine the antigen’s 
diagnostic value and its correlation with histologic findings. No PSA was detectable 
in the lymph nodes of either women or of men without prostate cancer. A dilution of 
prostate cancer tissue with nodal tissue showed that PSA is detectable in this assay 
to a concentration of 1:100 000. In 38 patients who underwent pelvic lymph node 
dissection for staging stage B prostate cancer the histologic findings were correlated 
with PSA content. All nine patients with histologic evidence of metastatic disease 
had measurable PSA in their nodes. Of the 29 patients with no histologic evidence 
of metastatic disease, 23 had no detectable PSA in their nodes. The six patients with 
negative histologic findings and positive findings for PSA had no progression of 
disease at 18-month follow-up. The authors conclude that the measurement of PSA 
in pelvic lymph nodes can add substantial information to that obtained by standard 
histologic examination.
Le traitement radical du cancer de la prostate a visee curative depend du diagnostic 
precis de l’envahissement metastatique des ganglions pelviens. Les auteurs ont 
mesure les taux d’antigene prostatique specifique (APS) dans un homogeneisat de 
ganglions lymphatiques pelviens, afin d’etablir l’interet de cet antigene pour le 
diagnostic et sa correlation avec l’examen histologique. Aucun APS n’a ete decele 
dans les ganglions lymphatiques de femmes ou dans ceux d’hommes qui n’avaient 
pas le cancer de la prostate. La dilution de tissu prostatique cancereux et de tissu 
ganglionnaire a montre que TAPS etait decelable par cette technique de dosage 
jusqu’a conurrence de 1:100 000. Chez 38 patients soumis a une dissection des 
ganglions pelviens pour la determination du stade B de revolution du cancer de la 
prostate, les resultats histologiques ont ete mis en rapport avec la teneur en APS. 
Les neuf patients qui presentaient des signes histologiques de metastases avaient 
tous des taux mesurables d’APS ganglionnaire. Des 29 patients sans signes 
histologiques d’envahissement metastatique, 23 n’avaient pas d’APS decelable dans 
les ganglions. Les six patients ayant des resultats histologiques negatifs et un test 
positif pour l’APS n’avaient pas montre devolution de la maladie apres 18 mois de 
surveillance. Les auteurs concluent que le dosage de TAPS dans les ganglions 
lymphatiques pelviens peut ajouter une information importante a l’examen 
histologique standard.
From the Division o f  Urology, The Toronto Hospital,
Toronto, Ont.
Accepted for publication Jan. 10, 1992
Reprint requests to: Dr. John Trachtenberg, Division o f  Urology, The Toronto Hospital, 
200 Elizabeth St., Toronto, ON M5C 2C4
The optimal treatment for clini­cally localized prostate cancer 
remains controversial. Radical cura­
tive therapy (radiotherapy or sur­
gery) is based on the premise that 
the tumour has not spread beyond 
the confines of the prostate. The 
standard diagnostic manoeuvre 
prior to radical therapy is a bilateral 
pelvic lymph node dissection, in­
cluding the obturator and external 
iliac nodes. Processing the nodes by 
frozen section at the time of radical 
prostatectomy is labour intensive, 
delays surgery and is associated 
with a 10% to 20% false-negative 
rate.
Prostate-specific antigen (PSA) 
is a serine protease that is speci­
fic to the prostate and has enjoyed 
widespread use as a serum marker 
for detecting and for monitoring 
prostate cancer.1-3 As well, it can 
be used in an immunoperoxidase 
stain to identify metastatic prostate 
cancer in the lymph nodes45 and 
in other tissues.6 The existence 
of PSA in the pelvic lymph nodes 
of healthy men is not known, and 
there are no data available on the 
ability to detect nodal spread of 
prostate cancer by the measurement 
of tissue PSA. To address these is­
sues, we studied the tissue content 
of PSA in normal lymph nodes and 
in malignant lymph nodes in an 
attempt to correlate histologic find­
ings with the presence of the tu­
mour marker.
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Materials and Methods
Controls
To determine the presence of 
PSA in normal pelvic lymph nodes, 
PSA was measured in the pelvic 
nodes of 42 women and men (both 
young and old) without prostate 
cancer. The nodes from women and 
men older than 40 years were ob­
tained at the time of cystectomy for 
transitional cell carcinoma; nodes 
from men 40 years of age or youn­
ger were obtained from cadaveric 
organ donors. The serum PSA level 
was normal in all men. No prostate 
cancer was noted in the histologic 
analysis of the prostates removed 
during cystoprostatectomy.
Assay Sensitivity
To determine the maximum sen­
sitivity of the assay to detect lymph 
node PSA, normal lymph nodes 
from female cadaveric organ donors 
were serially diluted with malignant 
prostatic tissue obtained from radi­
cal prostatectomy specimens. The 
lymph nodes were minced, homoge­
nized and mixed with homogenized 
prostate cancer tissue of known 
PSA content. Serial dilutions were 
continued to a concentration of 1:1 
X 10-6 of prostate. Each assay was 
adjusted to 2 mg of protein/mL of 
assay. All PSA levels were deter­
mined by Hybritech R reagents and 
techniques (Hybritech Div. Eli Lilly 
Inc., Canada, Toronto). All assays 
were performed in triplicate.
Study Group
Thirty-eight men with clinical 
stage B7 prostate cancer having 
negative findings on investigation 
for metastatic disease consented to 
radical prostatectomy. The investi­
gations for metastatic disease con­
sisted of measurement of the serum 
prostatic acid phosphatase (enzy-
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made) level, total body bone scan 
and abdominal and pelvic computed 
tomography (CT). PSA was less 
than 25 ng/mL (normal less than 
2.25 ng/mL) in all cases. Before 
prostatectomy, a modified pelvic 
lymph node dissection was per­
formed to include obturator and 
external iliac nodes. All nodal tissue 
was submitted for frozen section 
histologic examination. In addition, 
the highest node in the iliac dissec­
tion was bisected and half was snap 
frozen in liquid nitrogen, then 
stored at — 70°C for later analysis 
for PSA. The other half was sent 
for histologic examination. Patients 
with positive lymph nodes on quick 
histologic section did not undergo 
radical prostatectomy.
Nodes for PSA determination
were thawed and homogenized, 
then sonocated. After centrifuga­
tion, the specimen was weighed, 
then analysed for protein content. 
All specimens were adjusted in con­
centration to 2 mg of protein/mL, 
then processed by the Hybritech R 
PSA assay.
Results
Pure homogenates of prostate 
cancer tissue had PSA levels great­
er than 200 pg/L  (Table I). Female 
lymph nodes had no measurable 
PSA. When the homogenate of fe­
male lymph nodes was serially dilut­
ed with the homogenate of prostate 
cancer tissue, PSA was detectable 
to a dilution of 1:100 000. Similar-
Table 1. S e n s it iv ity  o f P ro s ta te -S p e c ific  A n tig e n  (P S A )*
Tissue Dilution PSA (Mg/L)
PC No d ilu tio n >  2 0 0
Lym ph  node  1 No d ilu tio n N o t d e tec ted
Lym ph  node  2 No d ilu tio n N o t d e tec ted
Lym p h  node  3 N o d ilu tio n N o t d e tec ted
PC 1 1 :10 >  2 0 0
PC 2 1 :10 >  2 0 0
PC 3 1 :10 >  2 0 0
PC 1 1 :100 > 2 0 0
PC 2 1 :1 00 >  2 0 0
PC 3 1 :1 00 > 2 0 0
PC 1 1 :1 00 0 > 2 0 0
PC 2 1 :1 00 0 > 2 0 0
PC 3 1 :1 0 0 0 > 2 0 0
PC 1 1 :10  000 37.1 ±  1 .2
PC 2 1 :10  000 2 5 .2  ±  2 .2
PC 3 1 :10  000 2 0 .2  ±  2 .2
PC 1 1 :1 00  000 4 .2  ±  0 .4
PC 2 1 :1 00  000 5 .2  ±  0 .3
PC 3 1 :1 00  000 4 .7  ±  0 .4
PC 1 1:1 0 0 0  0 0 0 N o t de tec te d
PC 2 1:1 0 0 0  0 0 0 N o t de tec te d
PC 3 1:1 0 0 0  0 0 0 N o t de tec te d
'P ro s ta te  ca n ce r (P C ) w a s  s e r ia lly  d ilu ted  
assays w e re  a d ju s te d  to  2  m g  p ro te in /m L .
w ith  hom ogen ized  fe m a le  ly m p h -n o d e  tis su e . A ll
Table II. P re se n ce  o f PSA in L ym p h  N odes o f 42  P atien ts  W ith o u t P ro s ta te  C ancer
Sex (age, yr)
No. of 
patients
Location of 
lymph node PSA
Fem ale 6 P elvis N o t de tec ted
Fem ale 4 A bdom en N o t de tec ted
M ale ( <  40 ) 8 P e lvis N o t de tec ted
M ale ( <  40 ) 8 A bdom en N o t de tec ted
M ale ( >  4 0 ) 8 P e lvis N o t de tec ted
M ale ( >  4 0 ) 8 A bdom en N o t de tec ted
PSA LEVELS IN PELVIC LYMPH NODES
ly, in all lymph node specimens 
from women or men without pros­
tate cancer, no PSA was detected 
(Table II).
Of the 38 men with prostate 
cancer, 8 had positive lymph nodes 
on frozen section histologic exami­
nation. All had PSA detected in 
their lymph node homogenates (Ta­
ble III). One further patient had 
negative nodes on frozen section 
but was later found to have positive 
metastatic nodes on permanent sec­
tion. This patient had detectable 
PSA in the lymph nodes.
Of the 29 men with negative 
lymph nodes on histologic examina­
tion, 23 had no detectable lymph 
node PSA. Six men, however, had
detectable lymph node PSA despite 
a negative histologic diagnosis. 
None of these patients subsequently 
had recurrent or metastatic disease, 
although the follow-up was short 
(range from 5 to 18 months).
Discussion
By definition, for radical therapy 
of prostate cancer to be curative, 
the lesion must be localized to the 
prostate. Preoperative assessment 
of nodal spread is limited by the 
efficacy of the imaging and bio­
chemical modalities available. CT 
can only detect substantially en­
larged nodes, while pedal lymphan­
giography may miss obturator or 
presacral nodes. Serum PSA values, 
when markedly elevated, almost al­
ways suggest locally aggressive or 
metastatic disease, or both;8 howev­
er, there is considerable overlap at 
intermediate levels. Pelvic lymph 
node dissection is the gold standard 
for diagnosing stage D1 disease. 
The reliance on quick-section inter­
pretations at the time of surgery 
may understate by as much as 10% 
to 20%.
This preliminary study set out to 
establish that the concentration of 
PSA found in pelvic lymph nodes of 
men with prostate cancer could be 
used to determine the presence of 
lymph node metastasis. The use of 
a biochemical marker theoretically 
could be more sensitive and specific 
than histologic examination, partic­
ularly with low volume of disease. 
Because the presence of any nodal 
disease portends a significantly 
worse prognosis,9 this greater sensi­
tivity could spare patients the mor­
bidity of noncurative radical ther­
apy. For those who believe that 
lymph node metastasis is not a 
contraindication to radical ther­
apy,10 the diagnosis of D1 disease 
still adds prognostic information 
and aids in the treatment stratifica­
tion. With the increased interest in 
laparoscopic pelvic lymph node dis­
section, PSA assay of the removed 
nodal tissue mass may be easier 
than standard histologic means 
(Gerald W. Chodak, personal com­
munication, 1992).
By using appropriate controls, we 
demonstrated that PSA could not 
be detected in normal lymph nodes 
and that PSA could be measured in 
very low concentrations in cancer­
ous nodes, probably in the order of 
1 cancer cell per 10 000 normal 
cells. Put another way, this theoret­
ically could detect one cancer cell in 
less than 0.1 mg of tissue.
This study also demonstrated an 
excellent correlation between the
Table III. Biochemical and Pathologic Comparison of PSA in Pelvic Lymph Nodes
Patient
no.
Histologic
findings* Tissue PSA Serum PSA (ng/mL)
1 — Not detected 12
2 - Not detected 8
3 + Detected 9
4 - Not detected 15
5 - Detected 9
6 - Not detected 11
7 - Detected 12
8 + Detected 8
9 + Detected 17
10 - Not detected 6
11 + Detected 12
12 - Detected 8
13 - Not detected 9
14 - Detected 15
15 - Not detected 9
16 - Not detected 5
17 - Not detected 12
18 + Detected 18
19 - Not detected 17
20 - Not detected 5
21 - Detected 12
22 - Not detected 8
23 + Detected 9
24 - Not detected 15
25 + Detected 9
26 - Not detected 11
27 - Not detected 12
28 - Not detected 8
29 + Detected 17
30 + Detected 15
31 - Detected 12
32 - Not detected 8
33 - Not detected 4
34 - Not detected 6
35 — Not detected 3
36 - Not detected 5
37 - Not detected 4
38 - Not detected 6
* -  = negative, + = positive
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presence of PSA in pelvic nodes and 
the presence histologically of me- 
tastases in pelvic nodes. All the men 
with positive histologic findings had 
PSA detected in their nodes. Six of 
23 men with negative histologic 
findings, however, were found to 
have PSA in the pelvic nodes. It is 
interesting to speculate whether 
this result is in keeping with the 
observation that metastatic disease 
still develops in 20% to 35% of men 
who undergo node dissection for 
prostate cancer and have negative 
findings on permanent sections. 
Further follow-up of these patients 
will determine whether this assay 
has a 25% false-positive rate or 
whether in fact it allows the identifi­
cation of patients with unsuspected 
low-volume metastatic disease.
Finally, although the current 
PSA assay takes too long for practi­
cal intraoperative use, the develop­
ment of newer enzymatic assays 
seeking an “all-or-nothing” effect 
could eventually be faster and less 
subjective than histologic analysis. 
These solid-state assays have been 
developed for the determination of 
small concentrations of substances 
in plasma, and the entire procedure 
usually takes less than 15 minutes. 
They require no special expertise or 
processing and would be extremely 
inexpensive to perform. The tests 
are presently being developed com­
mercially. The ideal situation, how­
ever, will probably combine the in­
formation the two tests provide, 
because tissue PSA may be able to 
detect metastasis too small to see 
with light histology, and very poor­
ly differentiated tumours that do 
not express PSA511 still could be 
recognized by histologic appear­
ance.
Conclusions
Measurement of PSA in nodal 
tissue is a viable diagnostic tool 
that correlates well with histologic 
examination for metastatic prostate 
cancer. PSA in nodes of women and 
of men without prostate cancer was 
undetectable, whereas all men with 
positive nodes on histologic exami­
nation had measurable PSA. Six 
men with negative histologic find­
ings had positive nodal PSA, sug­
gesting either a 25% false-positive 
rate or that this technique can 
detect previously unmeasurable 
low-volume metastatic disease. Res­
olution of this will require larger 
numbers with longer follow-up be­
cause of the slow growth rate of the 
disease.
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A Review of 1486 Transurethral 
Resections of the Prostate in a Teaching 
Hospital
Eric P. Estey, MD; David R. Mador, MD, FRCSC; Malcolm S. McPhee, MD, MSc, FACS, FRCSC
The authors reviewed retrospectively 1486 consecutive transurethral resections of 
the prostate (TURP) gland performed in a teaching hospital between 1985 and 
1987. The death rate was 0.8% in an institution where senior residents were the 
primary resectionists in approximately 75% of TURPs. The results of this review are 
compared with those of a 1974 study of 2223 patients. They indicated that TURP 
was a reasonably well-tolerated surgical procedure in the training environment and 
was associated with lower mortality and morbidity and a shorter hospital stay for the 
patient than in the 1974 study. The authors believe that with proper supervision 
and instruction, resident urologists can obtain satisfactory results while gaining 
competence and experience in performing TURPs.
Les auteurs ont etudie de fa?on retrospective 1486 resections transuretrales de la 
prostate (RTUP) consecutives pratiquees dans un hopital d’enseignement entre 
1985 et 1987. Le taux de mortalite a ete de 0,8 % dans un etablissement ou les 
residents seniors etaient les premiers intervenants dans 75 % des RTUP. Ces 
resultats ont ete compares a ceux d’une etude realisee en 1974 chez 2 223 patients. 
Ils indiquent que la RTUP est une intervention chirurgicale raisonnablement bien 
toleree en milieu de formation, et qu’elle est reliee a une mortalite et a une 
morbidity plus faibles et a un sejour hospitalier plus court que pour les patients de 
1974. Les auteurs croient qu’avec une surveillance et des instructions adequates, un 
resident en urologie peut obtenir des resultats satisfaisants tout en acquerant 
competence et experience dans l’execution des RTUP.
O ver 50 years have passed since transurethral resection of the 
prostate (TURP) gland was devised 
to relieve bladder outlet obstruction 
for those with benign or malignant 
disease. It has been estimated that 
the probability of a 40-year-old man 
undergoing a prostatectomy during
his lifetime is 29%, and 90% of 
patients who undergo an operation 
for bladder outlet obstruction will 
have a TURP.12 The mortality from 
TURP has declined steadily over the 
past 30 years, with rates as low as 
0.2% quoted in the American Uro­
logical Association Cooperative
Study in 1988.3 The literature con­
tains numerous reviews indicating 
that TURP is a reasonably safe 
procedure; however, few surveys 
have evaluated the safety of TURP 
for neophyte resectionists.
The purpose of this review is to 
evaluate the urologie care provided 
in a teaching hospital to determine 
if resident participation influences 
patient morbidity or mortality. A 
common surgical procedure, TURP, 
is the basis of this evaluation.
Patients and Methods
Hospital charts of all 1486 con­
secutive patients who underwent 
TURP in one institution between 
1985 and 1987 were reviewed. 
Each record was examined with 
respect to 25 variables. This review 
deals with patient evaluation, resec­
tion methods and early postopera­
tive complications.
The evaluation was performed at 
the Royal Alexandra Hospital, Ed­
monton, a teaching institution affili­
ated with the University of Alberta. 
Senior urology residents obtain a 
portion of their training at this 
centre under the supervision of staff 
urologists. Endoscopy is an impor­
tant part of their training. The 
urology resident is the primary re- 
sectionist in approximately 75% of 
the TURPs performed at the hospi­
tal. The resident receives supervi-
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sion and instruction from the at­
tending urologist during the opera­
tion with periodic endoscopic as­
sessment of the resection.
The resections were carried out 
in the conventional fashion, resect­
ing prostatic adenoma down to the 
fibres of the surgical capsule. Re­
sections were performed with inter­
mittent irrigating resectoscopes, 
using either 1.5% glycine solution 
or distilled water as an irrigant. All
6 0 0 ;
53 4
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Age, yr
FIG. 1. Age distribution of patients 
who underwent transurethral resection 
of prostate (TURP) between 1985 and 
1987.
FIG. 2. American Society of A n e s­
thesiologists (ASA) classification of 
physical condition. 1 =  no systemic 
disease, 2 = mild systemic disease, 3 =  
moderate systemic disease, 4 =  severe 
systemic disease, 5 =  moribund.
patients with a positive urinary cul­
ture, bacteriuria or indwelling Foley 
catheters were given appropriate 
antibiotics pre- and postoperatively. 
Others were maintained on appro­
priate antibiotics for several days 
postoperatively. A Foley catheter, 
with intermittent or continuous 
bladder irrigation, was maintained 
for at least 24 hours postoperative­
ly. Postoperative hospital stay in­
cluded the time from surgery to 
discharge or patient death.
Major nonfatal complications 
were noted. The overall mortality 
included any death that occurred 
while the patient was hospitalized, 
even if it was not directly related to 
the prostatectomy.
Findings
Patients
The average age was 63 years 
(Fig. 1). Physical condition was 
based on the American Society of 
Anaesthesiologists (ASA) physical 
status classification4 from 1 (no 
systemic disease) to 5 (moribund 
patients with little chance for sur­
vival). The patients were fairly even­
ly divided between class 1 and class 
2 (644 patients [43.3%] and 751 
[50.5%]). Only 91 patients (6.2%) 
were class 3 or 4 (Fig. 2).
Laboratory Findings
The serum creatinine level was
determined before TURP. Table I 
shows the distribution of patients 
with normal and elevated serum 
creatinine levels according to 
whether 1.5% glycine or distilled 
water was used as an irrigating 
fluid. The group with elevated 
serum creatinine levels and using 
distilled water had a death rate of 
3.8%.
Operative Findings
The operative technique and re­
sults are noted in Table II. The 
patients underwent TURP with in­
termittent irrigating resectoscopes 
using 1.5% glycine in 36% of cases 
and distilled water in 64% of the 
cases. Average time for the opera­
tion (patient in theatre until transfer 
to recovery room) was 60 minutes. 
Anesthesia was fairly evenly distrib­
uted between general and spinal. 
The average decrease in the hemo­
globin level was 14.2 g/L, and 9% 
of the patients required at least one 
unit of packed cells within 10 days 
of operation. The average postoper­
ative hospital stay was 5.75 days. 
The average stay decreased during 
the 3-year period of the study by 1 
day.
Pathological Findings
The weight of prostatic tissue 
resected ranged from 0.6 g to 160 
g (Fig. 3). The average weight of 
resected prostate was 24.3 g. 
Pathological examination of the
T a b le  1. Serum Creatinine Levels Before Transurethral Resection of the Prostate (TURP), 
According to Type of Irrigant Used
W ater Glycine
C reatin ine, ^ m o l/L
Patien ts , 
no. (%)
D eaths, 
no. (% )
P atien ts , 
no. (% )
D eaths, 
no. (% )
< 130 
> 130
830 (88.6) 
106 (11.4)
5 (0.6) 
4 (3.8)
445 (84.4) 
82 (15.6)
3 (0.7) 
0
Total* 936 (100) 9 (0.46) 527 (100) 3 (0.56)
*ln 23 patients the serum creatinine level was not measured before operation.
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specimens revealed that 85% were 
benign and 15% were malignant.
Complications
Major nonfatal complications oc­
curred in 7.8% of the patients (Ta­
ble III). Cardiovascular and throm­
boembolic events complicated the 
course of 1.1% of our patients. 
Documented hyponatremia and 
transurethral resection syndrome 
were found in only 0.5%. Patients 
who were readmitted for postopera­
tive bleeding or repeat resection 
were only accounted for if they 
were readmitted to the Royal Alex­
andra Hospital.
Minor complications were incon­
sistently documented in the hospital
Table II. Operative Information
Irrigation fluid, % of patients
1.5% glycine 36
Distilled water 64
Anesthesia, % of patients
Spinal 55
General 45
Average operation time, min 60
Average decrease in
hemoglobin, g/L 14.2
Patients requiring blood
transfusions, % 9
records and therefore are not in­
cluded in this review.
Mortality
Twelve patients in this series died 
— a death rate of 0.8%. The aver­
age age of these patients was 79 
years. Thirty-nine percent of those 
who died were more than 70 years 
old. The death rate for patients over 
70 years of age was 1.7% compared 
with 0.2% for those less than 70 
years of age. The median ASA 
classification was 3.
Preoperatively 57% of patients 
had mild to moderate systemic dis­
ease (ASA class 2 or 3). Of those 
who died, 67% were in ASA physi­
cal class 3 preoperatively. Four pa­
tients (0.3% of the total) died after 
elective admission for TURP. The 
other eight who died were long­
term admissions and were referred 
to the urology service. There were 
no intraoperative deaths. Eight pa­
tients (0.5%) died within 30 days of 
their prostatectomy. Of these, two 
had intraoperative myocardial in­
farction, two had pulmonary embo­
lism and the remaining four died of
FIG. 3. Weight of prostate resected.
respiratory or cardiac arrest more 
than 10 days postoperatively. The 
four patients who died without ob­
vious precipitating factors all had 
severe underlying systemic disease. 
None of the patients who died had 
urosepsis or electrolyte abnormali­
ties. However, in patients with renal 
dysfunction (an elevated serum cre­
atinine level) in whom distilled 
water was used as the irrigant, the 
death rate was 3.8%.
Nine percent of the patients re­
ceived blood transfusions for a low 
hemoglobin level as well as opera­
tive blood loss.
Residents were the primary resec- 
tionists for the surgery of 7 (58%) 
of the 12 patients who died.
Discussion
The most remarkable finding in 
this series with respect to the death 
rate was the fact that 3.8% of 
patients having an elevated serum 
creatinine level and distilled water 
used as the irrigating solution dur­
ing surgery died. Distilled water as 
an irrigating fluid has obvious bene­
fits of low cost and optical superior­
ity over other solutions. However, 
because of the risks of hemolysis 
and subsequent renal failure, many 
urologists believe that distilled 
water is contraindicated in TURP 
despite its advantages.56 As shown 
in this and other series, in patients 
without renal impairment, the 
choice of irrigating solution does
Table III. Nonfatal Complications, %
No. (%) of
Complication patients
Thromboembolic events 5 (0.3)
Myocardial infarction 
Transurethral resection
12(0.8)
syndrome/hyponatremia 7 (0.5)
Repeat resection — within 1 yr 25(1.7)
Bleeding* — < 60 d 67 (4.5)
Total 116(7.8)
'Requiring readmission
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not appear to affect outcome; how­
ever, care must be taken when 
using distilled water in those with 
reduced renal function. The appar­
ent safety of distilled water as an 
irrigating solution is probably ac­
counted for by improved surgical 
techniques limiting fluid absorption 
and by the surgeon’s experience. 
However, the use of distilled water 
cannot be universally recommend­
ed, especially when residents in the 
early stages of their careers are 
beginning to learn TURP, because 
there may be a significant risk to 
the patient.
To put this study into perspec­
tive, we compared the findings with 
those of a previous study by Melchi­
or and associates in 1974.7 They 
reported on the morbidity in a se­
ries of 2223 consecutive patients 
who underwent TURP.7 In their 
study, as in this one, both staff and 
resident urologists were included. 
The comparisons are made in Table 
IV. The two series have a similar 
ratio of staff to resident as the 
primary resectionist. The patients in 
our series were slightly younger, 
the group having a mean age of 63 
years. In both series the mean 
weight of specimen resected was 
similar; however, the surgery was 
performed, on average, 24 minutes
faster, and approximately 15% 
fewer patients received blood trans­
fusions at our institution.
The patients in our series were in 
hospital approximately 1 day less. 
This might reflect either an earlier 
removal of the catheter or a change 
in patient care over the 17 years 
between the two studies. Presently, 
it is the practice at our hospital to 
remove the catheter the 1st day 
postoperatively if bleeding is mini­
mal. Furthermore, with hospitals 
currently attempting to control 
spending and the implementation of 
continuing quality improvement 
measures, the hospital stay postop­
eratively for a patient undergoing 
TURP is now approximately 3 days 
in our institution.
The overall death rate in Melchi­
or’s review was 1.3%. In this series, 
the death rate within 30 days of 
operation was lower at 0.5%. Most 
of the deaths in both series oc­
curred in elderly patients with mod­
erately severe multisystem disease, 
and the TURP probably contributed 
little to their death.
Conclusions
From a review of TURP in a 
teaching hospital, the short-term
results appear favourable in com­
parison with other large reviews on 
this very common surgical proce­
dure. In this series, having senior 
residents perform the procedure 
does not have any adverse effect on 
patient morbidity or mortality. With 
proper supervision and instruction 
from staff urologists, residents are 
able to gain experience and techni­
cal competency and maintain low 
complication rates.
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Outpatient Laser Cone Biopsy 
Under Local Anesthesia
Gavin C.E. Stuart, MD; Jill G. Nation, MD
The authors report on 60 patients who had abnormal findings on cervical cytologic 
examination, necessitating conization of the cervix. The procedure was done in an 
ambulatory setting, with a carbon-dioxide laser unit and local anesthesia. The 
average operative time was 16.9 minutes. Fifty-one (85%) patients experienced no 
complications, and there were no cases of excessive bleeding. In all patients, the 
specimen was satisfactory for histologic review. Only 5% (three) of patients would 
have preferred to have the procedure performed under general anesthesia.
Laser cone biopsy of the cervix can be performed in an outpatient setting, with 
local anesthesia. Morbidity is minimal and there is potential for economic saving 
when compared with conventional methods for biopsy of the cervix.
Les auteurs ont etudie 60 patientes qui avaient eu un examen cytologique anormal 
du col uterin necessitant une conisation du col. L’intervention fut pratiquee en 
milieu ambulatoire, sous anesthesie locale, a l’aide d’un laser au bioxyde de carbone. 
Le temps operatoire moyen fut de 16,9 minutes. Cinquante-et-une patientes (85%) 
n’eurent aucune complication et il n’y eut aucun cas de saignement excessif. On 
obtint chez toutes les patientes un echantillon satisfaisant pour examen 
histologique. Seulement trois patientes (5%) auraient prefere subir l’intervention 
sous anesthesie generate.
La biopsie conoi'de du col au laser peut etre effectuee en milieu ambulatoire, sous 
anesthesie locale. La morbidity est minime et il y a possibility d’une economic par 
rapport aux methodes classiques de biopsie du col uterin.
S ince 1976, laser vaporization of cervical intraepithelial neoplas­
tic lesions has been reported to be 
of value in the management of this 
condition.1 The procedure has been 
performed in both inpatient and 
outpatient settings, with either local 
or general anesthesia. However, ex- 
cisional cone biopsy for diagnostic 
purposes has generally been per­
formed in an operating room under 
local or general anesthesia with 
either the scalpel or laser. The 
purpose of this paper is to report 
the use of the laser in performing 
excisional cone biopsies of the cer­
vix under local anesthesia in an 
outpatient setting in 60 patients. 
The ability to carry out this proce­
dure satisfactorily without the need 
for hospital admission or general 
anesthesia greatly reduces the mor­
bidity usually associated with cone 
biopsy and results in considerable 
cost saving.
Patients and Methods
Sixty consecutive women, who 
were referred to the Colposcopy 
Clinic of the Tom Baker Cancer 
Centre, in Calgary, and who re­
quired a diagnostic cone biopsy of 
the cervix were the subjects o f this 
report. The average age was 29.8 
years (range from 22 to 43 years). 
Twenty-four women had delivered 
at least one infant previously and 
the remainder were nulliparous.
All women had a history o f cervi­
cal cellular abnormalities. Repeat 
cytologic investigation was done be­
fore colposcopic assessment, and 
directed biopsy was done in all the 
women. The indications for diag­
nostic cone biopsy are listed in 
Table I. Endocervical curettage was 
not done routinely in all new pa­
tients but did constitute part of the 
regular follow-up in those who had 
previously received therapy for cer­
vical intraepithelial neoplasia (CIN). 
An unsatisfactory examination was 
one in which the entire squamo- 
columnar junction could not be 
seen or the area of white epithelium 
extended into the cervical canal. 
The colposcopic diagnosis prior to 
the cone biopsy is recorded in Table 
II. The new patient with benign 
atypia underwent cone biopsy be­
cause the initial cytologic findings 
were cells inconsistent with CIN 
grade III. After adequate examina­
tion, women in our clinic who are 
found to have CIN grade I only are 
not actively treated but are ob­
served in regular follow-up. The 
five women with histologic evidence 
o f CIN grade I underwent a cervical 
conization because of a discrepancy 
between cytologic and histologic 
findings. Of the 60 women, 40 were 
noted to have concomitant cytolog­
ic or histologic changes consistent 
with the presence of human papillo­
ma virus.
Informed consent for laser cone 
biopsy was obtained from all the
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women. They attended the Ambula­
tory Surgery Unit at the clinic 1 
hour before their scheduled proce­
dure. Lorazepam, 1 mg, was offered 
as an anxiolytic medication. All pro­
cedures were conducted in the 
treatment area, with oxygen and 
resuscitative equipment immediately 
available. Pulse and blood pressure 
were monitored autom atically 
throughout the procedure on a digi­
tal display with pulse oximetry. All 
procedures were performed by the 
same gynecologist. An anesthesiolo­
gist was not present. A nurse at­
tended throughout to observe the 
patient and to provide distraction 
through conversation.
After repeat colposcopic exami­
nation, the area to be excised was 
outlined with a Xanar-20 carbon- 
dioxide laser (Xanar, Div. of Coher­
ent Medical, Palo Alto, Calif.) at a 
power density of 2420 w atts/cm 2. 
This setting was chosen for a 1 mm 
spot size with maximal energy out­
put. Following this outline, the pa­
tient was offered a paracervical 
block (1% xylocaine without epi­
nephrine), which was administered 
with 5 mL of solution injected at 
the base of each uterosacral liga­
ment and then an additional 10 mL 
injected circumferentially on the 
cervix just distal to the line of 
excision. After establishment of a 
paracervical block, the line of exci­
sion was extended to a depth of 10 
to 15 mm to include the projected 
squamocolumnar junction. A small, 
20-cm skin hook was used to de­
Table 1. Indications for Diagnostic Cone
Biopsy
Indication No. of patients (%)
Positive endocervical
curettage 34 (57)
Unsatisfactory
examination 22 (37)
Microinvasive cancer 2(3)
No lesion seen 1 (2)
Adenocarcinoma in
situ 1(2)
Total 60 (100)
flect the specimen from the path of 
the laser beam. Once the specimen 
was mobilized in a cylindrical fash­
ion, a long Allis clamp (Codman 
Surgical Inc., Randolph, Mass.) was 
applied to the cut edges of the 
specimen, carefully avoiding trauma 
to the surface epithelium. An Allis 
clamp can be applied without crush­
ing viable tissue, hence preserving 
the histologic definition of the spec­
imen. By placing this clamp under 
traction and occasionally torsion, a 
conical incision can be made across 
the base of the specimen with the 
laser beam. After removal of the 
specimen, the base of the area was 
treated with the laser at a power 
density of 960 watts/cm 2 to 
achieve complete hemostasis. In five 
women, excisional laser cone biopsy 
was performed in combination with 
ablation of visible disease beyond 
the excised margins.
After the procedure, the women 
were asked to remain in the unit for 
at least 1 hour for observation of 
any delayed vasovagal response or 
other complication. All were con­
tacted by telephone 1 week later as 
part of the follow-up. The proce­
dure was evaluated subjectively by 
asking the women if they would 
choose to have the procedure done 
again under local anesthesia as op­
posed to general anesthesia if it was 
necessary. They were reviewed in 
the clinic 1 month after the biopsy 
to ensure adequate healing of the 
cervix. Repeat cytologic and colpo­
scopic assessment was conducted 
after a 6-month interval.
Histologic review was completed 
on all phosphate-buffered, form­
alin-fixed specimens by staining 
with hematoxylin and eosin.
Results
Nine patients (15%) declined the 
offer of anxiolytic medication before 
the procedure and received no pre­
medication. Eighteen patients (30%) 
did not wish to receive any local 
anesthetic or paracervical block. 
Three of the 60 patients had the 
procedure completed by choice 
without any premedication or local 
anesthesia. They tolerated the pro­
cedure well.
The procedure was completed in 
all patients. Exact blood loss was 
not recorded but was minimal with 
the use of gauze swabs and the 
application of ferric subsulfate 
(Monsel’s) solution in all but two 
women. These two required the 
insertion of a Grafco vaginal tam­
pon (Graham-Field Inc., Haupp- 
auge, NY) as a vaginal pack, and 
this was removed the morning after 
the procedure. The time spent by 
the patient in the procedure room 
averaged 16.9 minutes (range from 
10 to 40 minutes). The patient who 
remained for 315 minutes did so 
because of transportation difficul­
ties rather than for medical reasons.
Fifty-one (85%) of the 60 women 
experienced no significant complica­
tions (Table III). Five women, all of 
whom had a paracervical block ad­
ministered, experienced cramping 
pain and required oral analgesics
Table II. Pathological Findings in 60 Patients Before Laser Cone Biopsy
Findings
Referral
cytology
Directed
biopsy Colposcopy
Benign atypia 7 1 1
CIN I 11 5 6
CIN II 17 24 24
CIN III 14 27 29
Negative 11 3 0
Total 60 60 60
CIN =  cervical intraepithelial neoplasia
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OUTPATIENT CONE BIOPSY
before being discharged. Three 
women experienced a vasovagal re­
sponse as evidenced by transient 
bradycardia and hypotension. One 
woman was admitted to hospital 4 
days after the procedure with a 
clinical diagnosis of pelvic inflam­
matory disease and required intrave­
nous antibiotic therapy. None of the 
women experienced bleeding that 
required a return visit to the clinic. 
Retrospectively, when questioned, 
three women (5%) stated that if 
they had to undergo the procedure 
again they would elect to have the 
procedure performed under general 
rather than local anesthesia.
The cervical cone biopsy was ade­
quate for histologic review in all 
patients. The average dimensions of 
the specimen were 20 X 16 X 10 
mm. The final pathological diagno­
sis is reported in Table IV. No cases 
of invasive cancer were detected in 
this group.
Comments
In this paper we have addressed 
the need to perform a cone biopsy 
of the cervix under general anesthe­
T ab le  I I I .  C o m p lic a tio n s  o f La se r Cone
B iopsy
C om plication No. of pa tien ts  (°/o)
None 51 (8 5 )
Pain 5 ( 8 )
V asovaga l re spo nse 3 ( 5 )
P e lv ic  in f la m m a to ry
d isease 1 ( 2 )
To ta l 60  (1 0 0 )
T ab le  IV. Final D ia g n o s is  o f  La se r C one 
B io p s y
Final diagnosis No. of p a tien ts  (% )
N o ev idence  o f
d ysp las ia 7 ( 1 2 )
Ben ign  a typ ia 2 ( 3 )
CIN I 1 6 (2 7 )
CIN II 4 ( 6 )
CIN III 30  (5 0 )
A d e n o ca rc in o m a  in
s itu 1 (2 )
Tota l 6 0  (1 0 0 )
sia in the hospital operating suite, a 
situation which results in greater 
patient morbidity and increased 
cost, because of the need for an 
anesthesiologist and an operating- 
room facility, compared with the 
use of local anesthesia in a clinic 
setting.
It has been clearly documented2-4 
that a cone biopsy .of the cervix can 
be performed with the carbon-diox­
ide laser with less morbidity than 
with a conventional scalpel. Compli­
cations that occur with reduced 
frequency when the laser is used 
include bleeding, both immediate 
and delayed, cervical stenosis and 
premature delivery. The ability to 
perform this procedure in an out­
patient setting has been reported 
previously,5 but in the majority of 
patients general anesthesia was 
used. In 1987, Indman6 reported on 
101 women who underwent laser 
conization of the cervix in an office 
setting with anaproxen sodium as 
premedication and a paracervical 
block using 0.5% bupivacaine hy­
drochloride. Indman recommended 
the use of vasopressin intraopera- 
tively.
Our report further documents the 
efficiency of this procedure in an 
outpatient setting, with local anes­
thesia and a modified technique. 
Three of our patients had a vasova­
gal response in the form of brady­
cardia and hypotension. In the re­
port by Indman6 transient hyperten­
sion associated with the use of 
bupivacaine and vasopressin was de­
scribed in two patients. Although 
the risk of cardiovascular complica­
tions appears to be low, it is recom­
mended that, if the procedure is to 
be done in an ambulatory setting 
without the presence of an anesthe­
siologist, the pulse rate should be 
monitored routinely and supplemen­
tal oxygen and Trendelenberg posi­
tioning should be available. In this 
series, without the use of vasopres­
sin or epinephrine, bleeding was not
a problem. Any loss of blood not 
controlled by the use of the laser 
beam at a diffused setting can usu­
ally be controlled by the use of 
topical ferric subsulfate solution.
Although the technique of diag­
nostic conization of the cervix can 
be accomplished in an ambulatory 
setting with local anesthesia alone, 
the technique must be acceptable to 
the patient. Recognizing the limita­
tions of retrospective questioning, 
we found that only 5% of the 
women would have elected to have 
the procedure repeated under gen­
eral anesthesia. We cannot com­
ment on the role of premedication 
with lorazepam because there is no 
control group for comparison. It 
would appear, however, that the 
role of the nurse or other medical 
attendant, as a distractor for the 
patient, is essential and may be of 
more value as an anxiolytic and 
analgesic than the medication used.
Laser conization appears to be an 
effective, well-tolerated technique 
that can be used in the ambulatory 
setting with only local anesthesia. 
The economic advantages are likely 
to be significant while delivering 
appropriate patient care with mini­
mal morbidity.
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VASOTEC
(enalapril maleate, Frosst Std.) 
Tablets 2.5, 5 ,10, 20 mg"VASOTEC
(enalaprilat)
1.25 mg/mL
Angiotensin Converting Enzyme Inhibitor
INDICATIONS AND CLINICAL USE
VASOTEC® is indicated in the trea tm ent of 
essential or renovascular hypertension; usually 
adm inistered in association with other drugs, 
particularly thiazide diuretics. Consider the risk of 
angioedema (see WARNINGS). Normally used 
when a diuretic or beta-blocker was ineffective or 
associated with unacceptable adverse effects. 
Can also be tried as initial agent where a diuretic 
and/or beta-blocker is contraindicated or could 
cause serious adverse effects.
Oral enalapril is also indicated in the treatment of 
congestive heart failure, as adjunctive therapy in 
patients not responding adequately to digitalis and 
diuretics.
Use of ACE inhibitors during the second and 
third trimesters of pregnancy can cause injury 
or death of a developing fetus. When pregnancy 
is detected, discontinue VASOTEC® as soon as 
possible (see WARNINGS; Use in Pregnancy).
VASOTEC® I.V. (enalaprilat) is an active meta­
bolite of enalapril; the onset of action after admin­
istration occurs within 15 minutes, with the maximum 
effect within 1 to 4 hours.
VASOTEC® I.V. is indicated for the treatment of 
hypertension when oral therapy is not practical. 
VASOTEC® I.V. has been studied with only one 
other antihypertensive agent, furosemide, which 
showed additive effects on blood pressure. Due to 
insufficient experience in the treatment of acceler­
ated or malignant hypertension, VASOTEC® I.V. is 
not recom m ended in such s itu a tio n s  (see 
DOSAGE and ADMINISTRATION).
CONTRAINDICATIONS
Hypersensitivity to any component; history of 
angioneurotic edema related to ACE inhibitor 
therapy.
WARNINGS
Angioedema, with laryngeal edema and/or shock, 
have been reported and may be fatal. In such 
cases, discontinue drug promptly and observe 
patient until swelling subsides. Swelling confined 
to the face, lips, and mouth usually resolves 
without treatment, although antihistamines may be 
useful in relieving symptoms. However, where 
there is involvement of the tongue, glottis and 
larynx, likely to cause airway obstruction, prompt 
administration of subcutaneous adrenaline (0.5 mL 
1:1000) may be indicated. Patients with a history of 
angioedema, unrelated to ACE inhibitor use, may 
be at increased risk (see CONTRAINDICATIONS). 
Symptomatic hypotension has occurred, usually 
during in itia l therapy or when the dose was 
increased, and is more likely in patients who are 
vo lum e-dep le ted . In p a tien ts  w ith  severe 
congestive heart failure, excessive hypotension 
may be associated w ith o ligu ria  and/or pro­
gressive azotemia. For patients in whom the 
excessive hypotension could result in severe or 
fa ta l com p lica tions, i.e . those  w ith  severe 
co n ges tive  heart fa ilu re , ischem ic  heart or 
cerebrovascular disease -  start therapy under 
close medical supervision, usually in a hospital. 
Such patients should be followed closely for the 
potential fall in blood pressure during first two 
weeks of therapy or when enalapril or a diuretic is 
increased. If hypotension occurs, place patient in 
supine position and if needed, adm inister IV 
infusion of normal saline. A transient hypotensive 
response is not a contraindication to further doses 
of enalapril or enalaprilat.
®Trademark Merck & Co., Inc.
Merck Frosst Canada Inc., R.U.
Neutropenia/agranulocytosis and bone marrow 
depression have been caused by ACE inhibitors. 
Current experience with enalapril shows incidence 
to be rare. Consider periodic monitoring of white 
blood cell counts in patients with collagen vascular 
disease and renal disease.
Use of ACE inhibitors in pregnancy can cause 
fetal and neonatal morbidity and mortality. When 
pregnancy is detected, discontinue VASOTEC® 
as soon as possible. Rarely, no alternatives to an 
ACE inhibitor will be found and mothers should be 
apprised to the potential hazards to the fetus. 
Ultrasound should be performed to assess fetal 
development, well-being and volume of amniotic 
fluid. If oligohydramnios is observed, discontinue 
VASOTEC® unless lifesaving for the mother. 
A non-stress test and/or a biophysical profiling 
may be appropriate however, if concerns persist, a 
contraction stress testing should be considered. 
Oligohydramnios may only appear after fetus has 
sustained irreversible injury.
Closely observe infants exposed in utero to ACE 
inhibitors for hypotension, oliguria and hyper­
ka lem ia , and in itia te  approp ria te  corrective 
medical procedures.
Human Data: Exposure to ACE inhibitors during 
second and third trimesters has been associated 
with hypotension, neonatal skull hypoplasia, 
anuria, reversible or irreversible renal failure and 
death of the fetus. Oligohydramnios, associated 
with fetal limb contractures, craniofacial defor­
mation, and hypoplastic lung development also 
has been reported. Prematurity and patent ductus 
arteriosus also reported but unknown if due to 
ACE inhibitor use. It is not known whether expo­
sure limited to the first trimester can adversely 
affect fetal outcome.
PRECAUTIONS
Impaired renal function: Renal function should 
be assessed before initiating therapy with enalapril 
or enalaprilat. Patients with renal insufficiency may 
require reduced or less frequent doses, and their 
renal function must be monitored appropriately (see 
DOSAGE). Renal failure, which has been reported 
mainly in patients with severe congestive heart failure 
or underlying renal disease including renal artery 
stenosis, is usually reversible when treated promptly. 
Some hypertensive patients with no apparent 
renal disease have developed increases in BUN 
and creatinine w hile on concurrent d iure tic / 
enalapril therapy. Dosage reduction or discontin­
uation of one or both drugs may be required. 
Hyperkalemia: In clinical trials, hyperkalemia 
(>5.7 mmol/L) was observed in approximately 1% 
of hypertensive patients, and caused discontin­
uation of therapy in 0.28% of such patients. Risk 
factors for hyperkalemia development may include 
renal insufficiency, diabetes mellitus, and con­
comitant use of agents to treat hypokalemia (see 
ADVERSE REACTIONS).
Valvular Stenosis: Theoretically, patients with 
aortic stenosis, who do not develop as much 
afterload reduction, might be at risk of decreased 
coronary perfusion when treated with vasodilators. 
Surgery/Anaesthesia: During major surgery or 
anaesthesia with hypotensive agents, enalapril 
blocks angiotensin II form ation secondary to 
compensatory renin release. Hypotension that 
develops due to this mechanism can be corrected 
by volume expansion.
Impaired liver function: Hepatitis, jaundice 
(hepatocellular and/or cholestatic),elevation of 
liver enzymes and/or serum bilirubin, which have 
occurred in patients with or without pre-existing 
liver abnormalities, were usually reversed on 
discontinuation of enalapril or enalaprilat. For any 
unexplained symptoms, particularly within the first 
months of treatment, a full set of liver function tests 
and other necessary investigations are recom­
mended. Consider discontinuation of enalapril or 
enalaprila t when approp ria te . Use enalapril 
or enalaprilat with particular caution in patients with 
pre-existing liver abnormalities. Obtain baseline 
liver function tests before in itia ting drug and 
monitor response and metabolic effects closely. 
Cough: A dry, persistent cough has been report­
ed, which usually disappears after withdrawal or 
lowering the dose of enalapril or enalaprilat. 
Nursing mothers: Enalapril and enalaprilat are 
secreted in human m ilk  in trace  am ounts 
therefore, nursing should be interrupted.
Pediatric use: This use is not recommended 
because enalapril and enalaprilat have not been 
studied in children.
Hemodialysis patients: Anaphylactoid reactions 
have been reported with high-flux membranes (eg.
polyacrylonitrile [PAN]) and treated concomitantly 
with an ACE inh ib itor. If sym ptom s such as 
nausea, abdominal cramps, burning, angioedema, 
shortness of breath and severe hypotension 
occur, stop dialysis immediately. The symptoms 
are not relieved by antihistamines and the use of a 
different type of dialysis membrane or class of 
antihypertensive agent should be considered. 
Drug Interactions
Hypotension - Patients on Diuretic Therapy:
Particularly when diuretics recently initiated, 
patients occasionally experience hypotension 
after initiating therapy with enalapril or enalaprilat. 
To minimize the hypotensive effects, discontinue 
the diuretic or increase the salt intake prior to 
starting the drug. If the diuretic cannot be dis­
continued, patients should be placed under close 
medical supervision for at least one hour after the 
initial dose of enalaprilat (see WARNINGS).
Agents Increasing Serum Potassium: Since 
enalapril and enalaprilat decrease aldosterone 
production, elevation of serum potassium may 
occur. D iu re tics  such as sp irono lac tone , 
triamterene or amiloride, or potassium supple­
ments should be given cautiously for documented 
hypokalem ia on ly and should be monitored 
frequently. Potassium containing salt substitutes 
should be used with caution.
Agents Causing Renin Release: Diuretics, for 
example, augment the antihypertensive effect of 
enalapril and enalaprilat.
Agents A ffecting  S ym pathetic  A ctiv ity :
Ganglionic blocking agents or adrenergic neuron 
blocking agents, for example, may be used with 
caution. Beta-adrenergic blockers add some 
further antihypertensive effect to enalapril.
Lithium  S alts : L ith ium  c lea rance  may be 
reduced; therefore, monitor serum lithium levels 
carefully if they are administered.
ADVERSE REACTIONS
VASOTEC®: In controlled clinical trials involving 
2314 hypertensive patients and 363 heart failure 
patients, the most severe adverse reactions were: 
angioedema (0.2%), hypotension (2.3%) and renal 
fa ilu re  (5 cases). In hypertens ive  patients, 
hypotension occurred in 0.9% and syncope in 
0.5%, with a discontinuation rate of 0.1%. In heart 
failure patients, hypotension occurred in 4.4% and 
syncope in 0.8%, with a discontinuation rate of 
2.5%. The most frequent clinical adverse reactions 
in controlled clinical trials were: headache (4.8%), 
dizziness (4.6%) and fatigue (2.8%). Discontin­
uation of therapy was required in 6.0% of the 
2677 patients.
Hypertension Heart Failure 
% %
(2314 Patients) (363 Patients)
CARDIOVASCULAR
Hypotension 0.9 4.4
Chest Pain 0.9 1.7
Palpitations 
Myocardial Infarction,
0.6 0.3
Acute
Myocardial Infarction, 
Recurrent
GASTROINTESTINAL
0.2 0.6
— 0.3
Nausea 1.4 1.1
Vomiting 0.8 1.7
Dysphagia 0.1 —
Diarrhea 1.4 3.0
Abdominal pain 
RENAL
0.7 1.4
Renal failure 0.1 0.6
Oliguria 1 case
Proteinuriat 0.1 —
DERMATOLOGIC
Rash 1.4 1.9
Pruritus 0.4 1.4
NERVOUS SYSTEM
Headache 5.2 2.2
Dizziness 4.3 6.6
Insomnia 0.5 0.3
Nervousness 0.6 __
Somnolence 0.6 __
Paresthesia 0.6 —
ALLERGIC
Cough 1.3 1.4
Angioedema 0.2 —
HEMATOLOGIC
Anemia 0.1 __
Leukopenia
MISCELLANEOUS
1 case —
Muscle cramps 0.6 0.3
Dyspnea 0.6 1.1
Hyperhidrosis 0.7 —
Impotence 0.4 0.3
Fatigue 3.0 1.4
Taste disturbance 0.4 0.3
t  Defined as >1g/24h or >0.5g/12h on two conse^  
measurements, at least one month apart.
ABNORMAL LABORATORY FINDINGS
Hyperkalemia: (see PRECAUTIONS).
Creatinine, Blood Urea Nitrogen: Increases were 
reported in about 20% of patients with renovascular 
hypertension and about 0.2% of patients with 
essential hypertension on enalapril alone. In­
creases, which usually were reversible upon 
discontinuation of enalapril or concomitant therapy, 
were reported in 9.7% of heart failure patients who 
were receiving diuretics and/or digitalis.
Hemoglobin and Hematocrit: Decreases (mean 
approximately 0.34 g% and 1.0 vol%, respectively) 
occurred frequently, but were rarely of clinical 
importance. In clinical trials, less than 0.1% of 
patients discontinued therapy due to anemia.
Hepatic: Elevations of liver enzymes and/or serum 
bilirubin have occurred (see PRECAUTIONS).
ADVERSE REACTIONS REPORTED IN UN­
CONTROLLED TRIALS AND/OR MARKETING 
EXPERIENCE
With an incidence of 0.5 to 1%: Insomnia, im­
potence, renal dysfunction, renal failure and 
oliguria.
With an incidence < 0.5%:
Cardiovascular: Myocardial infarction or 
cerebrovascular accident, possibly secondary to 
excessive hypotension in high risk patients (see 
WARNINGS); cardiac arrest; pulmonary em­
bolism; rhythm disturbances; angina pectoris. 
Gastrointestinal: Anorexia; ileus; pancreatitis; 
dyspepsia; constipation. Hemopoeitic: Neutro­
penia; thrombocytopenia; bone marrow depres­
sion. Hepatic: Liver function abnormalities; 
hepatitis; jaundice (hepatocellular and/or 
cholestatic). Nervous System/Psychiatric: Vertigo; 
depression; confusion; ataxia. Respiratory: 
Bronchospasm/asthma; rhinorrhea. Other: Ery­
thema multiforme; exfoliative dermatitis; Stevens- 
Johnson syndrome; toxic epidermal necrosis; 
urticaria; photosensitivity; alopecia; flushing; tin­
nitus; hearing impairment; glossitis; blurred vision. 
A symptom complex has been reported which may 
include fever, serositis, vasculitis, myalgia, 
arthraigia/arthritis, a positive ANA, elevated 
erythrocyte sedimentation rate, eosinophilia and 
leukocytosis. Rash, photosensitivity or other 
dermatologic manifestations may occur. These 
symptoms have disappeared after discontinuation 
of therapy.
LABORATORY TEST FINDINGS: Hyponatremia
VASOTEC® I.V.: Since enalapril is converted to 
enalaprilat, those adverse reactions associated 
with VASOTEC® tablets might also be expected to 
occur with VASOTEC® I.V. The incidence of symp­
tomatic hypotension is 3.4% with VASOTEC® I.V. 
Other adverse experiences occurring in greater 
than 1% of patients were headache (2.9%) and 
nausea (1.1%). Adverse reactions occurring in 0.5 
to 1.0% of patients in controlled clinical trials 
include myocardial infarct, fatigue, dizziness, 
fever, rash and constipation.
SYMPTOMS AND TREATMENT 
OF OVERDOSAGE
Limited human data are available. The most likely 
manifestation of overdosage would be hypo­
tension, which can be treated by I.V. infusion of 
normal saline solution. Enalaprilat may be 
removed from the general circulation by 
hemodialysis.
DOSAGE AND ADMINISTRATION
VASOTEC®
FOR ORAL ADMINISTRATION ONLY
Dosage must be individualized. The absorption of 
enalapril maleate is not affected by food.
HYPERTENSION
Initiation of enalapril requires consideration of 
extent of blood pressure elevation, salt restriction 
and recently used antihypertensive agents, the 
dosage of which may need to be adjusted.
The recommended initial dose of enalapril maleate 
in patients not on diuretics is 5 mg once a day. 
Adjust dosage according to blood pressure 
response; the usual range is 10 to 40 mg daily, in 
a single dose or divided in two doses. Some 
patients on once-daily dosage may have 
diminished antihypertensive effect toward the end 
of dosing interval and require an increase in 
dosage, or twice daily administration. If blood 
pressure is not controlled, a diuretic may be 
added. Raising the daily dose above 40 mg is not 
recommended because adverse reactions may be 
increased.
Occasionally symptomatic hypotension may occur 
following the initial dose, more likely in patients 
currently taking a diuretic. Therefore, if possible, 
discontinue the diuretic two to three days before 
initiating enalapril therapy (see WARNINGS). If 
the diuretic cannot be discontinued, use an initial 
dose of 2.5 mg.
In the absence of sufficient experience in the 
treatment of accelerated or malignant hyper­
tension, enalapril is not recommended in such 
situations.
Dosage in the Elderly (over 65 years): Start at 
2.5 mg daily. Some elderly patients may be more 
responsive than younger patients.
Dosage Adjustment in Renal Impairment: (see 
PRECAUTIONS - Hemodialysis patients)
Guidelines for reducing doses in hypertensive 
patients:
Renal Status
Creatinine
Clearance
mL/min(mL/s)
Initial Dose 
mg/day
Normal renal >80 mL/min 5 mg
function (>1.33 mL/s)
Mild impairment <80 >30 mL/min 
(<1.33 >0.50 mL/s)
5 mg
Moderate to <30 mL/min 2.5 mg
severe impairment (<0.50 mL/s)
Dialysis patients — 2.5 mg on 
dialysis days*
* Enalaprilat is dialysable. Dosage on nondialysis days 
should be adjusted depending on the blood pressure 
response.
CONGESTIVE HEART FAILURE
Use in conjunction with a diuretic and digitalis. 
Initiate therapy under close medical supervision, 
usually in a hospital. Monitor blood pressure and 
renal function before and during treatment with 
enalapril, because severe hypotension, and more 
rarely, consequent renal failure have been 
reported (see WARNINGS and PRECAUTIONS). 
When initiating enalapril consider the recent 
diuretic therapy and possibility of severe salt/ 
volume depletion. Before beginning enalapril 
reduce diuretic therapy if possible.
The recommended initial daily dose is 2.5 mg. 
While managing symptomatic hypotension, 
increase dose gradually, depending on individual 
response, to the usual maintenance dose of 10- 
20 mg daily, given in a single dose or divided in 
two doses. This dose titration may be performed 
over a two- to four-week period, or more rapidly if 
indicated by residual signs and symptoms of heart 
failure. The maximum daily dose is 40 mg.
VASOTEC® I.V. FOR INTRAVENOUS 
ADMINISTRATION ONLY
VASOTEC® I.V. vials should be inspected visually 
and should not be used if particulate matter or 
discoloration is observed.
VASOTEC® I.V. may be administered in tra ­
venously as supplied, or mixed with up to 50 mL of 
one of the following diluents:
5% Dextrose Injection
0.9% Sodium Chloride Injection
0.9% Sodium Chloride Injection in 5% Dextrose
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Disseminated Leiomyomatosis 
Peritonealis: Report of a Case 
in a Postmenopausal Woman
Gia-Khanh Nguyen, MD
Disseminated leiomyomatosis peritonealis (DLP) is a rare condition that to date has 
been reported only in premenopausal women. The author reports a case of DPL 
occurring in a postmenopausal woman who had undergone total hysterectomy 30 
years before and had received no hormonal therapy subsequently. The lesions were 
multiple and consisted of smooth-muscle cells that proliferated from medium-sized 
blood vessels. The author concludes that the patient’s lesions likely represent a 
histologic variant of DLP.
La leiomyomatose peritoneale disseminee (LPD) est une affection rare qui n’a ete 
signalee, a ce jour, que chez la femme en premenopause. L’auteur decrit un cas de 
LPD survenant chez une femme en periode postmenopausique qui avait subi une 
hysterectomie totale 30 ans plus tot et n’avait pas refu d’hormonotherapie 
subsequente. Les lesions etaient multiples et etaient constitutes de cellules de 
muscle lisse qui proliferaient a partir de vaisseaux sanguins de taille moyenne. 
L’auteur conclut que les lesions retrouvees chez cette patiente represented 
vraisemblablement une variante histologique de la LPD.
D isseminated leiomyomatosis pe­ritonealis (DLP) is an infre­
quently reported lesion. About 30 
cases have been documented.1"8 It 
has been found exclusively in 
women during their childbearing 
years. Most cases were detected 
incidentally at cesarean section.1-7 
DLP lesions in women taking con­
traceptive steroids and in women 
who were not on contraceptive pills 
have also been reported.5 One pa­
tient with an ovarian granulosa-cell 
tumour was found to have DLP at 
laparotomy.81 report a case of DLP 
incidentally found at laparotomy in 
a postmenopausal woman.
Case Report
A 63-year-old white woman, para 
5 gravida 5, was admitted to the 
University of Alberta Hospitals for 
an elective cholecystectomy for 
cholelithiasis. Her medical history 
included a total abdominal hysterec­
tomy performed at 30 years of age 
for a benign endometrial lesion as­
sociated with persistent vaginal 
bleeding. No peritoneal lesions were 
noted during that operation. She 
had mild hypertension controlled by 
hydrochlorothiazide and a low-salt 
diet. She had not been on hormonal 
therapy since her hysterectomy.
At laparotomy, several sub- 
peritoneal round nodules of brown­
ish tissue, ranging from 0.5 to 3 cm 
in diameter, were found attached to 
the parietal peritoneum and the 
antimesenteric borders of both 
small and large intestine. They cov­
ered about 7% of the peritoneal 
surface. A few small nodules were 
present under the pelvic serosa. 
Frozen-section examination of a 
large peritoneal nodule gave a his­
tologic diagnosis of neurofibroma. 
The patient underwent an explora­
tion of the common bile duct and a 
cholecystectomy. Her postoperative 
course was smooth, and she was 
discharged from the hospital 10 
days later. She is currently well 
with no evidence of malignant dis­
ease, 10 years after her cholecystec­
tomy.
Pathological Examination
The largest fragment of peritone­
al nodules was ovoid and measured 
3 X 3 X 2  cm. It was firm, and its 
cut surface was glassy white with 
no hemorrhagic necrosis. Five tis­
sue blocks, 1 mm3 of fresh tissue, 
were fixed in 4% buffered glutaral- 
dehyde and processed according to 
the routine techniques for transmis­
sion electron microscopic (EM) 
study. Several tissue blocks were 
fixed in formalin and processed for 
light microscopic examination. Tis­
sue sections 5 /am thick were 
stained with hematoxylin and eosin, 
Masson’s trichrome and reticulin 
stains.
From the Department o f  Laboratory Medicine and Pathology, Walter C. Mackenzie Health 
Sciences Centre, University o f  Alberta, Edmonton, Alta.
Accepted for publication Feb. 17, 1992
Reprint requests to: Dr. Gia-Khanh Nguyen. Division o f  Anatomical Pathology, Walter C. 
Mackenzie Health Sciences Centre, Edmonton, AB T6C 2B7
46 JCC. VOL. 36, N ° 1, FEVRIER 1993
DISSEMINATED LEIOMYOMATOSIS PERITONEALIS
FIG. 1. Peritoneal lesion shows prolif­
eration of smooth-muscle cells radiat­
ing from media of muscular blood 
vessel (hematoxylin-eosin, original 
magnification X 100).
Light Microscopic Findings
The submitted lesions were sub- 
peritoneal round nodules consisting 
of bundles of spindle-shaped cells 
with a considerable amount of colla­
gen tissue and numerous muscular 
blood vessels of different size and 
variable mural thickness. Many of 
them appeared to be arteriolar in 
type. Radiating from the media of 
these vessels were spindle-shaped 
smooth-muscle cells with cigar­
shaped nuclei (Fig. 1). They encir­
cled the vessels and spread away in 
the mass lesion in an irregular 
pattern. Less than one normal mi­
totic figure was noted per 10 high- 
power fields. No nerve trunks were 
identified. Reticulin fibres and thin 
bundles of collagen fibres were seen 
scattered between smooth-muscle 
cells. The histologic findings sug­
gested that the lesions represented 
angiomyomatosis.
Ultrastructural Findings
Ultrathin sections of the lesion 
confirmed a spindle-cell lesion that 
was rich in blood vessels. The spin­
dle-cell component consisted of ma­
ture smooth-muscle cells with abun­
dant intracytoplasmic bundles of 
microfilaments with focal densities 
(Fig. 2). Pinocytotic vesicles were 
noted along the cell membrane, 
which was often surrounded by in­
complete basal lamina. These cells 
appeared to be derived from the 
media of adjacent small blood ves­
sels. The supporting stroma con­
tained delicate bundles of collagen 
fibres and occasional fibroblasts 
with irregular and indented nuclei 
and abundant intracytoplasmic
FIG. 2. Proliferated mature smooth-muscle cells show irregular and elongated nuclei, intracytoplasmic bundles of microfilaments 
with focal densities (arrow), membranous pinocytotic vesicles (arrow heads) and incomplete basal lamina. Collagen fibres can be 
seen in interstitial spaces (uranyl acetate and lead citrate stains, original magnification X 16 000).
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rough endoplasmic reticula. No 
nerve axons or cells with digitating 
cytoplasmic processes were identi­
fied, nor were there cells with the 
features of a myofibroblast. The EM 
findings suggested a smooth-mus­
cle lesion of vascular origin.
Discussion
The peritoneal lesions in this pa­
tient were highly unusual. They 
clearly arose from the media of the 
subperitoneal arterioles. Their his­
tologic features were in keeping 
with those of an angiomyoma, 
which has not been described in the 
literature, although solitary angi­
omyoma is a common tumour of 
the subcutis, accounting for 25% to 
50% of all superficial leiomyomas.9 
Our patient’s peritoneal lesions 
were different from those of infan­
tile myofibromatosis (IM), peritone­
al leiomyosarcoma and benign me­
tastasizing leiomyoma of the uterus 
in several aspects.
In patients with IM, the lesions 
can be solitary or multicentric with 
visceral involvement.10 In about 
89% of patients with IM the condi­
tion is diagnosed during the first 2 
years of life. Histologically, the le­
sions are composed of short curving 
bundles of spindle-shaped cells and 
collagen tissue extending in a fin­
gerlike fashion into the surround­
ing tissue with a hemangio­
pericytoma-like pattern at the cen­
tre.10 Histochemical and EM studies 
suggest that the constituent cells 
are myofibroblasts. The lesions in 
IM have a tendency to regress, and 
they may be hamartomatous in na­
ture as suggested earlier by Shnit- 
ka, Asp and Horner,11 Bartlett, Otis 
and Laasko12 and Beatty.13 Lei­
omyosarcoma involving the perito­
neum is characterized by nodules of 
smooth-muscle cells with marked 
cellular atypia and a high mitotic
index.1 The benign metastasizing 
leiomyoma generally presents as 
one or more pulmonary nodules. 
When leiomyosarcoma occurs in 
the pelvis, the metastatic nodules 
tend to locate near the round liga­
ments of the uterus and iliac veins.1
Lesions of DLP are seen in 
women during their childbearing 
ages. They usually regress after 
pregnancy but may persist.5 These 
findings indicate that estrogen and 
progesterone do play an important 
role in the pathogenesis of DLP. 
The experimental work of Fujii and 
associates14 on guinea pigs also 
supports this hypothesis. Micro­
scopically, DLP is characterized by 
numerous subperitoneal nodules of 
spindle cells consisting of smooth- 
muscle cells, a mixture of smooth- 
muscle cells and myofibroblasts or 
altered smooth-muscle cells and fi­
broblasts. These cells are seen ar­
ranged in fascicles orientated in 
irregular or perpendicular patterns 
similar to those of the common 
uterine leiomyoma.1-8 No lesions re­
ported were found arising from 
smooth-muscle cells of the media of 
blood vessels.13-8 However, in one 
report, the lesions appeared to orig­
inate from a muscular blood vessel. 
The DLP lesions are most likely 
formed by fibroblastic replacement 
of subperitoneal decidua in preg­
nant women.56 They seem to arise 
from an abnormal metaplastic 
change of submesothelial stem cells 
in nonpregnant patients whose 
ovarian hormonal levels can be nor­
mal or elevated.45 It is most likely 
that this patient's peritoneal lesions 
represent a histologic variant of 
DLP. The abundance of collagen 
fibres might indicate that the le­
sions formed a long time before 
they were incidentally found at lap­
arotomy for cholecystectomy. They 
might have formed years or months 
after the patient’s previous total 
abdominal hysterectomy in 1948 
and persisted.
I thank Dr. H. Kiltz of Athabasca, Alta., 
for clinical information on the patient 
and Ms. S. Todd of the Department of 
Pathology, University of Alberta for 
preparing the manuscript.
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Spontaneous Rupture of the Spleen 
in Patients With Infectious Mononucleosis
Jameel Ali, MD, FRCSC, FACS
The author describes two cases of spontaneous splenic rupture .occurring with 
infectious mononucleosis in young, previously healthy patients. The reports 
illustrate the variable clinical presentation — from sudden, fatal hemorrhage to 
bleeding that stops spontaneously. Although conservative nonoperative treatment 
may be successful in carefully selected cases, laparotomy with splenectomy appears 
to be the safest therapeutic approach.
When a nonoperative approach is selected, the patient should be observed in a 
critical-care facility with immediate access to an operating room. Normal activity 
should not be resumed until the spleen has returned to its normal size as 
demonstrated by computed tomography or ultrasonography.
L’auteur decrit deux cas de rupture spontanee de la rate survenant en cours de 
mononucleose infectieuse chez des patients jeunes, prealablement en bonne sante. 
Les deux cas illustrent l’etendue du tableau clinique allant de l’hemorragie soudaine 
et fatale, au saignement qui s’arrete spontanement. Meme si un traitement 
conservateur, non chirugical, peut suffire dans certains cas choisis, la laparotomie 
avec splenectomie parait etre l’abord therapeutique le plus sur.
Si une approche non chirurgicale est choisie, le malade devrait etre garde dans un 
service de soins intensifs ayant un acces immediat au bloc operatoire. Les activites 
normales ne devraient etre reprises qu’une fois la rate revenue a sa taille normale, 
verifiee par la tomographie par ordinateur ou l’echographie.
I nfectious mononucleosis is a common disorder, particularly 
among young, previously healthy 
individuals. Although splenomegaly 
is reported in approximately half of 
these patients,1'2 the disease usually 
runs a benign course without un­
toward long-term sequelae. Howev­
er, it has been reported3 that 0.5% 
of these patients, who present with 
abdominal pain, suffer spontaneous 
splenic rupture, which is associated 
with a high death rate. Therefore, 
physicians should be acutely aware 
of the possibility of spontaneous 
splenic rupture in infectious mono­
nucleosis. Even when the diagnosis
is made there is controversy con­
cerning the management and out­
come.4'5
We present two cases of sponta­
neous rupture of the spleen in pre­
viously healthy young individuals, 
in whom the presentation, manage­
ment and outcome were quite differ­
ent.
Case Reports
Case 1
An 18-year-old girl had been 
healthy until she experienced a sore
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throat and mild fever with some 
cervical lymphadenopathy. She was 
seen by her family physician who 
treated her with erythromycin for 
what appeared to be pharyngitis 
due to Streptococcus. She was ad­
vised to stay in bed until the fever 
subsided. Four days later, approxi­
mately 12 hours before being ad­
mitted to hospital, she experienced 
increasing pain in the abdomen and 
felt dizzy on getting out of bed. 
There was no history of recent 
trauma. She fainted during one epi­
sode of dizziness. Approximately 6 
hours later she was found to be 
unresponsive, so she was admitted 
to hospital. At Sunnybrook Health 
Science Centre there was electrical 
cardiac activity but no palpable 
spontaneous peripheral pulse. Ex­
ternal cardiopulmonary resuscita­
tion was applied. Large-bore intra­
venous lines were established with 
administration of emergency blood. 
The abdomen was quite distended.
At emergency laparotomy, there 
was gross blood throughout the 
peritoneal cavity. A bleeding spleen 
was delivered into the wound and 
quickly removed by clamping the 
hilum of the spleen. Hemostasis 
was then established and fluid infu­
sion continued in the operating 
room. At the termination of the 
operation the patient’s vital signs 
had stabilized. Her blood pressure 
was 110/70 mm Hg and her heart 
rate was 110 beats/min, but her 
pupils remained fixed and dilated 
and her core temperature was re­
corded as 32°C. Upon closure of 
the abdomen diffuse bleeding was 
noted in the wound and the patient
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was given fresh frozen plasma and 
platelets. She also received 10 units 
of packed cells in the operating 
room for resuscitation.
She was transferred to the inten­
sive care unit where her neurologic 
status did not improve. Signs of 
disseminated intravascular coagula­
tion developed with persistent pro­
longation of the prothrombin (more 
than 30 seconds) and partial throm­
boplastin (150 seconds) times and a 
depression of her platelet count. 
She continued to have bright red 
bloody drainage from her peritoneal 
drains. In our opinion the hypo- 
coagulable state resulted from the 
hypothermia. Her hypocoagulabi- 
lity was relatively resistant to plate­
lets, plasma, cryoprecipitate and 
l-deamino-8-D-arginine vasopressin 
(DDAVP). Subsequently, severe res­
piratory failure, necessitating the 
administration of 100% oxygen, and 
high positive end-expiratory pres­
sures (up to 20 cm H20) developed, 
with demonstration of florid pulmo­
nary edema consistent with acute 
respiratory distress syndrome. 
Acute renal failure gradually devel­
oped, and, because of the continu­
ing hemorrhage from her peritoneal 
drains, the possibility of mechanical 
bleeding in the abdomen was con­
sidered. She was returned to the 
operating room, and her abdomen 
was re-explored. The ligatures in 
the splenic hilum and other areas of 
the abdomen were intact, and no 
mechanical source of bleeding was 
identified. After 72 hours of normo- 
thermia and correction of her coag­
ulation defect there was still no 
improvement in her neurologic sta­
tus. Acute renal failure developed 
with continuing deterioration of her 
respiratory status. Primarily be­
cause of her persistent deep coma 
with no brain stem reflexes after 
normothermia further aggressive 
therapy was discontinued and the 
patient died.
At autopsy there was still consid­
erable blood in the peritoneal cavi­
ty. The enlarged spleen, which 
weighed 350 g, was examined 
grossly and histologically. There 
was evidence of denudation of the 
capsule in the area of the hilum 
(Fig. 1). Histologic examination of 
the spleen demonstrated findings 
consistent with infectious mononu­
cleosis. From a blood sample taken 
at the time of admission the latex 
agglutination test gave a positive 
result for infectious mononucleosis.
Case 2
A 29-year-old man, who was oth­
erwise healthy and athletic, present­
ed to the emergency department of 
Sunnybrook Health Science Centre 
6 hours after experiencing abdomi­
nal pain and faintness. He gave a 
history of malaise and sore throat 
for 7 days for which penicillin had 
been prescribed. He denied any his­
tory of trauma or unusual exertion.
His blood pressure was 110/70 
mm Hg, his pulse rate was 70 
beats/min and regular and his 
chest was clear. Abdominal exami­
nation revealed diffuse tenderness. 
The hemoglobin level was 129 g/L  
and the leukocyte count was 14.5 
X 109/L  with a lymphocytosis 
(lymphocyte count 7.2 X 109/L  
[normal 1 to 4 X 109/L]). After 2 L 
of fluids were administered over 
approximately 6 hours his hemoglo­
bin level was 109 g/L . The pre­
sumptive diagnosis was a perforated 
viscus, but upright chest films and 
an upper gastrointestinal series 
with Gastrografin contrast medium 
gave negative results, and ul­
trasonography demonstrated free 
intraperitoneal fluid raising the pos­
sibility of a lacerated spleen.
Because the patient was relatively 
stable and his pain had occurred 
approximately 6 hours previously, 
he was taken to the critical care 
unit where his blood pressure was 
measured frequently and his cardiac
status was monitored. It was decid­
ed to treat him conservatively for a 
ruptured spleen. A latex agglutina­
tion test gave a positive result for 
infectious mononucleosis.
A smear of a peripheral blood 
sample showed abnormal lympho­
cytes consistent with infectious 
mononucleosis. Computed tomogra­
phy (CT) of the abdomen demon­
strated a laceration through the 
spleen, which appeared to have tri­
pled in size compared with the size 
of a normal spleen on CT scans 
(Fig. 2). The patient remained sta­
ble over the next 5 days with no 
further deterioration in his vital 
signs or drop in hemoglobin level. 
He was then transferred out of the 
critical care unit and slowly mobi­
lized. Upon discharge from hospital 
7 days after admission, he was 
taking iron orally and had specific 
instructions not to be involved in 
any vigorous activity and to return 
to the hospital immediately if ab­
dominal pain or dizziness recurred.
At follow-up 8 weeks later his 
hemoglobin level and leukocyte 
count were normal (153 g/L  and 
4.9 X 109/L  respectively). Upon 
repeat CT of the abdomen 12 weeks 
after his admission the size of the 
spleen had decreased to normal and 
the laceration had healed. The pa­
tient was advised to avoid vigorous 
sports and body contact sports for 
at least 3 months and to report any 
abdominal pain immediately.
FIG. 1. Case 1. Gross appearance of 
spleen showing denudation of capsule 
and large splenic laceration.
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Discussion
These two cases demonstrate 
that spontaneous rupture of the 
spleen can occur in association with 
infectious mononucleosis and that 
the course is variable and may in­
clude a fatal outcome.
Several authors4 have cautioned 
against conservative management 
of a ruptured spleen associated with 
infectious mononucleosis because 
of a higher death rate than in 
traumatic rupture of the spleen. 
However, our case 2 demonstrates 
that conservative management and 
close observation can be successful.
The mechanism of splenic rup­
ture in infectious mononucleosis is 
not completely understood. Spleno­
megaly appears to be a common 
accompaniment of splenic rupture 
in this disorder.1'2 Edema, increase 
in cell size and lifting of the splenic 
capsule would suggest that stretch­
ing of the capsule may result in 
spontaneous hemorrhage. Intense 
inflammatory reaction and vasculitis 
may also contribute. As seen in 
both these cases the splenomegaly 
can occur very rapidly in infectious 
mononucleosis in contrast to other 
causes of splenomegaly, and this
may predispose to splenic rupture. 
However, a history of trauma usual­
ly precedes splenic rupture in sple­
nomegaly from other causes. It has 
beeen claimed that splenic rupture 
is unlikely during the first 2 weeks 
of infectious mononucleosis.6 How­
ever, our two cases have demon­
strated that rupture can occur with­
in 1 week. Although spontaneous 
rupture of the spleen is rare, it is 
the most common cause of death in 
patients with infectious mononucle­
osis.7
The timing of return to normal 
activities remains unclear. As in our 
case 2, it seems reasonable to re­
strict activity until the spleen has 
returned to normal size. Recom­
mendations for return to sports 
activities in athletes vary from 3 
weeks to 6 months after clinical 
resolution of the illness.3'8'9 A rea­
sonable recommendation is that vig­
orous activity should not be re­
sumed until the spleen has returned 
to normal size as determined by 
imaging techniques.
Because of the usually benign 
course and the ubiquitous nature of 
infectious mononucleosis, compla­
cency may exist among many physi­
cians. However, splenic rupture in
infectious mononucleosis is a seri­
ous complication, and precautions 
should be taken once the diagnosis 
is made to avoid vigorous sports 
activity. The patient should be alert­
ed to the possibility of spontaneous 
rupture of the spleen. Any signifi­
cant abdominal pain should prompt 
further investigation and medical 
supervision of care. Shoulder tip 
pain or any signs of severe abdomi­
nal pain require CT or ultrasonog­
raphy for evaluation of the abdo­
men. Splenomegaly, even in the 
absence of a fall in hemoglobin, 
calls for bed rest for the patient and 
close observation. As with traumat­
ic splenic rupture conservative man­
agement requires close observation 
in an intensive care setting, so that 
emergency laparotomy can be car­
ried out if there is any deterioration 
of the patient’s condition.
All criteria for spontaneous sple­
nic rupture in infectious mononu­
cleosis as outlined by Rutkow7 were 
met in our case 1. In case 2, 
although the spleen could not be 
evaluated histologically, all other 
criteria were met.
It has been estimated that spon­
taneous rupture of the spleen oc­
curs in 0.5% of cases of infectious 
mononucleosis,3 and the death rate 
for splenic rupture has been report­
ed to be as high as 30%.8 In 
Rutkow’s report7 all patients sur­
vived when splenic rupture was rec­
ognized and treated early. This em­
phasizes the need for rapid diagno­
sis and treatment.
The argument for surgical re­
moval is that the risks associated 
with blood transfusion for ongoing 
hemorrhage are of similar magni­
tude to those of sepsis following 
splenectomy and that the abnormal 
spleen seen at operation may also 
be more prone to rupture later.9 
However, as seen in case 2, these 
spleens do return to normal size. If 
a period of observation and conser­
vative management is considered,
FIG. 2. Case 2. Computed tomography scan of abdomen demonstrating spleno­
megaly, large laceration of spleen and intraperitoneal blood.
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the patient should be under close 
supervision until the spleen returns 
to normal size.
A case of sudden death due to 
spontaneous splenic rupture in in­
fectious mononucleosis, as in case 
1, has also been reported previous­
ly.10 This suggests that the magni­
tude of the hemorrhage from sple­
nic rupture can vary from simple 
small subcapsular hematomas to ex­
sanguinating hemorrhage. Where 
critical care facilities for close ob­
servation and immediate surgery are 
not available, splenectomy appears 
to be the safest treatment.11
In case 2 nonoperative manage­
ment was prompted by the fact that 
the symptoms were present for at 
least 6 hours before the patient 
presented to the emergency depart­
ment with stable vital signs. Had 
this patient presented with hemody­
namic instability or signs of contin­
uing hemorrhage the decision to 
operate would have been easier. 
The patient was also fully informed 
of the risk of nonoperative manage­
ment as well as the risk of blood 
transfusions. It was decided that if 
blood transfusions became neces­
sary to maintain hemodynamic sta­
bility in this patient then operative 
intervention would be the course of 
action.
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SESAP VII Critique /  Critique SESAP VII
Item 360
Pulmonary complications after operation are a leading cause of morbidity and mortality. The site of surgical 
incision has a pronounced effect on the development of postoperative respiratory complications. Thoracic and 
upper abdominal operations are associated with the highest risk.
Diaphragmatic function is markedly altered after upper abdominal operation. Abdominal pain, inflammation, 
and local irritation are believed to be responsible for the decrease in lung volumes found postoperatively. 
Intercostal nerve blockade is helpful in decreasing patient discomfort, but has not produced the expected 
beneficial effect on lung volumes after midline incisions.
Patients with chronic obstructive pulmonary disease are at high risk for postoperative pulmonary 
complications because of decreased maximum expiratory flow rates that make them unable to produce an 
adequate cough. Without treatment, 60% of these patients develop a pulmonary complication. Preoperative 
bronchodilators, antibiotics, and physiotherapy decrease the postoperative complication rate to 22%.
The lower limit of FEVj below which patients should not be given general anesthesia has not been clearly 
defined. Patients at risk should be studied with preoperative pulmonary function tests. An FEV] less than 65% of 
the predicted value indicates significant disease, and preoperative preparation is warranted prior to abdominal 
operation. The decrease in vital capacity postoperatively is not related to the specific anesthetic agent used.
0
Reference
3 6 0 /1 .  Gass GD, Olsen GN: Preoperative pulmonary function testing to predict postoperative morbidity and 
mortality. Chest 89: 1 2 7 -1 3 5 , 1986
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Sulfhydryl-Containing Agents 
in the Treatment of Gastric Bleeding 
Induced by Nonsteroidal 
Anti-inflammatory Drugs
Aws S. Salim, PhD(Surg), FRCS(Edin), FRCS(Glasg), FICS, FCICD
In a double-blind study involving 172 patients, the author investigated the effect of 
sulfhydryl-containing agents (cysteine and methylmethionine sulfonium chloride 
[MMSC]) on hematemesis resulting from erosive gastritis induced by nonsteroidal 
anti-inflammatory drugs.
The 56 patients who received cysteine (200 mg orally four times a day) and the 59 
patients who received MMSC (500 mg orally four times a day) were significantly 
(p < 0.01) more hemodynamically stable, with no rebleeding, than the 57 patients 
who made up a control group. Endoscopy carried out 48 hours after admission 
demonstrated that gastric erosions were still present in a significantly (p < 0.01) 
higher number of patients in the control group (20 [35%]) than in patients receiving 
cysteine (6 [11%]) and in patients receiving MMSC (7 [12%]).
Eighteen patients (32%) in the control group required blood transfusion because 
of continued bleeding or rebleeding compared with only 3 patients (5%) receiving 
cysteine and 2 patients (3%) receiving MMSC (p < 0.01). Emergency surgery was 
necessary in 13 patients (23%) in the control group and in 1 patient (2%) in the 
group receiving cysteine who had rebleeding. Four patients in the control group 
died postoperatively.
The results show that sulfhydryl-containing agents stimulate the healing of 
erosive gastritis induced by nonsteroidal anti-inflammatory drugs and protect 
against the complications of bleeding produced by the gastritis.
Dans cette etude a double insu impliquant 172 patients, on a etudie l’effet de 
composes ayant des groupements sulfhydryles (cysteine et chlorure de 
methylmethionine sulfonium [CMMS]) sur l’hematemese resultant de la gastrite 
erosive provoquee par les anti-inflammatoires non steroidiens.
Les 56 patients qui regurent la cysteine (200 mg, quatre fois par jour, par voie 
orale) et les 59 patients qui regurent le CMMS (500 mg, quatre fois par jour, par 
voie orale) se sont averes significativement plus stables (p < 0,01) au plan 
hemodynamique, puisqu'ils n’eurent aucune recidive hemorragique, que les 57 
patients qui formaient le groupe temoin. L’endoscopie pratiquee 48 heures apres 
l’entree a l’hopital a revele des erosions gastriques encore presentes chez un 
nombre significativement plus eleve (p < 0,01) de patients du groupe temoin (20 
[35 %]) que chez ceux qui avaient regu la cysteine (6 [11 %]) ou le CMMS (7 [12 %]).
Dix-huit patients (32 %) du groupe temoin necessiterent des transfusions a cause 
d'une persistance ou d’une recidive des saignements, comparativement a seulement 
3 patients (5 %) du groupe cysteine et 2 (3 %) du groupe CMMS (p < 0,01). line 
intervention chirurgicale d’urgence fut requise chez 13 patients (23 %) du groupe 
temoin et 1 patient (2 %) du goupe cysteine qui eprouverent une rechute 
hemorragique. Quatre patients du groupe temoin sont decedes en postoperatoire.
Ces resultats demontrent que les composes possedant des groupements 
sulfhydryles stimulent la guerison de la gastrite erosive provoquee par les 
anti-inflammatoires non steroidiens et protegent des complications des saignements 
causes par la gastrite.
Some nonsteroidal anti-inflam­matory drugs (NSAIDs), such 
as acetylsalicylic acid or indome- 
thacin, irritate the gastrointestinal 
mucosa, causing bleeding or ulcer­
ation, or both.1'2 The irritation 
ranges in severity from a few small 
acute ulcers to erosive gastritis, in 
which the entire gastric mucosa is 
inflamed and studded with erosions. 
The latter condition may produce 
life-threatening bleeding that re­
quires surgical intervention. The 
death rate associated with such in­
tervention is at least 30%.3'4
Sulfhydryl-containing agents, 
such as DL-cysteine and methyl­
methionine sulfonium chloride 
(MMSC), have been shown, in the 
rat,5 to convey gastric mucosal cy- 
toprotection by sustaining the phy­
sicochemical properties of the mu­
cosal barrier, thus affording protec­
tion against injury from ischemia or 
noxious substances. Sulfhydryls 
bind the oxygen-derived free radi­
cals that mediate tissue damage.6-7 
These radicals were recently shown 
to be directly implicated in gas­
troduodenal ulceration, and scav­
enging them protects against ulcer­
ation by maintaining mucosal integ-
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rity in the face of deleterious 
agents.8-10 Sulfhydryl-containing 
agents make an essential contribu­
tion to protein synthesis,11 and the 
repair of tissue loss requires large 
quantities of sulfur-containing 
amino acids.11 The gastrointestinal 
mucosa is highly anabolic and will 
rapidly incorporate these amino 
acids, which will then donate sulfur 
for the sulfation of the acid muco­
polysaccharides of gastrointestinal 
mucin as well as for the synthesis 
of mucosal and mesenchymal tis­
sues.11 Furthermore, it has been 
reported that sulfhydryls stimulate 
the release of gastric mucin glyco­
proteins in rats.7 Zalewsky and 
Moody12 noted that mucus cells on 
the surface and in gastric pits con­
tained a highly sulfated mucin, and 
Starkey, Snary and Allen13 demon­
strated that the gel structure of 
gastric mucin depends on disulfide 
bridges. These actions suggest that 
sulfhydryl-containing agents may 
promote the repair of breaches of 
the gastrointestinal mucosa and, 
thus, maintain the integrity of this 
mucosa and enhance its ability to 
withstand forces tending to injure 
it.
Since the possibility exists that 
sulfhydryl-containing agents might 
be beneficial in the treatment of 
NSAIDs-induced upper gastrointes­
tinal bleeding, the present study 
was undertaken. It covered the peri­
od October 1978 to December 
1980.
Patients and Methods
Sulfhydryl-containing Agents
A 4% solution of DL-cysteine and 
a 10% solution of MMSC (Sigma 
Chemical Co., St. Louis, Mo.) were 
prepared in double-distilled water 
and placed in 300 mL dark glass 
bottles. The double-distilled water 
was given to the control patients.
Study Design
The study was prospective, ran­
domized, double blinded and con­
trolled. It was conducted on con­
secutive patients with rheumatoid 
arthritis or osteoarthritis who pre­
sented with hematemesis caused by 
NSAIDs-induced gastric erosions. 
Patients were randomized by draw­
ing sealed envelopes.
Treatment was begun immediate­
ly after the diagnosis was made. A 
patient was judged suitable for the 
study when all of the following 
applied: hematemesis started within 
2 hours of presentation; the patient 
had received no treatment; there 
were no clinical signs of shock or 
any apparent hemodynamic distur­
bance (pulse rate less than 
100/min, systolic blood pressure 
more than 100 mm Hg, hemoglobin 
level more than 10 g/dL, packed 
red cell volume in men more than 
0.4 and in women more than 0.37). 
Exclusion criteria included any of 
the following: erosions extending 
beyond the stomach; previous 
upper gastrointestinal hemorrhage; 
a history of dyspepsia; bleeding di­
athesis or any hematologic disorder; 
well-established causes for the de­
velopment of stress-induced acute 
gastric mucosal injury (trauma, sur­
gery, burns, shock or sepsis); treat­
ment with any gastrointestinal ulcer 
healing agent during the 4 weeks 
before presentation; hiatus hernia; 
esophageal erosions or ulcers; coex­
istent or previously noted gastric or 
duodenal ulceration; a visible vessel, 
a spurting vessel or a clot adherent 
to a vessel seen during endoscopy; 
previous anti-ulcer surgery; the use 
during the month preceding the 
bleeding episode of corticosteroids, 
antineoplastic agents, antimalarial 
agents, gold preparations, multiple 
NSAIDs, anticholinergic agents, 
phenothiazines or tetracyclines; the 
presence of significant symptoms 
from other gastrointestinal disor­
ders that would make it difficult to 
evaluate efficacy and safety of the 
trial drugs (e.g., severe irritable 
bowel syndrome); cardiorespiratory 
problems; hepatic or renal disor­
ders; pregnancy or alcoholism.
NSAIDs-induced erosive gastritis 
was diagnosed when at endoscopic 
examination, with the patient sedat­
ed, most of the gastric mucosa 
showed hemorrhagic inflammation 
studded with erosions (breaches of 
the mucosa regardless of their 
shape, size, site or number).
When patients with hematemesis 
were judged suitable for the study, 
a complete history was obtained, 
followed by physical examination. 
After a complete fast the patients 
were admitted to the hospital and 
hydrated intravenously. Endoscopy 
was undertaken within 6 hours of 
admission. After erosive gastritis 
was diagnosed, patients were ran­
domized to one of the study groups 
and allowed free fluids and milk 
(the intravenous line was discon­
nected soon after these were taken). 
Standard hematologic and biochem­
ical measurements were made, and 
urinalysis was performed and re­
peated daily until patients were dis­
charged home or until complica­
tions developed. Plain abdominal 
radiography was always undertaken 
to exclude visceral perforation. Pa­
tients whose condition remained 
stable with no further hematemesis 
were examined by endoscopy again 
48 hours after the start of treat­
ment (preceded by a complete fast 
for 3 hours) to study the integrity 
of the gastric mucosa. These pa­
tients were then allowed solid food, 
and if that was well tolerated for 24 
hours, the treatment was with­
drawn, and they were discharged 
home. Resumption of the NSAIDs 
was not permitted until a week 
later.
A central venous line was insert­
ed when clinical signs of shock or 
hemodynamic disturbance devel-
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oped, or when rebleeding occurred. 
Restoration of the circulating blood 
volume was attained by blood trans­
fusion, and the effectiveness of re­
suscitation was determined by clini­
cal observations and monitoring of 
central venous pressure.
The decision to abandon conser­
vative management and to under­
take emergency surgery — vago­
tomy and antrectomy with under- 
running of any obviously bleeding 
points — was based on the follow­
ing criteria: for patients older than 
60 years — four units of blood 
required within 24 hours or one 
episode of rebleeding; for patients 
60 years of age or younger — eight 
units of blood required in 24 hours 
or two episodes of rebleeding dur­
ing the same admission.
The compliance of patients with 
their regimen and any adverse reac­
tions to this regimen that they 
experienced were carefully moni­
tored on special charts.
The end point for this study, 
when the treatment code was bro­
ken, was when patients were dis­
charged home or when they re­
quired insertion of a central venous 
line.
Ethical Considerations
This investigation was approved 
by the Ethical Committee on 
Human Experimentation at the hos­
pital, and every patient gave written 
informed consent.
Study Groups
Two hundred and thirteen con­
secutive patients who presented 
with hematemesis caused by 
NSAIDs-induced erosive gastritis 
were randomized. In the first group, 
patients were given 5 mL of double- 
distilled water orally every 6 hours. 
In the second group, patients were 
given 5 mL of 4% cysteine (200 mg) 
orally every 6 hours. In the third
group, patients were given 5 mL 
of 10% MMSC (500 mg) orally 
every 6 hours. All patients were 
given the same volumes of solu­
tions and they were treated for 3 
days unless their condition deterio­
rated.
Statistical Analysis
A sample size of 150 patients was 
initially chosen, with 50 patients in 
each group. On the basis of a 
two-tailed Ltest, such a size will 
detect a significant difference of 
30% between active and placebo 
therapy (p < 0.05) with a probabi­
lity of 80% for the overall sample. 
Because of the anticipated problems 
of nonevaluability of some patients, 
which could weaken any conclusion 
drawn, the aim was to enter approx­
imately 70 patients in each group. 
The differences detectable within 
any subgroup are considerably larg­
er than 30%.
Results are expressed as percent­
ages or the mean value. The x 2 test 
with Yates’ correction was used to 
determine statistical significance 
(p < 0.05) of observed differences 
in the percentage incidence between 
the groups, and the Mann-Whitney 
“U-statistic” test for nonparametric 
data was used to establish the sta­
tistical significance of observed dif­
ferences in mean values among the 
study groups.
Life-table analyses with Mantel- 
Cox (log rank) and Breslow general­
ized Wilcoxon’s statistics were used 
to evaluate the statistical differ­
ences in the results of treatment 
between the groups. Pair-wise 
comparisons were made between 
groups with or without sulfhydryl- 
containing agents. Cox proportion­
al hazards models were then 
used to investigate the effect of 
these agents on the outcome of 
treatment when account was taken 
of the other patient factors as co­
variants.
Exclusion o f Patients From Efficacy 
Analysis
Patients were excluded from the 
efficacy analysis on the basis of the 
following rules, which were rigidly 
applied: adverse reaction to the 
therapeutic regimen; intolerance of 
the therapeutic regimen; failure to 
comply with the regimen; the use of 
any form of medication, other than 
the trial regimen, to avoid therapeu­
tic activities of unknown origin.
The decision to exclude patients 
from the efficacy analysis was un­
dertaken before breaking the treat­
ment code. Additional intention-to- 
treat analyses were performed rein­
cluding such patients and using 
various theoretically possible out­
comes to examine what influence 
their exclusion had on the conclu­
sions reached.
Results
Patient Characteristics
Seventy-two patients (45 women 
and 27 men) with an age range of 
28 to 74 years (mean 57 years) 
were randomized to the control 
group. Seventy patients (38 women 
and 32 men) with an age range of 
25 to 71 years (mean 55 years) 
were randomized to the cysteine 
group. Seventy-one patients (43 
women and 28 men) with an age 
range of 27 to 76 years (mean 59 
years) were randomized to the 
MMSC group. These patients were 
randomized from a total of 391 
patients seen during the study peri­
od. Fifteen patients in the control 
group, 14 patients in the cysteine 
group and 12 patients in the MMSC 
group were excluded (Table I). The 
characteristics of the remaining pa­
tients were similar with respect to 
numbers, age range, sex ratio, num­
ber of smokers and social drinkers 
(Table II). None of the patients were
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heavy consumers of alcohol, but all 
drank coffee every day. The daily 
coffee intake and amount of smok­
ing (all cigarettes) were comparable 
among the groups. Thirteen women 
in the control group, 15 women in 
the cysteine group and 11 women 
in the MMSC group had used the 
contraceptive pill at some time in 
their lives.
Comparison Between the Groups 
No significant differences were
noted among the three groups with 
respect to the indication for 
NSAIDs, the type of NSAIDs used 
or the duration of therapy (Table 
ID.
Approximately 10% of patients in 
each of the groups given sulfhydryl- 
containing agents experienced ad­
verse effects. These were mostly 
headache, nausea, dyspepsia and 
abdominal pain. They were suffi­
ciently troublesome, however, to 
lead to withdrawal of medication in 
four patients receiving cysteine and
in two patients receiving MMSC. 
Three patients in the cysteine group 
and two patients in the MMSC 
group were intolerant of their regi­
men (Table I). There were no obvi­
ous treatment-related changes in 
hematologic or biochemical values.
Clinical Progress
Thirty-nine patients (68%) in the 
control group remained stable 48 
hours after admission and had no 
further hematemesis or signs of 
continued blood loss. The number 
of patients in the cysteine group 
(53 [95%]) and MMSC group (57 
[97%]) achieving the same outcome 
was significantly (p < 0.01) higher. 
The second endoscopic examination 
demonstrated signs of hemorrhagic 
inflammation in every stomach in­
spected; however, erosions were 
present in a significantly (p < 0.01) 
higher number of controls relative 
to the cysteine (6 [11%]) and MMSC 
(7 [12%]) groups. The clinical prog­
ress of these patients continued, 
and they were all discharged home 
after 3 days of hospitalization. It 
follows that the number of patients 
tolerating solid food and then 
allowed home was significantly 
(p < 0.01) larger in the cysteine 
and MMSC groups than in the con­
trol group (Table III).
Eighteen controls (32%) required 
blood transfusion because of contin­
ued blood loss (8 patients [14%]) or 
an episode of rebleeding (10 pa­
tients [18%]). Two patients (4%) 
taking cysteine required blood be­
cause of continued hemorrhage, 
and another patient in the same 
group (2%) required blood because 
of an episode of rebleeding. In the 
MMSC group, two patients (3%) 
required blood transfusion for con­
tinued bleeding. Emergency surgery 
was necessary in six control pa­
tients (11%) who continued to lose 
blood, in seven control patients 
(12%) who had an episode of re-
T a b le  1. Patients in Study Groups and Reasons for Exclusion
Group
Inc lus ion /exclu sion Control C ysteine M M S C *
No. patients entered 
No. available for
72 70 71
complete assessment 57 56 59
No. excluded 
Excluded because of:
15 14 12
Drug intolerance 0 3 2
Adverse effects 0 4 2
Prohibited drugs used 3 1 2
Noncompliance 12 6 6
'Methylmethionine sulfonium chloride
T a b le  II .  Patient Characteristics
Group
Control C ysteine M M SC
C h arac te ris tics ( n  =  5 7 ) (n  =  56 ) (n =  59 )
Age, yr
Range 2 8 -7 1 2 7 - 6 9 2 9 -7 5
Mean 56 59 57
Sex
Men 22 24 23
Women 35 32 36
Smokers 
Social drinkers,
27 24 30
<  14 units/wkf 
Indication for NSAIDsf
22 25 27
Rheumatoid arthritis 32 35 30
Osteoarthritis 
Duration of NSAIDs
25 21 29
therapy, mo
<  3 41 47 44
3 - 1 2 9 5 8
> 12 7 4 7
NSAIDs used
Diclofenac 22 19 24
Piroxicam 11 14 16
Mefenamic acid 10 9 11
Naproxen 7 8 4
Ibuprofen 6 4 4
Other 1 2 0
tOne unit =  284 mL of beer, 100 mL of wine or 40 mL of liquor
JNonsteroidal anti-inflammatory drugs
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bleeding and in the only patient in 
the cysteine group (2%) who had 
rebleeding. Four control patients 
died postoperatively (one of cardiac 
arrest and three of bronchopneumo­
nia) giving an operative death rate 
of 31% and an overall group death 
rate of 7%.
A series of Cox proportional haz­
ards models was fitted using, as 
covariates, all factors other than 
treatment with the sulfhydryl-con- 
taining agents to obtain a group of 
patients and conditions that inde­
pendently and significantly influ­
enced recovery from the bleeding 
episode. Treatments with cysteine 
and MMSC were then added as 
separate covariates. Age over 60 
years, an episode of rebleeding dur­
ing the same admission, transfusion 
of blood, continued bleeding after 
hospitalization and shock all had a 
significantly (p < 0.001) detrimen­
tal effect upon the recovery rate. 
When these and all the other non­
significant variables were allowed 
for, treatment with cysteine or 
MMSC continued to exert a signifi­
cantly beneficial effect upon recov­
ery from the hemorrhagic episode 
(p < 0.01).
Intention-to-treat analyses were 
performed to determine what might 
have happened if all patients had 
been evaluable. This required postu­
lating that some patients would
have remained stable and experi­
enced no rebleeding or continued 
blood loss whereas others would 
have had further rebleeding or con­
tinued blood loss at various times.
When all the excluded patients 
were assumed to have remained 
stable after admission to the hospi­
tal and had no further blood loss or 
rebleeding or wlien they were as­
sumed to have deteriorated, treat­
ment with cysteine or MMSC con­
tinued to afford a significant thera­
peutic advantage (p < 0.01) in 
terms of the numbers of patients 
remaining stable and their complete 
recovery from the bleeding episode. 
This advantage, however, was lost 
when only the patients excluded 
from the control group were as­
sumed to have remained stable and 
to have made a full recovery where­
as all those excluded from the other 
groups were assumed to have dete­
riorated because of rebleeding or 
continued blood loss.
Discussion
NSAIDs can produce damaging 
effects on the gastric and duodenal 
mucosa, ranging from acute gastric 
mucosal injury to perforation of 
peptic ulceration.1-3 The incidence 
of this injury is approximately 30% 
and may increase to 51% in patients
taking multiple NSAIDs.2 Inhibition 
of cyclo-oxygenase by NSAIDs 
leads to inhibition of prostaglandin 
synthesis, an action that can initiate 
the development of acute gastric 
mucosal injury.14 Prevention of 
prostaglandin synthesis depresses 
gastric mucosal blood flow and bi­
carbonate secretion, reduces mucus 
production and causes atrophy of 
the gastric epithelium.15 Thus, the 
mucosal defensive properties are 
impaired, allowing gastric acid to 
attack and injure the mucosa.1516
This investigation demonstrates 
that sulfhydryl-containing agents 
stimulate the healing of acute gas­
tric mucosal injury produced by 
NSAIDs and protect against the 
complications of the hemorrhagic 
episode caused by such injury (Ta­
ble III). Continued hemorrhage and 
rebleeding are among the complica­
tions and are particularly serious 
because they may necessitate emer­
gency surgery, which is associated 
with a death rate of up to 30%. The 
similarity in efficacy between cys­
teine and MMSC and the fact that 
the latter is converted via the trans- 
sulfuration pathway to cysteine11 
suggest that the actions of the 
sulfhydryl-containing agents used 
were provided by cysteine.
Adverse effects, whether mild or 
sufficiently troublesome to lead to 
withdrawal, occurred in small num­
bers of patients (Table I), and there 
were no obvious treatment-related 
changes in hematologic or biochem­
ical values. These findings illustrate 
the safety of cysteine and MMSC. It 
would be an advantage if their daily 
doses could be reduced without 
compromising efficacy.
The compliance of patients with 
the regimen was carefully moni­
tored, and any violation led to ex­
clusion of the patient (Table I). 
Compliance was similar among the 
groups, so the results cannot be 
ascribed to differences in patient 
compliance or to an unintended bias
Table I I I .  C lin ica l C ou rse  o f P a tien ts
Clinical course
Control 
(n =  57)
Group, no. (% )
Cysteine 
(n =  56)
MMSC 
(fl =  59)
C o n d itio n  s tab le  a fte r 48  h 39  (6 8 ) 5 3  (95 ) 57 (9 7 )
S econd  endosco p y
H e m o rrha g ic  in f la m m a tio n 39  (6 8 ) 5 3  (95 ) 57 (9 7 )
E ros ions 2 0  (3 5 ) 6 ( 1 1 ) 7 ( 1 2 )
B lood  tra n s fu s io n  fo r:
C on tinued  b lood  lo ss 8 ( 1 4 ) 2 ( 4 ) 2 ( 3 )
R eb leed ing 1 0 (1 8 ) 1 ( 2 ) 0
S urge ry  fo r:
C o n tinued  b lood  loss 6 (1 1 ) 0 0
R eb leed ing 7 (1 2 ) 1 ( 2 ) 0
R e turn  to  so lid  fo o d
a fte r 48  h 3 9  (68 ) 5 3  (9 5 ) 57 (9 7 )
D ischa rge  a fte r 3 d 3 9  (68 ) 5 3  (95 ) 57 (9 7 )
CJS. VOL. 36, NO. 1, FEBRUARY 1993 57
SALIM
in favour of a particular group, 
which may influence compliance.
Although sulfhydryl-containing 
agents can be detected on the 
breath, this was never raised by any 
patient as a significant source of 
inconvenience. Furthermore, it 
could not be seen as a source of 
bias in favour of any of the study 
groups, since the primary parame­
ters of assessment were objective 
(Table III).
I am grateful to Dr. S.H. Alwash for the 
opportunity to undertake this work at 
the Medical City and to the nursing 
staff for their help during the course of 
the investigation. 1 am also grateful to 
Mrs. Jutta Gaskill and to Mrs. Moira 
Cairney for secretarial work.
References
1. P emberton RE, Strand LJ: A review of 
upper gastrointestinal effects of the 
newer nonsteroidal anti-inflammatory 
agents. Dig Dis Sci 1979; 24: 53-64
2. B ijlsma JWJ: Treatment of NSAID- 
induced gastrointestinal lesions with 
cimetidine: an international multicentre 
collaborative study. Aliment Pharmacol 
Ther 1988; 2S: 85-96
3. Raimes SA, Venables CW: Acute upper 
gastrointestinal bleeding. Hosp Update 
1987; 13: 669-684
4. S nyman JH, W heatley KE, Keichley
MRB: Management of non-variceal
upper gastrointestinal bleeding. Hosp 
Update 1990; 16: 40 2 -4 1 7
5. Salim AS: Gastric mucosal cytoprotec- 
tion in the rat by cysteine. J Pharm 
Pharmacol 1987; 39: 553-555
6. Szabo S, Trier JS, Frankel PW: Sulf- 
hydryl compounds may mediate gastric 
cytoprotection. Science 1981; 214: 
200-202
7. Lamont JT, Ventola AS, Maull EA et 
al: Cysteamine and prostaglandin F2/3 
stimulate rat gastric mucin release. Gas­
troenterology 1983; 84: 306-313
8. S alim AS: Role of oxygen-derived free 
radicals in the mechanism of chronic 
gastric ulceration in the rat. Implica­
tions for cytoprotection. Digestion 
1989; 43: 113-119
9. Idem: Role of oxygen-derived free radi­
cals in mechanism of acute and chronic 
duodenal ulceration in the rat. Dig Dis 
Sci 1990; 35: 73-79
10. Idem: The significance of removing oxy­
gen-derived free radicals in the treat­
ment of acute and chronic duodenal
ulceration in the rat. J Pharm Phar­
macol 1990; 42: 64-67
11. T urner FP, Brum VC, B ilodeau EG: 
Incorporation of 355 L-methionine by 
the rat with steroid ulceration. J Maine 
Med Assoc 1977; 68: 227-243
12. Zalewsky CA, Moody FG: Mechanisms 
of mucus release in exposed canine 
gastric mucosa. Gastroenterology 1979: 
77: 719-729
13. S tarkey BJ, S nary D, Allen A: Charac­
terization of gastric mucoproteins isolat­
ed by equilibrium density-gradient cen­
trifugation in caesium chloride. Biochem
NOTICES
AVIS
Lake Tahoe Annual Vascular 
Conference
The course entitled “Strategies in Vas­
cular Disease: Minimizing the Morbidity 
in Diagnosis and Treatment” will be 
offered at the Lake Tahoe Annual Vas­
cular Conference to be held from Mar. 
15 to 17. 1993. at the Resort at Squaw 
Creek in Olympic Village, Squaw Val­
ley. Calif. The conference is sponsored 
by the Office of Continuing Medical 
Education, UC Davis School of Medi­
cine and Medical Center. The course is 
designed for surgeons and radiologists 
who deal with the complexities and 
challenges of peripheral vascular dis­
ease. For information contact: Office of 
Continuing Medical Education, UC 
Davis Medical Center, 2701 Stockton 
Blvd., Sacramento, CA 95817; phone: 
(916)734-5390
Symposium VIII on Operating 
Room Environment
This symposium will be held from May 
3 to 5, 1993, at the Stouffer Harbor- 
place Hotel in Baltimore. The sympo­
sium is presented by the American 
College of Surgeons in cooperation 
with the American Society of Anesthesi­
ologists and the Association of Operat­
ing Room nurses. Five separate infor­
mation sessions will be presented on 
timely operating-room topics of ethical 
conflicts in patient care, leadership, 
environmental hazards, operating-room 
efficiency and technology assessment.
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J 1974; 141:633-639
14. Hogan D, T homas F, Isenberc J: A 
single dose of cimetidine prevents As­
pirin-induced gastric damage in man. 
Dig Dis Sci 1986; 31 (suppl): 481S
15. Hawkey CJ, Ramptom DS: Prostagland­
ins and the gastrointestinal mucosa: Are 
they important in its function, disease, 
or treatment? Gastroenterology 1985; 
89:1162-1188
16. B ennett A. Collins P, T avares I: 
Human gastric mucosal damage by anti­
inflammatory drugs. Dig Dis Sci 1986; 
31 (suppl): 483S
For more information contact: Ameri­
can College of Surgeons, Committee on 
Operating Room Environment, 55 E 
Erie St., Chicago. IL 60611-2797; 
phone: (312) 664-4050, ext. 250 or 
361.
Progress in Gastrointestinal 
Surgery
A course entitled "Progress in Gastroin­
testinal Surgery” will be presented as 
the major topic of the 57th Annual 
Surgery Course, to be held from June 
16 to 19, 1993, at the University of 
Minnesota. The course is presented by 
the Department of Surgery of the Uni­
versity of Minnesota Medical School. 
For more information contact: Office of 
Continuing Medical Education, Univer­
sity of Minnesota, Radisson Hotel Met- 
rodome, Suite 107, 615 Washington 
Ave. SE, Minneapolis, MN 55414; 
phone: 1-800-776-8636; fax: (612) 
626-7766
International Surgical Week
The 35th World Congress of Surgery of 
the International Society of Surgery 
with its integrated societies presents 
International Surgical Week from Aug. 
22 to 27, 1993, in Hong Kong. For 
more information contact: Congress 
Secretariat, 1SW Hong Kong, Depart­
ment of Surgery, University of Hong 
Kong, Queen Mary Hospital, Hong 
Kong; phone: (852) 819-2235; fax: 
(852)855-1897.
ORIGINAL ARTICLES
Hematuria and Intravenous Pyelography 
in Pediatric Blunt Renal Trauma
Paul F. Middlebrook, MD, FRCSC;* John F. Schillinger, MD, FRCSCt
Because the traditional protocol for investigating blunt renal trauma in children has 
been questioned and because of societal awareness of health care costs, the authors 
carried out a retrospective review of blunt renal trauma in 138 children over a 
5-year period to establish criteria for urgent radiologic investigation of those with 
suspected renal trauma. From their findings, they recommend that in the absence of 
the suspected major injuries and hypotension a threshold count of 40 red blood cells 
per high-power field is necessary before urgent intravenous pyelography should be 
done.
Vu la remise en question du protocole traditionnel d'investigation des traumatismes 
renaux fermes chez l’enfant et la conscientisation du public a l’augmentation des 
frais de sante, les auteurs ont mene une etude retrospective portant sur 138 enfants 
victimes de traumatismes renaux fermes au cours d’une periode 5 ans, afin d’etablir 
les criteres commandant l’examen radiologique d’urgence de ceux soup^onnes de 
traumatismes renaux. Des resultats obtenus, ils recommandent qu’en l’absence de 
lesions importantes et d’hypotension, un seuil de 40 hematies par champ 
microscopique a fort grossissement soit necessaire avant de pratiquer une 
pyelographie intraveineuse d’urgence.
A lthough hematuria is widely recognized as an indicator of 
potential urinary tract injury in 
trauma, controversy persists over 
the necessity of investigation in all 
patients having hematuria after 
blunt trauma and about the urgen­
cy with which such investigation 
should be performed. This contro­
versy is further compounded by the 
fact that current management for 
most blunt renal injuries is conser­
vative, so imaging results lead to 
few changes in management. The 
traditional method of investigating
these patients has been with intra­
venous pyelography (IVP), although 
enhanced computed tomography 
(CT) is routinely used in many cen­
tres.
The majority of patients with 
blunt renal trauma have minor renal 
involvement. Traditionally, children 
have a greater propensity to pedicle 
injuries with minimal hematuria. 
Further, the incidence of congenital 
anomalies in children is higher than 
in adults, which may account for 
renal injury with minor trauma. 
Complicating this, is the incidence
on routine analysis of microscopic 
hematuria in children with no mor­
bid condition. Hitherto, we have 
investigated urgently all children 
with significant abdominal trauma 
who have hematuria. Recent arti­
cles questioning this approach plus 
a societal awareness of health care 
costs led to a retrospective appraisal 
of this approach.
Method
The standard management of 
blunt trauma patients with either 
gross or microscopic hematuria by 
the urology service at the Chil­
dren’s Hospital of Eastern Ontario, 
Ottawa, has been urgent imaging 
with IVP unless other suspected 
injuries warrant alternative initial 
procedures (e.g., CT). Patients with 
normal findings on IVP have been 
assumed to have minor renal contu­
sions and have been managed with 
bedrest in hospital until their urine 
is clear. Major renal injuries have 
been managed with bedrest for at 
least 10 days and ambulation only 
after the urine is clear and further 
imaging indicates some resolution 
of the local lesion. The records of 
all patients with a diagnosis of renal 
trauma (including contusion, lacera­
tion, fracture and pedicle injury) 
seen at our institution between Jan­
uary 1986 and December 1990 
were reviewed. For each patient, the 
following data were collected: age, 
sex, mechanism of injury, present­
ing blood pressure, severity of he­
maturia, result of initial imaging, 
final diagnosis, associated injuries, 
blood transfusion requirements and
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length of hospitalization. Note was 
also made of adverse reactions to 
the radiocontrast agent used in im­
aging these patients. For purposes 
of analysis, renal injuries diagnosed 
as contusions (including those with 
no identifiable lesion on imaging) 
were classified as minor. Major inju­
ries consisted of renal lacerations, 
fractures and pedicle injuries. He­
maturia was quantified as follows: 
gross, greater than 40 red blood 
cells per high-power field (rbc/hpf), 
20 to 40 rbc/hpf and less than 20 
rbc/hpf. A patient was considered 
to be hypotensive if the first record­
ed systolic blood pressure was 
below 100 mm Hg. Associated inju­
ries were considered major if they, 
independently, would require hospi­
talization beyond 24 hours. The 
severity of renal injury was correlat­
ed with the severity of hematuria, 
the presence of hypotension, the 
presence of associated major inju­
ries, the mechanism of injury, the 
duration of hospitalization and the 
need for blood transfusion.
shock, underwent immediate lapa­
rotomy. IVP successfully identified 
all major renal injuries among the 
children who underwent this inves­
tigation.
A number of significant non-renal 
abdominal injuries were also detect­
ed (Table III), most of which were 
identified by IVP. The exceptions 
were three splenic contusions, one 
hepatic contusion and one hema­
toma in the gastrosplenic ligament. 
These were identified by ul­
trasonography or CT.
FIG. 1. Age range of 138 children with blunt renal trauma.
Findings
The records of 138 children (104 
boys, 34 girls) were reviewed. No 
child in the study had sustained 
penetrating renal trauma. The chil­
dren ranged in age from 2 to 17 
years (Fig. 1), with a trend toward 
the early to middle teenage years. 
Falls and traffic accidents were the 
most common mechanisms of injury 
(Table I). Only 12 children sus­
tained major renal injuries.
In itia l Im aging Investigations
IVP was the initial investigation 
in 121 children, ultrasonography in 
12 children and CT in 3 (Table II). 
Two children did not undergo initial 
diagnostic imaging: one had mini­
mal microscopic hematuria: the oth­
er, who was admitted in profound
Table 1. Mechanisms of Injury
No. of patients
Minor renal Major renal
Mechanism injury injury Total
Fall 47 7 54
Traffic accident 46 4 50
Sports 21 0 21
Blow 12 1 13
Total 126 12 138
Table II. Results of Initial Diagnostic Investigation*
No. of patients
Result
Intravenous
pyelography Ultrasonography
Computed
tomography Total
Normal 80 7 0 87
Contusion 32 4 2 38
Laceration 6 1 1 8
Fracture 3 0 0 3
Pedicle injury 0 0 0 0
Total 121 12 3 136
*No imaging in two patients: one had minimal microscopic hematuria; the other was admitted in 
profound shock with massive hemorrhage and underwent emergency laparotomy.
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Severity of Hematuria
The severity of hematuria corre­
lated with the presence of major 
renal injuries (Table IV). For those 
whose urinalysis results were re­
corded, no child with fewer than 40 
rbc/hpf in the urine had a major 
renal injury. One had an isolated 
major renal injury with micro­
hematuria (> 40 rbc/hpf) alone. 
This represents a positive predictive 
value of 21% for gross hematuria 
and 12% if all hematuria greater 
than 40 rbc/hpf is considered. The 
child admitted in profound shock 
with massive intra-abdominal inju­
ries who underwent immediate lapa­
rotomy had no urine obtained for 
analysis. This was the only patient 
in the series who required laparoto­
my.
Congenital Renal Anomalies
Congenital renal anomalies were 
noted in four patients. Two had a 
duplex collecting system, which had 
previously been diagnosed in one
child. One horseshoe kidney and 
one ureterocele were also identified. 
None of these patients sustained 
major renal injuries.
Hospital Stay
The mean hospital stay for those 
with minor renal injuries was 5.0 
days (range of 0-to 14 days). The 
longer hospitalizations were due to 
associated nonrenal injuries. How­
ever, the mean hospital stay for the 
nine children with major renal inju­
ries who were discharged was 18.5 
days (range from 10 to 30 days).
Nonrenal Injuries
Forty-four major nonrenal inju­
ries were sustained by 33 patients 
(Table III). Six (18%) of the 33 
patients had major renal injuries 
compared with 12 (8.7%) of 138 
patients in the total study popula­
tion who had renal injuries.
Hypotension was seen in 12 pa­
tients, only 2 of whom had major 
renal injury. (Both had coexisting
major nonrenal injuries.) Thus, only 
2 (17%) of the 12 patients sustain­
ing major renal injury had hypoten­
sion.
Other Considerations
Seven patients required blood 
transfusion in the form of packed 
red blood cells. Of these, five had 
sustained major renal injuries. In 
most of these cases, associated inju­
ries were responsible for the blood 
loss, but one patient had an isolated 
major renal injury requiring trans­
fusion. Four patients suffered com­
plications directly related to their 
renal injuries or to investigation for 
these injuries. Although no patient 
had a major reaction to radiocon­
trast agents, two minor reactions 
were recorded requiring antihista­
mine therapy. One child had hyper­
tension, which responded well to 
medical therapy. Persistent hematu­
ria was seen in one patient who 
eventually required angioinfarction 
of a renal segment to control the 
bleeding. Both patients with compli­
cations not related to radiocontrast 
agents had major renal injuries.
Mortality
Three children died: two from a 
closed head injury and one from 
massive intra-abdominal and pelvic 
hemorrhage (the child who required 
emergency laparotomy for multiple 
abdominal and pelvic injuries). All 
three patients had sustained major 
renal injuries, but these were not 
considered directly responsible for 
the deaths.
Discussion
Although the incidence of major 
renal injuries in the pediatric litera­
ture varies from 0%’ to 18%,2 our 
incidence of 8.7% is consistent with 
that of most series (5% to 10%).3~9
T a b le  111. M a jo r N o n re na l In ju rie s  in  T ra u m a  P a tie n ts  W ith  H e m a tu ria
No. of in ju ries
No. in pa tien ts  with
Type of injury T o ta l no. m ajor re n a l injury
M a jo r bone  fra c tu re 17 1
S p le n ic /h e p a tic  lace ra tion 11 6
S p le n ic /h e p a tic  co n tu s io n 8 0
S ig n ifica n t head in ju ry 6 2
M a jo r th o ra c ic  in ju ry 2 2
Tota l 4 4  (in  3 3  p ts ) 11 (in  6 p ts )
T a b le  IV . H em atu ria  in R enal T ra u m a  P a tien ts
No. of pa tien ts
D egree  of M inor ren al M a jo r  ren a l
h em atu ria , rb c /h p f* injury injury Total
G ross 38 10 48
>  40 41 1 42
2 0 - 4 0 21 0 21
<  20 25 0 25
2 +  on  d ip s tic k
(no  m ic ro h e m a tu ria ) 1 0 1
No u rine  sam p le  ava ila b le 0 1 1
Tota l 126 12 138
*R ed b lood  ce lls  pe r h ig h -p o w e r f ie ld
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Pedicle injuries are uncommon, and 
although they were absent in our 
series and that of others,7 they may 
represent up to 2.5% of renal inju­
ries, but they always occur with 
major associated injuries.9
Congenital anomalies are tradi­
tionally said to predispose the kid­
ney to injury and are found in up to 
17% of patients in blunt trauma 
series.7 Our incidence of 2% differs 
little from that expected in the 
general population. The diagnosis 
of renal injury with blunt abdominal 
trauma has generated controversy 
over the imaging modality used, the 
indications for imaging and the ur­
gency for performing imaging.
IVP is the traditional and most 
widely available imaging technique. 
In our series, only 22% of children 
with abnormal findings on IVP had 
major renal injury, but IVP missed 
no major renal injury subsequently 
found by other imaging techniques. 
However, 5 (26%) of 19 children 
with associated major nonrenal ab­
dominal injuries had normal find­
ings on IVP. This finding supports 
the conclusion of Taylor, Eichel- 
berger and Potter,8 who found that 
73% of patients with traumatic he­
maturia had significant other ab­
dominal injuries that were missed 
by IVP but were found by CT. They 
concluded, and we concur, that en­
hanced CT should be performed in 
any patient with hematuria and evi­
dence of other abdominal injury. 
Ultrasonography with Doppler flow 
or with nuclear renography may be 
superior to IVP in defining renal or 
other solid-organ injuries but is not 
available consistently on an emer­
gency basis in many centres, includ­
ing our own.
The indications for renal imaging 
with blunt trauma are controversial. 
Some have reported the association 
of major renal injury with micro­
scopic or no hematuria.9 These in­
stances are associated, however, 
with other major injuries. Oth-
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ers3’410 have indicated that if mi­
crohematuria with hypotension or 
gross hematuria alone are the indi­
cations for imaging, then 99% to 
100% of all major renal injuries will 
be identified.
In our series, 10 (91%) of 11 
patients (one excluded because no 
urinalysis was available) with major 
renal injury had gross hematuria. 
One, however, had microscopic he­
maturia (greater than 40 rbc/hpf) 
only and no other associated injury 
or hypotension. The predictive fac­
tors for major renal injury are far 
from perfect. From several se- 
ries3’4’10 the values reported were: 
hypotension 17%, associated nonre­
nal injuries 18%, gross hematuria 
21% and hematuria greater than 40 
rbc/hpf 8% (our series). If we had 
applied the criterion of the thresh­
old of hematuria being 40 rbc/hpf 
or greater, all major renal trauma 
would have been found by 90 imag­
ing studies to detect 11 cases (Ta­
ble IV). but 47 studies (34% of all 
studies) would have been eliminated 
(on an emergency basis at least).
From these studies and ours, we 
conclude that urgent renal imaging 
should be obtained in blunt abdomi­
nal trauma if there is gross hema­
turia or microscopic hematuria 
greater than 40 rbc/hpf. In these 
cases an IVP is adequate for diag­
nostic imaging. If other major trau­
ma or hypotension is present or 
suspected, and either of these is 
associated with gross or microscop­
ic hematuria of any degree, then 
contrast enhanced CT should be 
done. These criteria should be suffi­
cient to pick up all major renal 
injuries including pedicle injuries.
It must be remembered that 4% 
of primary school children have 
microscopic hematuria on a single 
urinalysis.11 Thus, children not 
meeting the above criteria but with 
less than 20 rbc/hpf should have a 
future repeat urinalysis before fur­
ther investigation. Those with a
count of 20 to 40 rbc/hpf should 
be put on bedrest and undergo 
non-urgent ultrasonography as a 
precaution against the error in the 
absolute precision of microscopic 
urinalysis.
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ORIGINAL ARTICLES
T h e Clinical Significance of Acute 
Hyperamylasemia After Blunt Trauma
Bernard R. Boulanger, MD, FRCSC;* David P. Milzman, MD;f Carl Rosati, MD, FRCSC;J 
Aurelio Rodriguez, MD, FACS§
The clinical value of total serum amylase (TSA) levels measured after blunt trauma 
remains controversial. To test the utility of this measurement, the authors surveyed 
the routine admission TSA levels of 4316 adults who were victims of blunt trauma. 
Most patients (58.2%) had been injured in motor vehicle accidents, and all were 
admitted directly from the accident scene. Patients were divided into two groups 
based on the admission TSA level: more than 125 U/L (abnormal) and 125 U /L  or 
less (normal). Of the 4316 patients, 3920 (90.8%) had a normal TSA level upon 
admission. Hyperamylasemia was associated with a greater injury severity score 
(ISS) and death rate, a lower admission Glasgow Coma Scale score and an increased 
incidence of facial fracture, brain injury, pancreatic and hollow-viscus injuries and 
hypotension (p < 0.01). However, the positive predictive value of an abnormal TSA 
level for pancreatic and hollow-viscus injuries was 1.5% and 3.0% respectively. Also, 
most patients with pancreatic (65%) and hollow-viscus (83%) injuries had a normal 
TSA level. There was no relation between the anatomic grade of pancreatic injury 
and the TSA level.
Acute hyperamylasemia after blunt trauma appears to be a poor predictor of 
pancreatic and hollow-viscus injuries. Therefore, urgent TSA determinations should 
not influence the clinical and radiologic evaluation of the blunt trauma victim.
L’interet clinique des niveaux d’amylase serique totale (AST) mesures apres un 
traumatisme ferme demeure sujet a controverse. Dans le but de mesurer l'importance 
de cette mesure, les auteurs ont mene une enquete sur les taux d’AST mesures de 
fa$on systematique chez 4316 adultes, victimes de traumatismes fermes. La plupart 
des patients (58,2 %) avaient ete blesses dans des accidents de la circulation et tous 
sont arrives directement de la scene de l’accident. Les patients furent divises en deux 
groupes selon leur niveau d’AST a l’arrivee : 125 U/L ou plus (anormal) ou moins 
de 125 U/L (normal). Sur les 4316 patients, 3920 (90,8 %) avaient des taux d’AST 
normaux. L’hyperamylasemie a ete relie a un indice de gravite des blessures (IGB) et 
a une mortality plus eleves, a une cote plus faible sur l’echelle devaluation du coma 
de Glasgow, et a une incidence plus elevee des fractures faciales, des lesions 
cerebrates, des blessures du pancreas et des visceres creux, et d’hypotension (p < 
0,01). Toutefois, les valeurs previsionnelles positives d’un AST anormal pour les 
blessures du pancreas ou des visceres creux ont ete de 1,5 % et 3,0 %, 
respectivement. De plus, la plupart des patients ayant des lesions pancreatiques 
(65 %) ou des visceres creux (83 %) avaient des AST normaux. II n’y avait aucune 
relation entre le grade anatomique des lesions pancreatiques et le niveau d’AST.
L’hyperamylasemie aigue post-traumatique semble un mauvais predicteur des 
blessures du pancreas ou des visceres creux. En consequence, les dosages de LAST 
en urgence ne doivent pas influencer revaluation clinique et radiologique des 
victimes de traumatismes fermes.
The role of serum amylase in the evaluation and management of 
nontraumatic pancreatic disorders 
is well established.12 Determination 
of the total serum amylase (TSA) 
level was first reported as useful in 
the evaluation of the blunt trauma 
victim in 1943.3 Since then there 
have been conflicting reports on the 
value of TSA in the acutely trauma­
tized patient.4-7 Hyperamylasemia is
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associated with severe brain injury, 
facial trauma and hypotension.8-10 
The recent literature appears to 
favour the hypothesis that acute 
TSA is not clinically useful in the 
blunt trauma victim.1112 However, 
this hypothesis has not been tested 
in a large group of blunt trauma 
victims whose TSA levels have been 
determined routinely.
Blunt pancreatic and hollow-vis- 
cus injuries are notoriously difficult 
to detect nonoperatively, and clini­
cians have sought reliable noninva- 
sive diagnostic methods. Hyperamy- 
lasemia has been demonstrated in 
61% to 90% of patients with blunt 
pancreatic injuries and is known to 
occur after bowel perforation and 
ischemia.13"16 These data and the 
lack of superior laboratory tests 
have become the impetus for rou­
tine determination of TSA levels in 
the initial evaluation of the blunt 
trauma victim with possible intra­
abdominal injury. It is our hypothe­
sis that acute hyperamylasemia is a 
poor marker of pancreatic and hol- 
low-viscus injury and that the inci­
dence of acute hyperamylasemia 
should not influence the clinical and 
radiologic evaluation of the blunt 
trauma victim.
Patients and Methods
The R Adams Cowley Shock 
Trauma Center of the Maryland 
Institute for Emergency Medical 
Services Systems (M1EMSS) in Bal­
timore is the clinical hub of Mary­
land’s statewide emergency medical 
services (EMS) system. Patients ad­
mitted to the trauma centre are 
managed with established institu­
tional protocols by a trauma team 
consisting of an attending trauma­
tologist, a trauma surgery fellow 
and three to four residents in sur­
gery or emergency medicine.17 Ab­
dominal injury is diagnosed or ex­
cluded by diagnostic peritoneal la-
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vage, computed tomography (CT) 
or repeated clinical examination. 
Blood for TSA determination is 
drawn routinely on admission to the 
Shock Trauma Center. TSA is mea­
sured by an enzymatic rate method 
(Beckman Synchron CX4; Beckman 
Instruments, Inc., Brea, Calif.) (nor­
mal, 125 U/L or less).
Between July 1987 and June 
1990, 4404 adult (more than 14 
years old) blunt trauma victims 
were admitted to the trauma centre 
directly from the accident scene 
(vital signs present). Of these, 4316 
(98%) had TSA concentrations mea­
sured within 90 minutes of admis­
sion. Prospectively collected data 
were obtained on these 4316 pa­
tients from the MIEMSS-Dunham 
clinical trauma registry.18 The study 
population of 4316 patients was 
divided into two groups: those with 
a normal TSA level (125 U/L or 
less) and those with an abnormal 
TSA level (more than 125 U/L). 
These groups were compared with 
respect to age, sex, mechanism of 
blunt injury, injury severity score 
(ISS), admission Glasgow Coma 
Scale (GCS) score, admission systol­
ic blood pressure, results of ethanol 
screening, the incidence of facial 
and skull fractures and brain injury 
and the incidence of pancreatic, 
gastric, duodenal, small-bowel, co­
lonic and rectal injuries. Ethanol 
screens were recorded as positive or 
negative. Brain injury was defined 
as an intracranial traumatic lesion 
demonstrated by CT. Hospital 
charts were examined for patients 
with a blunt pancreatic injury to 
anatomically grade the injury ac­
cording to the guidelines of Moore 
and colleagues.19
The sensitivity, specificity, posi­
tive predictive value and negative 
predictive value for admission TSA 
level as a test for pancreatic or 
hollow-viscus injury were calculat­
ed. Patient groups were compared 
by Student’s f-test or x2 analysis, as
appropriate. All values are present­
ed as means ± standard deviation.
Findings
The average age of the 4316 
patients was 33.3 ±  15.8 years. 
Males made up 69.6% of patients. A 
majority of patients (2513 [58.2%]) 
had been involved in motor vehicle 
accidents. The remainder were vic­
tims of motorcycle accidents (320 
[7.4%]), falls (610 [14.1%]), pedes­
trian trauma (309 [7.2%]), bicycle 
accidents (50 [1.2%]), blunt beat­
ings (209 [4.8%]) and miscellaneous 
mechanisms of injury (305 [7.1%]). 
The mean ISS was 13.8 ± 12.4 and 
the mean admission GCS score 13.8 
± 2.7. Patients were transported 
from the field by helicopter (2856 
[66.2%]) or land ambulance (1460 
[33.8%]). Hypotension (admission 
systolic blood pressure less than 90 
mm Hg) was present in 140 (3.2%) 
patients. The in-hospital death rate 
for these 4316 patients was 5.3% 
(229 patients).
Of the study population, 3920 
(90.8%) had an admission TSA con­
centration in the normal range (125 
U/L or less), and 396 patients 
(9.2%) had abnormal TSA concen­
trations (more than 125 U/L). Of 
the 396 patients with abnormal 
TSA levels, 309 (78.0%) had TSA 
levels ranging from 126 to 200 
U/L, 62 (15.7%) had levels ranging 
from 201 to 300 U/L, and 25 
(6.3%) had TSA levels greater than 
300 U/L (Fig. 1).
When the 3920 patients with 
normal TSA levels and 396 patients 
with abnormal TSA levels were 
compared (Tables I and II), signifi­
cant differences were found be­
tween the two groups for the fol­
lowing factors: ISS, GCS score, 
death rate and the frequency of 
admission hypotension, facial frac­
tures, and brain, pancreatic, and 
hollow-viscus injuries (p < 0.01).
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An abnormal TSA concentration 
was found in 30 (21.4%) of 140 
patients admitted with a systolic
blood pressure less than 90 mm Hg 
and in 366 (8.8%) of 4176 patients 
admitted with a systolic blood
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FIG. 1. Total serum amylase (TSA) levels among 4316 adult blunt trauma victims 
admitted directly from accident scene.
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Table I. Comparison of Clinical Factors in Patients With Normal and Abnormal Total Serum 
Amylase (TSA) Levels
Significance,
Clinical factor Normal (n =  3920) Abnormal (n = 396) /rvalue
Mean age, yr (SD) 33.0(15.6) 35.9(16.5) NS
Males, %
Mean injury severity
69.8 68.4 NS
score (SD)
Mean Glasgow Coma
13.1 (11.9) 18.2(14.9) <  0.001
Scale score (SD) 
Ethanol screen,
13.9(2.6) 12.9(3.5) <  0.001
% positive 31.4 35.3 NS
Motor vehicle accident, % 
Admission systolic 
blood pressure,
57.8 62.1 NS
< 90 mm Hg, % 2.8 7.6 <  0.001
Mortality, % 4.6 12.4 <  0.001
SD =  standard deviation
Table II. Comparison of Injuries in Patients With Normal and Abnormal TSA Levels
TSA, U/L
Normal, no. (%) Abnormal, no. (%) Significance,
Injury (rr =  3920) (n = 396) p value
Brain injury 495 (12.6) 69(17.4) <  0.01
Facial fracture 245 (6.2) 49(12.4) <  0.01
Skull fracture 351 (9.0) 43(10.9) NS
Pancreatic injury 11 (0.3) 6 (1.5) <  0.01
Hollow-viscus injury 59 (1.5) 12 (3.0) <  0.01
pressure greater than 90 mm Hg
(p <  0 .001).
The 3006 males and 1310 fe­
males in the study population had 
similar incidences of abnormal TSA 
concentrations (9.0% and 9.5% re­
spectively). An abnormal TSA con­
centration was equally prevalent 
among patients with positive and 
negative ethanol screens (10.2% 
and 8.7%, respectively). Of the 25 
patients with TSA levels greater 
than 300 U/L, 10 had a positive 
ethanol screen.
Of the 3920 patients with normal 
TSA levels, 11 (0.3%) had pancreat­
ic injuries and 59 (1.5%) a hollow- 
viscus injury, and of the 396 pa­
tients with abnormal TSA levels, 6 
(1.5%) had pancreatic injuries and 
12 (3.0%) a hollow-viscus injury 
(Tables II to IV).
The highest TSA level among the 
17 patients with pancreatic injuries 
was 362 U/L. The 17 blunt pancre­
atic injuries were graded according 
to the system of Moore and col­
leagues,19 and the injuries were 
evaluated according to the TSA 
levels (Table V).
No gastric or small-bowel injuries 
were sustained by the 25 patients 
with a TSA level greater than 300 
U/L. One patient had a duodenal 
injury, and another had colonic and 
pancreatic injuries. The patient with 
the highest recorded admission 
TSA level (730 U/L) had no pan­
creatic or hollow-viscus injury.
The TSA values for patients with 
pancreatic, stomach, duodenal, 
small-bowel and large-bowel inju­
ries are shown in Fig. 2.
At the MIEMSS Shock Trauma 
Center, the laboratory cost of a 
TSA level assay is $1.50 US. There­
fore, the cost of the routine TSA 
measurements in these 4316 pa­
tients was $6474.
The sensitivity, specificity, posi­
tive predictive value and negative 
predictive value for abnormal TSA 
as a test for blunt pancreatic and
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hollow-viscus injury are shown in 
Tables III and IV.
Discussion
Amylase, an enzyme that hydro­
lyzes glycoside bonds, is a product 
of two genes known as AMY 1 
(salivary) and AMY 2 (pancreatic) 
coded on chromosome number l .20 
The AMY 1 isoamylase, although 
predominantly salivary in origin, is 
also produced by the lacrimal
glands, lungs, breasts and mullerian 
tissues. The AMY 2 isoamylase is 
produced only by the pancreas.21 
Pancreatic isoamylase represents 
approximately 33% of TSA in a 
healthy human subject.22 Thus, 
there are two main sources of 
serum amylase: the pancreas and 
salivary glands.
Any insult to tissues that contain 
amylase may be associated with 
hyperamylasemia. Interestingly, ma­
lignant tumours of the lung, ovary, 
colon and pancreas may have the 
capacity to secrete amylase.23 In 
1929, Elman, Avneson and Gra­
ham24 reported the association be­
tween pancreatic disease and hype­
ramylasemia. Since their initial ob­
servation, attention on the amylases 
has focused on their use in the 
diagnosis and management of pan­
creatic diseases. Since the report of 
Naffziger and McCorkle3 in 1943, 
TSA determination has been used 
to assess the possibility of pancreat­
ic injury in the trauma victim, but 
its usefulness in blunt trauma re­
mains controversial.
In the multitraumatized patient, 
hyperamylasemia may result from 
circulatory shock, ingestion of 
ethanol or narcotics, starch plasma 
expanders and extra-abdominal in­
jury.8102526 Olsen27 found that only 
8% of patients with hyperamyla­
semia and blunt abdominal trauma 
had a pancreatic injury. In our 
patients, the positive predictive
Table V. Relationship Between Grade of 
Blunt Pancreatic Injury and Admission TSA 
Level in 16 Patients*
Grade19 TSA level, U/L
I 53,64,67,74,77,
95,96,98,170,178,
190,212
II 106,362
III 91
IV 86
V None
'One patient had an unknown grade of 
pancreatic injury and a TSA level of 208 
U/L.
Table III. Evaluation of Abnormal TSA Level as a Test for Blunt Pancreatic Injury*
Pancreatic injury, no.
TSA level Positive Negative Total
Normal 11 3909 3920
Abnormal 6 390 396
Total 17 4299 4316
'Sensitivity, 35.3%; positive predictive value, 1.5%; specificity, 91.3%; negative predictive value, 
99.7%
Table IV. Evaluation of Abnormal TSA Level as a Test for Blunt Hollow-Viscus Injury* 
Hollow-viscus injury, no.
TSA Positive Negative Total
Normal 59 3861 3920
Abnormal 12 384 396
Total___________________________ 71__________________4245________________ 4316
'Sensitivity, 16.9%; positive predictive value, 3.0%; specificity, 91.0%; negative predictive value, 
98.5%
FIG. 2. Distribution of TSA among patients with blunt pancreatic and hollow-viscus 
injuries. Horizontal line indicates upper limit of normal (125 U /L) for TSA. P = 
pancreas, S = stomach, D = duodenum, SB =  small bowel and LB =  large bowel. 
Numbers in brackets indicate number of patients with respective injury.
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value and sensitivity of hyperamyla- 
semia as a test for pancreatic injury 
were 1.5% and 35.3% respectively. 
It is clear that an abnormal TSA 
level is a poor marker of pancreatic 
injury and that most patients with a 
pancreatic injury will have a normal 
TSA value. Reports of the efficacy 
of pancreatic isoamylases and lipase 
in evaluating the status of a blunt 
trauma victim have also been disap­
pointing.1112 The quest for a simple 
blood test that will differentiate 
pancreatic from extrapancreatic in­
jury continues.
It is well accepted that the serum 
amylase level does not correlate 
with the severity of acute pancreati­
tis.28 There are many reports of 
severe pancreatic injuries in pa­
tients with normal TSA levels. In a 
series of 500 pancreatic injuries, 
only 65% of patients with complete 
pancreatic transection had elevated 
TSA levels.14 In a study of endo­
scopic retrograde cholangiopan­
creatography in pancreatic trauma, 
the degree of hyperamylasemia did 
not correlate with ductal rupture.29 
Table V19 relates the anatomic 
grade of the pancreatic injuries in 
our study to admission TSA levels. 
There was no clear relationship be­
tween the grade of pancreatic injury 
and the TSA level. Therefore, the 
admission TSA level is no measure 
of the severity of a pancreatic inju­
ry.
In both adults and children there 
are increasing reports of the conser­
vative management of radiologically 
detected intra-abdominal injuries. 
Surprisingly, pancreatic injuries 
have been managed nonoperative- 
ly.30,31 Clinical, laboratory and radi­
ologic criteria are required for the 
proper institution of such conserva­
tive protocols. Our study clearly 
demonstrates that admission TSA 
determination is not an appropriate 
guide to the conservative manage­
ment of patients with blunt pancre­
atic injuries.
Nontraumatic intestinal perfora­
tion and ischemia or infarction are 
associated with elevated TSA lev­
els.15 Pancreatic isoamylase is pre­
dominant because salivary amylase 
is degraded by gastric juice.22 Blunt 
traumatic intestinal injuries have 
been associated with high serum 
amylase levels in 52% of cases.16 
Fig. 2 displays the distribution of 
TSA levels among patients with 
hollow-viscus injuries. As is evident, 
most hollow-viscus injuries (83.1%) 
are associated with normal TSA 
levels. The positive predictive value 
and sensitivity of abnormal TSA 
levels as a test for hollow-viscus 
injury were 3.0% and 16.9% respec­
tively. Therefore, difficulty in the 
nonoperative diagnosis of blunt in­
testinal injury is not diminished by 
knowledge of the TSA levels.
Many factors may influence TSA 
concentrations in healthy subjects. 
Females have a higher mean TSA 
level than males.32 In our trauma 
population, 9.5% of females and 
9.0% of males had an abnormal 
TSA level. Mean TSA levels have 
been shown to increase with ad­
vancing age in both sexes.32 In one 
study, TSA activity was very low in 
infants, reached adult levels in 
10-year-old children and remained 
constant to the eighth decade, 
when there was a 40% increase.33 
The mechanism of age dependency 
of TSA concentration is thought to 
be an age-related decrease in renal 
function. It is interesting that there 
was no age difference between pa­
tients in the normal and abnormal 
TSA groups (Table I). However, 
trauma populations are skewed to 
young ages; thus, it is difficult to 
draw conclusions about the possible 
age dependency of TSA. There may 
be a genetic determinant of TSA, as 
observed by Tsianos and col­
leagues34 in a study of residents of 
the United Kingdom. Dubick and 
associates35 reported elevated serum 
amylase levels in cigarette smokers.
These studies shed light on the 
complexity of amylase metabolism.
The relationship between brain 
injury and hyperamylasemia further 
confounds the clinical application of 
TSA levels in the trauma victim. It 
appears that severe brain injury, 
specifically intracranial bleeding, 
may activate pathways that increase 
TSA levels.9 Vitale and colleagues8 
reported that 38% of patients with 
severe head injury had hyperamyla­
semia. In our study, 69 (12.2%) of 
564 patients with an intracranial 
traumatic lesion on CT scan had 
hyperamylasemia. This group in­
cluded patients with mild to moder­
ate head injury, which may explain 
the lower incidence of hyperamyla­
semia. Patients in the abnormal 
TSA group had a significantly 
greater incidence of brain injury (p 
< 0.01) (Table II).
The pancreas is susceptible to 
ischemic injury, resulting in hype­
ramylasemia. Also, hyperamyla­
semia has been correlated with the 
degree of lactic acidosis and, sepa­
rately, hypotension in the trauma 
victim.10,36 In our study, patients 
with an abnormal TSA level had 
greater anatomic injury, as mea­
sured by ISS and GCS scores and 
an increased death rate (p < 0.001). 
The incidence of hypotension on 
admission was significantly higher 
in the abnormal amylase group (p < 
0.001). Blood lactate concentration 
was not included in our study, but 
our findings indirectly support the 
association between lactic acidosis 
and hyperamylasemia. Thus, elevat­
ed TSA levels soon after a blunt 
traumatic event is an indirect pre­
dictor of the degree of anatomic 
and physiologic insult.
Hyperamylasemia has been well 
documented following oral or max­
illofacial trauma. Isoamylase deter­
minations confirmed the predomi­
nance of salivary hyperamylasemia 
in this subset of patients.37 In our 
study population, 17% of patients
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with facial fractures had an abnor­
mal TSA level. Facial fractures were 
much more common in patients 
with an abnormal TSA level (p < 
0.01) (Table II). Our findings con­
firm those of previous studies and 
cast further doubt on the utility of 
TSA estimation in the multiple trau­
ma victim.
The association between alcohol 
consumption and pancreatitis is 
well described. Some have ques­
tioned whether acute alcohol con­
sumption or binges raise serum 
amylase levels. Bloch, Weaver and 
Bouwman20 reported that 30 of 58 
clinically intoxicated individuals had 
hyperamylasemia, which was most 
frequently salivary in nature. In 
contrast, only 1% of patients with 
recent significant ethanol consump­
tion had amylase elevations more 
than twice the upper limit of nor­
mal.38 Our findings do not support 
a relationship between a positive 
ethanol screen following trauma 
and TSA, because the incidence of a 
positive ethanol screen was similar 
in patients with normal and abnor­
mal TSA levels. Also, patients with 
a positive ethanol screen were 
equally as likely to have an abnor­
mal TSA level as patients with a 
negative ethanol screen. The inci­
dence of ethanol consumption in 
the blunt trauma victim appears to 
have no influence on acute TSA.
Blunt pancreatic injury is an un­
common lesion in blunt trauma. It 
is theorized that this is due to the 
well-protected retroperitoneal loca­
tion of the pancreas and the high 
immediate mortality with associated 
intra-abdominal vascular injuries.39 
Blunt trauma victims should be 
assumed to have an intra-abdominal 
injury until such injury is excluded 
by either repeated clinical examina­
tions, CT or diagnostic peritoneal 
lavage. In this study, the incidence 
of pancreatic injury (0.4%) among a 
large group of patients (4316) at 
risk for intra-abdominal injury
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would have been greater if we were 
to select patients with intra-abdomi­
nal injury or those undergoing lapa­
rotomy. However, the purpose of 
this study was to determine the 
utility of TSA determination in all 
trauma victims, not in a selected 
subgroup with heightened suspi­
cion of abdominal injury.
It is important to emphasize that 
our study population consisted of 
patients transported directly from 
the accident scene. In Maryland’s 
well-developed EMS system, prehos­
pital response and transport times 
are minimized. The majority 
(66.2%) of patients are transferred 
from the accident scene by Mary­
land State Police helicopter. Thus, 
an admission TSA level is obtained 
on this group of patients very soon 
after the traumatic event. A rising 
TSA level after admission may indi­
cate pancreatic injury.40 Similarly, a 
patient transferred from a referring 
hospital, hours to days after trau­
ma, may have a high TSA level. Our 
study did not evaluate the utility of 
TSA levels under these circum­
stances.
In the practice of surgery, utiliza­
tion review and quality assessment 
of diagnostic tests have become 
increasingly important in efforts to 
curb escalating health care costs. 
For the 4316 patients in our study, 
the cost of routine TSA measure­
ment was approximately $6500 
over a 3-year period. Also, when 
faced with an elevated TSA level, 
clinicians may be inclined to per­
form expensive diagnostic proce­
dures, delay enteral feedings and 
prolong nasogastric suctioning and 
hospital stay. With the demonstrat­
ed poor positive predictive value of 
TSA for pancreatic and hollow-vis- 
cus injury (1.5% and 3.0% respec­
tively), enormous costs will be in­
curred to rule out intra-abdominal 
injuries. Clearly, early determina­
tions of TSA in the trauma victim 
are of low cost-benefit. As the cost
analysis of TSA has demonstrated, 
closer scrutiny of diagnostic proce­
dures and tests that are regarded as 
routine in the evaluation of the 
trauma victim is required.
In conclusion, acute TSA deter­
minations should not influence the 
clinical or radiologic evaluation of 
adults who are victims of blunt 
trauma.
We thank Linda Kesselring, Mary-Joan 
McHugh and Kim Mitchell for their 
expert assistance.
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into and to read the critiques. I did not 
find it provided a true or penetrating 
test of any depth or breadth of surgical 
knowledge.
I believe this is a book that would be 
better borrowed than bought.
Christopher Heughan, MB, BChir, FRCSC
Division of Surgery
Memorial University of Newfoundland
St. John’s, NF
A1B3V6
SURGICAL REVASCULARIZATION 
OF THE HEART: THE INTERNAL 
THORACIC ARTERIES. Edited by 
George E. Green and Ram N. Singh. 
Illust. Igaku-Shoin Medical Publish­
ers, Inc., New York. 1991. Price not 
stated. ISBN 0-89-640-198-7
The internal thoracic arteries have be­
come standard conduits in coronary 
artery bypass surgery, due largely to 
the persistence and proselytizing of Dr. 
George Green, who pioneered the con­
cept and who has edited this mono­
graph.
This book’s greatest virtue is a long 
chapter, written by Dr. Frank Sims, on 
the histologic features of the internal 
thoracic arteries, offering explanations 
for its resistance to atherosclerosis, and 
its excellent long-term patency. This 
chapter is lucidly written and contains 
excellent photomicrographs. It offers 
insight to surgeons on the rationale for 
the use of these vessels as bypass 
conduits.
The remainder of the text is devoted 
to issues that have been extensively 
covered elsewhere. The opening chapter 
is a concise history of coronary surgery 
by a participant in its beginnings, Dr. 
Donald Effler. Three chapters are devot­
ed to the angiographic anatomy of 
these vessels, postoperative assessment 
of them and clinical results.
Eight chapters written by Dr. Green 
outline his philosophies and techniques 
of coronary bypass surgery, from mak­
ing the incision and cannulating vessels 
for cardiopulmonary bypass to a discus­
sion of postoperative management and 
complications. Since beginning these
techniques, Dr. Green has used the 
operating microscope in place of the 
optical loupes favoured by most cardiac 
surgeons, and he extols the virtue of 
this instrument and his rationale for its 
use. There are many operative photo­
graphs detailing the differences in oper­
ative fields at different magnifications.
Dr. Green devotes a chapter to refut­
ing the notion that spasm of these 
arteries can and does contribute to 
postoperative cardiac dysfunction. He 
has even reviewed the cineangiograms 
of patients cited in case reports in the 
literature to back up his views.
The final chapter is a discussion of 
arterial conduits other than the internal 
thoracic arteries, including splenic, radi­
al, right gastroepiploic and inferior epi­
gastric arteries.
This small book should be of interest 
to many cardiac surgeons because of 
the interesting material on the histopa- 
thology of the internal thoracic arteries. 
The appeal of the remainder of the 
book will be limited, though the surgi­
cal technique of a fine and respected 
pioneer in coronary artery bypass sur­
gery will always be of interest. It is 
conceivable that for housestaff it could 
serve as a primer for coronary artery 
surgery.
Elliot T. Gelfand, MD, FRCSC, FACS
Department of Surgery 
3H2.11 W.C. Mackenzie 
Health Sciences Centre 
University of Alberta 
Edmonton, AB 
T6G 2B7
THE PRINCIPLES OF TRAUMA 
SURGERY. Edited by Joseph A. Moy- 
lan. 343 pp. Illust. Gower Medical 
Publishers, New York. 1992. $155. 
ISBN 1-56375-013-9
This guide will attract anyone who is 
faced with emergency treatment of the 
multiply injured patient. Once one 
starts reading any of the 20 chapters 
that might be of particular interest, it is 
difficult to put the text down before 
reading it from cover to cover. In my
experience of reviewing trauma texts 
over many years, this is one of the very 
best.
Multiple American authorities cover 
each of the subjects from the points of 
view of prehospital, emergency depart­
ment and trauma specialists. Topics are 
covered thoroughly and concisely and 
are emphasized clearly with highlighted 
tables and illustrations. The subject 
matter is presented definitively, and 
where controversy exists, the schools of 
thought are explained. The pathophysi­
ology of the mechanics of injury, respi­
ratory failure and ventilatory support 
for both penetrating and blunt injury 
are clearly presented. Specific injuries 
to the face, neck, chest, abdomen and 
extremities are dealt with individually, 
and appropriate surgical exposure and 
techniques are described. Various organ 
injuries are classified by severity, and 
each classification of injury is separate­
ly described with regard to the most 
appropriate treatment. Pediatric trau­
ma, various forms of nutrition, burn 
management and specific injuries to the 
face and hands are dealt with in detail. 
Each chapter is thoroughly referenced.
The organization of various levels of 
hospital trauma category are explained. 
This, I believe, is particularly important 
in Canada, where such great distances 
separate the major trauma centres. A 
thorough knowledge of the resource 
base of each hospital is extremely im­
portant so that undue delay in organiz­
ing transfer to a major trauma centre, 
where indicated, is avoided. The princi­
ples of advanced trauma life support 
(ATLS) are well covered, and, more 
importantly, the management beyond 
ATLS in resuscitation and specific treat­
ment is appropriately explained.
1 find it difficult to criticize this work 
because it is comprehensive and well 
done. However, some emphasis might 
have been directed toward the assess­
ment of neurosurgical injury, indicating 
when further resuscitation is contraindi­
cated. Similarly, the significance of cer­
tain orthopedic injuries such as the 
crushed, disrupted pelvis, which is fre­
quently associated with blunt trauma to 
the colon and small bowel, and mesen-
continued on page 80
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ORIGINAL ARTICLES
Laparoscopic Gastrointestinal 
Anastomoses
Dawn L. Anderson, BSc(Med), MD; Patrick J. O’Regan, MB, BCh, BAO, FRCSC
In a preliminary study of laparoscopic gastrointestinal anastomosis, a gastric outlet 
obstruction was created under laparoscopic control in six domestic pigs, weighing 
an average of 25 kg. A simultaneous gastroenterostomy was formed with an 
end-stapling device. All animals recovered clinically, and good anastomotic healing 
was documented 1 week postoperatively. The authors suggest that an end-stapling 
device could be one method of creating a gastrointestinal anastomosis for humans 
that is safe and reliable, allows rapid recovery and decreases hospital stay.
Au cours d’une etude preliminaire portant sur l’anastomose gastro-intestinale 
laparoscopique, une obstruction de la sortie gastrique a ete creee sous controle 
laparoscopique chez six pores domestiques pesant, en moyenne, 25 kg. 
Concomitamment, une gastroenterostomie a ete effectuee a l’aide d’une agrafeuse a 
alimentation par le bout. Tous les animaux ont recupere cliniquement et le succes de 
de l’anastomose a ete verifie 1 semaine apres l’operation. Les auteurs suggerent 
qu’une agrafeuse a alimentation par le bout pourrait servir a creer une anastomose 
gastro-intestinale chez l’humain de fa$on sure et fiable, tout en assurant une 
guerison rapide et en diminuant le temps d’hospitalisation.
S ince the report in 1989 on laparoscopic cholecystectomy,1 
the age of videoendoscopic general 
surgery has been expanding at an 
explosive rate. Laparoscopic chole­
cystectomy and appendectomy are 
common,2-4 and techniques for 
other procedures are being rapidly 
developed. In this paper we describe 
a technique of laparoscopic gas- 
troduodenostomy in domestic pigs 
using an end-stapling device, and 
we discuss possible human applica­
tions.
Materials and Methods
Six domestic pigs weighing 25
kg each were used for this study. 
Under general anesthesia and with 
antibiotic coverage, a Veress needle 
was used to create a pneumoperito­
neum with a Storz 9.9-L high-flow 
insufflator (Laparoflator 26012C; 
Karl Storz, Tuttlingen, Germany). A 
Storz ST-615C xenon light source, 
ST 599C flash generator, ST 9050 
Supercam laparoscopic camera and 
a Sony Trinitron monitor (model 
PVM 1943 MD; Sony Corp., Tokyo, 
lapan) were used, all supplied on 
loan for research purposes by R. 
Laborie Surgical Ltd. (Brossard, 
Que.), as were all of the laparoscop­
ic instruments. A forward-viewing 
laparoscope was inserted near the 
umbilicus, and three additional
working ports made up the total of 
four punctures. Ampicillin and gen­
tamicin were used perioperatively 
for antibiotic prophylaxis.
A gastric outlet obstruction was 
created by placement of a ligature 
of 0 Prolene around the proximal 
duodenum and tying it tight with a 
Roeder loop knot. The duodenum 
was chosen as the small-bowel seg­
ment to use in the anastomosis, 
because in the pig the duodenum is 
long, has an easily mobilized por­
tion and is of similar diameter and 
wall thickness to human jejunum. 
This type of procedure performed in 
humans would most likely use the 
jejunum. A segment of duodenum 
distal to the obstruction was 
brought up to the anterior wall of 
the stomach where it was held by 
corner stay sutures placed directly 
through the abdominal wall. Open­
ings were made in stomach and 
duodenum with cautery and scis­
sors. An Endopath, single-loading 
end-stapling device (Figs. 1 and 2) 
applied on loan by Ethicon, Peter­
borough, Ont., was used to place 
15 titanium staples individually 
along the back and front walls of a 
2-cm diameter anastomosis. The an­
imals were kept on intravenous hy­
dration for 24 hours. Their diet was 
advanced over 3 days, and they 
were killed 1 week postoperatively. 
The site of gastroduodenostomy 
was examined with the organs in­
tact, the stomach was then opened 
to allow inspection and measure­
ment of the anastomosis. A probe 
was also inserted through the pylo­
rus to confirm that the laparoscopi- 
cally created gastric outlet obstruc-
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tion was complete. The appearance 
was recorded photographically.
Results
In terms of visual and manual 
examination, healing of the gas­
troduodenal anastomosis was virtu­
ally complete in all six animals at
FIG. 2. Staple formation.
the time of sacrifice (Fig. 3). The 
anastomotic diameter was always 
between 15 and 20 mm. In every 
case the obstructing suture around 
the proximal duodenum was intact, 
confirming that the anastomosis 
was the sole route of gastric empty­
ing.
One animal, the second in the 
series, showed signs of intermittent 
obstruction, manifested by vomiting
after ingestion of large amounts of 
food or water. It tolerated frequent 
small liquid feeds, however. At au­
topsy it was found that, although 
the anastomosis itself was well 
healed and widely patent, the loop 
of duodenum used had been inad­
vertently twisted 360° intraopera- 
tively, causing the short afferent 
limb to obstruct the efferent limb 
whenever the stomach was very 
distended.
Two animals appeared sick post- 
operatively, but the attending veter­
inarian diagnosed the source of 
their sepsis as pneumonia, and they 
were given appropriate antibiotics. 
In both animals, the diagnosis of 
respiratory infection, not intra­
abdominal infection, was confirmed 
after sacrifice.
Discussion
The benefits of laparoscopic over 
traditional open general surgical 
techniques have only been well doc­
umented for a few procedures such 
as cholecystectomy and appendec­
tomy.5-7 However, extrapolation 
from the observed decrease in post­
operative pain, length of hospital­
ization and rapidity of return to 
work has led many surgeons to 
explore the frontiers of this tech­
nology. Many reports are found in 
the literature of familiar common 
operations with well-established in­
dications being performed under la­
paroscopic control, such as vago­
tomy, Nissen fundoplication, feed­
ing jejunostomy and others.8-11 
There are many situations that re­
quire bypassing a segment of the 
gastrointestinal or biliary tract for 
established benign or malignant ob­
struction or for prophylaxis as with 
a vagotomy. A substantial benefit of 
decreased narcotic analgesics would 
be more rapid recovery of gastroin­
testinal function. For patients with 
malignant disease and reduced life-
FIG. 1. Endopath (Ethicon, Peterborough, Ont.) end-stapling device.
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span, the avoidance of a major 
laparotomy, especially for a pallia­
tive procedure, would certainly add 
to their quality of life. Thus, laparo­
scopic cholecystojejunostomy, with 
use of the end-stapling device, 
might be appropriate treatment in 
certain cases of obstructive jaundice 
due to carcinoma of the head of the 
pancreas.
Conclusions
The ability to perform a safe, 
reliable gastrointestinal anastomosis 
under laparoscopic control would 
allow a wide variety of patients the 
same benefits in terms of rapid
recovery and decreased hospital 
stay currently enjoyed by patients 
who undergo laparoscopic cholecys­
tectomy. The authors suggest that 
an end-stapling device is one meth­
od of creating a suitable anastomo­
sis for humans. This technique 
could also be used to supplement 
other methods — to complete an 
endoscopic anastomosis, as an ad­
junct to other stapling devices or 
for suturing. An appropriate mul­
tifire instrument would reduce oper­
ating time.
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O pen Cholecystectomy: Its Morbidity and 
Mortality as a Reference Standard
Robert M. Girard, MD; Michel Morin, MD
In a retrospective study of 10 471 cholecystectomies, performed between 1971 and 
1990, the incidence and causes of death and morbidity of cholecystectomy were 
analysed. There were 47 postoperative deaths (0.4%); 6 deaths occurred in 5841 
patients less than 50 years old, 23 in 3898 patients between 50 and 70 years old and 
18 in 732 patients more than 70 years old. Death rates in each group were, 
respectively, 0.1%, 0.6% and 2.5% (p < 0.001). The death rate in 9339 patients who 
had cholecystectomy alone was 0.3% and the death rate in 1132 patients who had a 
concomitant common bile duct exploration (CEDE) was 1.6% (p < 0.001). 
Cardiovascular complications were the main cause of death, and biliary, pulmonary 
and wound complications were the most common. There were 614 complications in 
529 patients; 176 of these patients were less than 50 years old, 252 were between 
50 and 70 years old and 101 were more than 70 years old. Complication rates were, 
respectively, 3.0%, 6.5% and 13.8% (p < 0.001). For patients with cholecystectomy 
alone the morbidity was 3.6% and for patients who had a concomitant CBDE the 
morbidity was 17% (p < 0.001). The mortality and morbidity of cholecystectomy 
increase significantly with age and a concomitant CBDE. However, patients who 
underwent cholecystectomy electively or for acute cholecystitis had comparable 
mortality and morbidity.
Dans une etude retrospective portant sur 10 471 cholecystectomies effectuees entre 
1971 et 1990, on a analyse la frequence et les causes de la mortalite et de la 
morbidite. Quarante-sept deces postoperatoires ont ete enregistres (0,4 %); 6 deces 
sont survenus chez 5841 patients de moins de 50 ans, 23 chez 3898 patients de 50 a 
70 ans et 18 chez 732 patients de plus de 70 ans. La mortalite dans chaque groupe a 
ete, respectivement, de 0,1 %, 0,6 % et 2,5 % (p < 0,001). La mortalite chez 9339 
patients qui avaient subi une cholecystectomie simple a ete de 0,3 %, alors qu’elle 
etait de 1,6 % chez 1132 patients qui avaient eu, concurremment, une exploration du 
choledoque (EC) (p < 0,001). Les complications cardiovasculaires represented la 
principale cause de deces, alors que les complications biliaires, pulmonaires et de 
plaies ont ete les plus frequentes. II y a eu 614 complications chez 529 patients 
(5 %); 176 patients avaient moins de 50 ans, 252 patients, entre 50 et 70 ans et 101, 
plus de 70 ans. Les taux de morbidite respectifs etaient de 3,0 %, 6,5 % et 13,8 % (p 
< 0,001). La morbidite chez les patients qui ont subi une cholecystectomie simple a 
ete de 3,6 %, contre 17 % (p < 0,001) pour les patients qui ont eu une EC 
concurrente. La mortalite et la morbidite reliees a la cholecystectomie augmentent 
significativement avec 1’age et avec l’execution d’une EC concomitante. Toutefois, la 
mortalite et la morbidite ont ete comparables, que les patients aient subi une 
cholecystectomie non urgente ou pour une cholecystite aigue.
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Cholecystectomy has been the standard therapy for patients 
with symptomatic gallstone disease 
for many decades and has proven to 
be a safe and effective procedure. 
The mortality and morbidity are 
low.1-6 Long-term results are excel­
lent, with most patients being 
asymptomatic after surgery.5 De­
spite the good results with tradi­
tional cholecystectomy, the treat­
ment of gallstones has undergone 
drastic changes in the past few 
years. Several alternative nonsurgi- 
cal options for the management of 
biliary lithiasis have been intro­
duced, including extracorporeal 
shockwave lithotripsy,6 chemical 
dissolution7 and endoscopic and 
percutaneous extraction.8 More re­
cently, laparoscopic cholecystecto­
my has emerged as a promising 
surgical alternative to traditional 
cholecystectomy,9 We carried out a 
retrospective study of traditional 
cholecystectomy to analyse the inci­
dence and causes of mortality and 
morbidity and to compare our expe­
rience with that o f others.
Patients and Methods
The medical records of 10 501 
patients who underwent cholecys­
tectomy between April 1971 and 
April 1990 at Maisonneuve- 
Rosemont Hospital were reviewed. 
Excluded from the analysis were 30 
patients who died after cholecystec­
tomy but in whom the cause of 
death was unrelated to the proce­
dure. Twenty-two of these patients 
died of complications secondary to
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major surgery in which cholecystec­
tomy was only incidental. The other 
eight patients died of serious diseas­
es up to 90 days after cholecystec­
tomy performed for acute cholecys­
titis, which complicated the course 
of their disease.
Among the remaining 10 471 pa­
tients, 6574 (63%) underwent cho­
lecystectomy alone, 2765 (26%) un­
derwent cholecystectomy with other 
concomitant non-biliary procedures 
(the most frequent being incidental 
appendectomy, hernia repair, tubal 
ligation and liver biopsy) and 1132 
(11%) underwent cholecystectomy 
with common bile duct exploration 
(CBDE) for presumed choledocholi- 
thiasis.
Most of the operations were per­
formed by a right subcostal inci­
sion. Cholecystectomy was usually 
performed from the porta hepatis to 
the fundus (anterograde) after iden­
tification of the anatomic structures 
at the porta hepatis. If it was impos­
sible or unsafe to perform antero­
grade cholecystectomy, usually be­
cause of acute cholecystitis, chole­
cystectomy was then performed 
from the fundus downward to the 
porta hepatis (retrograde). Routine 
operative cholangiography was per­
formed when technically possible.
Cholecystitis was considered acute 
when inflammation and edema of 
the gallbladder were present at op­
eration and confirmed histopatho- 
logically. Until 1976, the subhepat- 
ic space was drained in every case 
with a soft Penrose drain. After 
1976, a drain was used less fre­
quently, and since 1985 it has been 
used selectively in patients who had 
a cholecystectomy for acute chole­
cystitis or a cholecystectomy with 
CBDE. When choledochotomy was 
performed, the common duct was 
closed over a T tube.
Differences were analysed by the 
X2 test. Differences were considered 
statistically significant at p < 0.05.
Findings
Of the 10 471 patients, 7277 
(69.5%) were female and 3194 
(30.5%) were male. There were 
5841 (55.8%) patients less than 50 
years of age, 3898 (37.2%) between 
50 and 70 years of age and 732 
(7.0%) more than 70 years of age. 
The youngest patient was 7 years 
old and the oldest was 96 years old. 
Routine intraoperative cystic duct 
cholangiography was performed 
when technically possible, in ap­
proximately 90% of the patients. 
Histopathological examination of 
the gallbladder showed chronic cal­
culous cholecystitis in 8484 
(81.0%), chronic acalculous disease 
in 296 (2.8%), acute calculous 
cholecystitis in 1639 (15.7%) and 
acute acalculous cholecystitis in 52 
(0.5%).
Deaths
Forty-seven patients died, for an 
overall mortality of 0.4%. Six (0.1%) 
were younger than 50 years, 23 
(0.6%) were between 50 and 70 
years and 18 (2.5%) were older than 
70 years. The difference between 
each group is significant (p < 
0.001). The indications for opera­
tion in those who died are shown in 
Table I. Twenty-two of them had 
either associated acute pancreatitis 
or jaundice, or both, at the time of 
surgery. Four had acute suppura­
tive cholangitis.
The surgical procedures per­
formed for chronic and acute chole­
cystitis and the death rates are 
depicted in Table II. Among the 
8780 patients with chronic disease, 
36 died (0.4%), while among the 
1691 patients with acute cholecysti­
tis, 11 died (0.6%). This difference 
is not significant, and patients with 
acute cholecystitis had a death rate 
comparable to that of patients who 
underwent elective cholecystecto­
my. The death rate in 9339 patients 
who had cholecystectomy alone was 
0.3%, whereas in 1132 patients who 
had cholecystectomy with CBDE 
the death rate was 1.6% (p < 
0.001). Death rates according to
Table I. Indications for Operation in Patients Who Died After Cholecystectomy
.. . No. with associated disease
Indication patients Acute pancreatitis Jaundice
Chronic cholecystitis 36 7 8
With cholelithiasis 22 3 0
With choledocholithiasis 14 4 8
Acute cholecystitis 11 2 5
With cholelithiasis 7 2 1
With choledocholithiasis 4 0 4
Table II. Surgical Treatment for Acute and Chronic Cholecystitis
Chronic cholecystitis Acute cholecystitis
No. of No. of No. ot No. of
Treatment patients deaths % patients deaths %
Cholecystectomy 7841 22 0.3 1498 7 0.5
Cholecystectomy with CBDE 939 14 1.5 193 4 2.1
Total 8780 36 0.4 1691 11 0.6
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age and type of cholecystitis are 
shown in Table III. The only signifi­
cant difference found was in pa­
tients with acute cholecystitis: in 
patients between 50 and 70 years of 
age the death rate was 0.4%, where­
as in patients over 70 years of age 
the death rate was 4.0% (p < 
0.005). The most frequent cause of 
postoperative hospital death was 
cardiovascular complications (Table 
IV), which accounted for 50% of the 
deaths. Among the 23 patients who 
died of cardiovascular complica­
tions, 10 had myocardial infarction, 
4 had cardiac insufficiency, 3 had 
pulmonary embolism, 2 had mesen­
teric thrombosis, 2 had cerebrovas­
cular thrombosis, 1 had endocardi­
tis and 1 had a dissecting thoracic 
aneurysm. There were nine intra­
abdominal extrahepatic deaths 
caused by perforated duodenal ulcer 
in three patients, abscess in three 
patients and gastrointestinal bleed­
ing in two patients. The other pa­
tient died of a duodenal fistula with 
peritonitis after an emergency pro­
cedure for biliary ileus, during 
which a cholecystectomy with re­
pair of a cholecystoduodenal fistula 
was also performed. Six of these 
patients had cholecystectomy with 
CBDE and had pancreatitis or jaun­
dice, or both, at surgery.
Six patients died of hepatobiliary 
complications, five of them after 
cholecystectomy with CBDE. Three 
deaths were attributed to septicemia 
in patients with acute suppurative 
cholangitis at operation, and two 
deaths were caused by hepatic in­
sufficiency. The other patient died 
of a prolonged biliary fistula with 
dehydration 4 months after a chole­
cystectomy with CBDE. The other 
causes of death were pulmonary 
(four patients) and renal (one pa­
tient) complications, infection from 
a fulminant necrosis of the abdomi­
nal wall (one patient) and undeter­
mined causes (three patients).
Postoperative Complications
Postoperative complications were 
found in 529 patients (5.1%). Of 
these, 176 patients (3.0%) were less 
than 50 years old, 252 patients 
(6.5%) were between 50 and 70 
years old and 101 patients (13.8%) 
were more than 70 years of age. 
The difference between each group 
is significant (p < 0.001). In those 
who underwent cholecystectomy 
alone, 121 patients less than 50 
years old had complications (mor­
bidity 2.3%), 169 patients between 
50 and 70 years old had complica­
tions (morbidity 5.0%) and 47 pa­
tients more than 70 years old had 
complications (morbidity 9.2%) {p < 
0.01). Among the 8742 patients 
with chronic disease, 403 (4.6%) 
had complications, whereas among 
the 1680 patients with acute chole­
cystitis, 126 (7.5%) had complica­
tions. The incidence of complica­
tions after cholecystectomy alone 
was 3.6% (3.1% for chronic chole­
cystitis and 6.1% for acute chole­
cystitis) whereas after cholecystec­
tomy with CBDE the incidence was 
17% (16% for chronic cholecystitis 
and 24% for acute cholecystitis)
(p < 0.001).
In the 529 patients, 614 compli­
cations were seen, the most fre­
quent being biliary, pulmonary and 
wound complications. There were 
169 wound complications among 
which 126 were infected wounds. 
Pulmonary complications were seen 
in 140 patients. Among the 174 
biliary complications, 75 were ex­
ternal biliary fistulas, 64 were resid­
ual stones and 5 were bile peritoni­
tis. In addition, there were 30 in-
Table IV. Causes of Death
Procedure, no. of patients
Cause Cholecystectomy
Cholecystectomy 
with CBDE Total
Cardiovascular
Intra-abdominal
17 6 23
(extra-hepatic) 3 6 9
Hepatobiliary 1 5 6
Pulmonary 3 1 4
Infectious 1 0 1
Renal 1 0 1
Undetermined 3 0 3
Total 29 18 47
Table III. Age-related Mortality and Type of Cholecystitis
Age, yr
Chronic cholecystitis Acute cholecystitis
No. of 
patients
No. of 
deaths %
No. of 
patients
No. of 
deaths %
< 50 5089 5 0.1 752 1 0.1
5 0 - 7 0 3145 20 0.6 753 3 0.4 “ I
> 70 546 11 2.0 186 7 4.0 J
Total 8780 36 0.4 1691 11 0.6
*p < 0.005
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traoperative bile duct injuries 
(0.3%); 24 occurred in 9339 pa­
tients who had cholecystectomy 
alone: 17 were considered minor 
(small lacerations or punctiform 
wounds) and 7 were considered 
major (section or ligation). Eighteen 
bile duct injuries occurred during 
cholecystectomy for chronic chole­
cystitis and 6 during cholecystecto­
my for acute cholecystitis. There 
were 6 cases of trauma to the 
common or right hepatic duct, 12 
in the area of the cystocholedochal 
junction, 5 in the common bile duct 
and 1 in a right accessory hepatic 
duct. Except for one, all these trau­
mas were recognized at the initial 
operation and repaired. The only 
unrecognized trauma was a partial 
section of the common hepatic 
duct, which led to a prolonged 
postoperative biliary fistula and 
later bile duct stenosis. This steno­
sis was repaired 1 year later by a 
Roux-en-Y hepaticojejunostomy. 
Two other patients had reoperation 
for drainage of a bile collection.
Two of the six bile duct injuries 
that occurred during cholecystecto­
my with CBDE were major and four 
were minor. All were recognized 
and repaired at initial operation 
with no further problem.
The other complications that 
should be mentioned were intra- or 
postoperative hemorrhage in 20 pa­
tients, postoperative intra-abdomi­
nal abscesses in 21 patients and 
cardiovascular nonlethal complica­
tions in 26 patients.
Sixty-seven patients underwent a 
second procedure for complications 
1 to 45 days after cholecystectomy, 
the most frequent being closure of 
wound dehiscence, drainage of an 
intra-abdominal abscess and control 
of postoperative bleeding (Table V).
Discussion
In general, three factors are al­
leged to increase the death rate in 
patients who undergo cholecystec­
tomy: increasing age, the addition 
of a concomitant CBDE and the 
degree of inflammation of the gall- 
bladder.1'3'4
A major risk factor is age. Of the 
9339 patients who had cholecystec­
tomy without CBDE, 5383 were 
less than 50 years of age, and there 
were four deaths in this group 
(death rate 0.07%). In the group of 
3431 patients between the ages of 
50 and 70 years, there were 12 
postoperative deaths (death rate 
0.3%); in the group of 525 patients 
over 70 years of age, there were 
13 deaths (death rate 2.5%). Our 
experience confirms that the death 
rate increases significantly with age 
(p < 0.001), due primarily to 
associated medical conditions, parti­
cularly cardiovascular problems.
The addition of a concomitant 
CBDE also increases mortality. Al­
though the death rate recorded for 
9339 patients who had cholecystec­
tomy alone was 0.3%, it increased 
fivefold to 1.6% in 1132 patients 
who had cholecystectomy with 
CBDE (p < 0.001). Although the 
addition of a CBDE is an important 
factor influencing the death rate of 
cholecystectomy, we believe that, 
rather than the choledochotomy per 
se, the main influencing factor is 
that CBDE is most often necessary 
in patients of advanced age with 
associated medical conditions. In 
addition, the increased likelihood of
sepsis in many patients with com­
mon duct stones also influences the 
death rate. Not only does the death 
rate increase with the addition of a 
CBDE, but also the causes of death 
differ (Table IV). Whereas 17 (59%) 
of the 29 deaths after cholecystec­
tomy alone were caused by cardio­
vascular complications, this was the 
cause of death in only 6 (33%) of 
the 18 deaths after cholecystectomy 
with CBDE. In this last group, the 
causes of death were more frequent­
ly related to the intra-abdominal 
condition at the time of surgery 
(pancreatitis or cholangitis) and to 
postoperative complications that de­
veloped secondary to the associated 
acute pancreatitis or cholangitis.
Many series have shown that the 
presence of acute cholecystitis is an 
important determinant of operative 
mortality related to cholecystecto­
my.1'3-4 But our experience as well 
as that of Pickleman and Gonzalez2 
cannot confirm that the presence of 
acute cholecystitis increases the 
death rate significantly. In our se­
ries, as shown in Table II, the 
degree of inflammation of the gall­
bladder was not a significant deter­
minant of operative mortality. Of 
1691 patients with acute cholecysti­
tis, 11 died (death rate 0.6%). Cho­
lecystectomy without CBDE was 
performed in 1498 of these 1691 
patients and 7 died (death rate 
0.5%). In contrast, 8780 patients 
were operated on for chronic chole­
cystitis and 36 died (death rate
Table V. Indications for Reoperation
After cholecystectomy
Indication
After cholecystectomy 
no. of patients
with CBDE, 
no. of patients Total
Wound dehiscence 19 7 26
Intra-abdominal abscess 13 5 18
Intra-abdominal bleeding 7 3 10
Biliary fistula 3 3 6
Fixed Penrose drain 3 0 3
Small-bowel obstruction 2 0 2
Gastrointestinal bleeding 1 0 1
Hemobilia 1 0 1
Total 49 18 67
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0.4%). Cholecystectomy without 
CBDE was performed in 7841 of 
these 8780 patients and 22 died 
(death rate 0.3%). Table III shows 
that the difference in mortality for 
patients with chronic or acute 
cholecystitis is not affected by age. 
Only patients more than 70 years 
old with acute cholecystitis have an 
increased death rate when com­
pared with younger patients.
Acute pancreatitis or jaundice, or 
both, may also be considered as 
factors increasing mortality and 
morbidity. Of the 29 patients who 
died after cholecystectomy alone, 5 
had pancreatitis at surgery. Of the 
18 patients who died after cholecys­
tectomy with CBDE, 4 had pan­
creatitis and 12 had jaundice at 
surgery. The high incidence of 
jaundice in patients who died tends 
to confirm the observation of others 
that it increases the risk of chole­
cystectomy with CBDE.10
There is much published data 
proving the safety of cholecystecto­
my. A study on biliary tract surgery 
appeared in 1970 and summarized 
the results of treatment in over 
28 000 patients requiring cholecys­
tectomy.1 The overall death rate 
was 1.8%, with a rate of 1.5% for 
elective cholecystectomy and 3.5% 
for cholecystectomy for acute 
cholecystitis. More recent studies, 
however, have reported an operative 
death rate of less than 1% (Table 
VI2-6). These rates vary from 0% to 
0.5% in elective cholecystectomy to 
1.1% to 1.7% in urgent cholecystec­
tomy.2-6 One of the largest series 
reported showed that cholecystecto­
my alone performed in 10 749 pa­
tients was associated with an opera­
tive death rate of 0.6% (0.4% for 
chronic cholecystitis and 1.2% for 
acute cholecystitis); furthermore, in 
the last 1693 cholecystectomies 
performed, there were only three 
deaths for a mortality of 0.2%.4 In 
addition, two series of patients who 
underwent elective cholecystectomy 
reported no deaths.3’5
Our overall death rate of 0.3% in 
elective cholecystectomy does not 
differ substantially from these se­
ries. But in this series the overall 
death rate of 0.5% for cholecystec­
tomy in acute cholecystitis is much 
lower than that reported in other 
series.4'6 This difference possibly 
can be explained by a more aggres­
sive approach at the Maisonneuve- 
Rosemont Hospital where patients 
with acute cholecystitis are operat­
ed on as soon as the diagnosis is 
made. Another explanation is that 
the patients in this series were 
younger than those in other series. 
As to the death rate associated with 
cholecystectomy with CBDE, recent 
series reported a mortality between 
0.7% and 4.4%,34 whereas in the 
present series it was 1.6%.
As with mortality, the morbidity 
of cholecystectomy also increased 
with age and the addition of a 
CBDE. From 2.3% in those less 
than 50 years old it increased to 
5.0% for those between 50 and 70 
years old and 9.2% for those more 
than 70 years old (p < 0.01). 
Similarly, the addition of a concomi­
tant CBDE increases the morbidity 
of cholecystectomy from 3.6% to
17.5% (p < 0.001). Contrary to the 
mortality, which has decreased 
since 1970, the morbidity has not 
changed substantially. In the Ohio 
report,1 the incidence of complica­
tions was approximately 4%. In the 
more recent series, the incidence 
varied from 3.7% to 5.5%, being 
higher after operation for acute 
cholecystitis.24’5 Our overall mor­
bidity of 3.6% (3.1% in chronic 
cholecystitis and 6.1% in acute 
cholecystitis) does not differ signifi­
cantly from the rates in these series.
We encountered 30 intraopera­
tive iatrogenic bile duct injuries 
(0.3%). Twenty-four of these inju­
ries occurred in the 9339 patients 
who had cholecystectomy alone, 
and 6 occurred in the 1132 patients 
who had cholecystectomy with 
CBDE. The incidence of bile duct 
injury during cholecystectomy usu­
ally reported in the literature varies 
between 0.1% and 0.3% but most 
often includes only major trauma.11 
In this series, we considered minor 
as well as major traumas. If only 
major traumas (section or ligation) 
had been included, the incidence 
would be 0.07% for cholecystecto­
my alone and 0.2% for cholecystec­
tomy with CBDE.
In this review an attempt was 
made to analyse the mortality and 
morbidity in a large number of 
patients who had undergone chole­
cystectomy over the last two dec­
ades. The findings confirm that 
open cholecystectomy is a safe pro­
cedure that can be performed with 
low mortality and morbidity. Mor­
tality and morbidity of cholecystec­
tomy increase with advancing age 
and with the addition of a concomi­
tant CBDE. The presence of acute 
cholecystitis at cholecystectomy 
does not increase mortality or mor­
bidity significantly. Cardiovascular 
complications, especially myocardial 
infarction, are the main causes of 
death.
Because of its low mortality and
T a b le  V I. Operative Mortality After Cholecystectomy
S eries Y ea r
No. of 
patien ts M o rta lity , %
Gallbladder Survey Committee1 1970 28 621 1.8
Pickleman and Gonzalez2 1986 389 0.8
Ganey and associates3 1986 1 024 0.5
McSherry4 1989 10 749 0.6
Gilliland and Traverso5 1990 671 0.0
Heberer and associates6 1990 898 0.4
Present series 1993 9 339 0.3
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morbidity, traditional cholecystecto­
my is still the gold standard with 
which the numerous new nonopera­
tive techniques for gallstone man­
agement as well as laparoscopic 
cholecystectomy must be compared.
I thank Dr. Serge Dube for his statisti­
cal assistance and Mrs. Anne DeNon- 
court for her secretarial work.
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teric injury should have been stressed. 
These injuries are very difficult to diag­
nose because of associated abdominal 
physical signs, poor specificity by ab­
dominal lavage and poor definition by 
plain radiography or computed tomog­
raphy. Rectal injury is well emphasized; 
however, in my experience it is a far 
less common injury than the others.
At the Health Sciences Centre in 
Winnipeg, we follow the guidelines of a 
crash protocol in patients who have 
class IV hemorrhage on arrival at the 
hospital, have no blood pressure or 
exhibit no electromyographic activity 
or, finally, those who suffer cardiac 
arrest within minutes of entering the 
emergency department. In the young, 
otherwise-healthy patient, this is usual­
ly secondary to massive hemorrhage, so 
we quickly determine the site of bleed­
ing by insertion of right and left thora­
costomy tubes, abdominal lavage and 
pericardiocentesis, if indicated. Each
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sion or clamping, and resuscitation by 
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ing room. Review of such cases in our 
experience has provided a 12% survival 
rate in cardiac arrest and myocardial 
activity categories and a 77% survival 
rate in class IV deteriorating shock. 
These principles are covered in the text 
of this book, but they are buried in the 
discussion of intra-abdominal injuries. 
As far as the chest is concerned, the 
author of that section recommends 
emergency thoracotomy and determina­
tion of the site of bleeding in the 
operating room. I would suggest that 
our principle of crash guidelines avoids 
the misadventure of performing an ex­
cellent surgical exercise and controlling 
hemorrhage in the chest, while the 
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abdominal hemorrhage. Obviously, it is
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unfair to criticize something that is 
present, albeit hidden, in the text. How­
ever, I believe these guidelines and the 
principle of surgery as part of resuscita­
tion should be emphasized. Otherwise 
those patients balancing between death 
at the accident scene and arrival in the 
emergency department in extremis will 
fall through the crack and die.
This text is a superb resource as a 
reference and basic teaching vehicle for 
those practising any form of trauma 
surgery and those practising as emer­
gency physicians. I would recommend it 
for all hospital libraries, surgical pro­
grams and as a personal reference text.
C.M. Burns, MD, FRCSC
Director, Trauma Services 
Health Sciences Centre 
820 Sherbrook St. 
Winninpeg, MB 
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Endoscopic Retrograde 
Cholangiopancreatography 
in the Management of Choledocholithiasis 
With Laparoscopic Cholecystectomy
Andre Roy, MD, FRCSC; Vivian McAlister, MB, FRCSC, FRCSI; Ronald B. Passi, MD, FRCSC
With the advent of laparoscopic cholecystectomy, endoscopic retrograde 
cholangiopancreatography (ERCP) has an increasing role in perioperative 
management. To assess this role, the authors studied, retrospectively, 12 patients 
who underwent ERCP out of a series of 475 who had laparoscopic cholecystectomy. 
ERCP was indicated preoperatively for biliary colic in four patients, gallstone 
pancreatitis in two and common bile duct stone on ultrasonography in one. ERCP 
was performed postoperatively for jaundice in three patients, for cholangitis in one 
and for a positive intraoperative laparoscopic cholangiogram in one. 
Choledocholithiasis was diagnosed in six patients preoperatively and in three 
postoperatively. Only one patient had an unsuspected residual bile duct stone 
postoperatively. Of nine patients with stones, endoscopic sphincterotomy was 
performed in eight and stones were cleared in all with no complications; a stone 
passed spontaneously in the other patient. ERCP is indicated before laparoscopic 
cholecystectomy in cases of jaundice, gallstone pancreatitis, cholangitis, abnormal 
liver biochemistry suggesting cholestasis and ultrasonographic demonstration of 
either a common bile duct stone or a common bile duct greater than 8 mm in 
diameter. Operative laparoscopic cholangiography is indicated when the anatomy is 
unclear or the bile duct appears dilated. If choledocholithiasis is founded, the 
options include open or laparoscopic common bile duct exploration and intra- or 
postoperative endoscopic sphincterotomy.
Avec l’avenement de la cholecystectomie laparoscopique, la
cholangiopancreatographie endoscopique retrograde (CPER) joue un role de plus en 
plus important dans la demarche peroperatoire. Afin d’evaluer ce role, les auteurs 
ont etudie, en retrospective, 12 patients qui avaient subi une CPER d’un groupe de 
475 patients qui avaient subi une cholecystectomie laparoscopique. L’indication 
preoperatoire de la CPER fut une colique biliaire chez quatre patients, une 
pancreatite lithiasique chez deux et une choledocholithiase identifiee a l’echographie 
chez un. Une CPER postoperatoire fut pratiquee pour ictere chez trois patients, 
pour cholangite chez un et pour un cholangiogramme laparoscopique positif en 
cours d’intervention chez un. Une choledocholithiase fut diagnostiquee en 
preoperatoire chez six patients et en postoperatoire, chez trois. Un seul patient 
presenta un calcul biliaire residuel insoupfonne apres l’intervention. Sur neuf 
patients presentent des calculs, une sphincterotomie endoscopique fut pratiquee 
chez huit patients et les calculs furent elimines dans tous les cas, sans 
complications; un calcul fut elimine spontanement chez l’autre patient. Une CPER 
preoperatoire est indiquee avant la cholecystectomie laparoscopique dans les cas 
d’icteres, de pancreatite lithiasique ou de cholangite, quand les enzymes hepatiques 
anormaux suggerent une cholestase ou que l’echographie demontre soit un calcul 
dans le choledoque, soit un choledoque de diametre superieur a 8 mm. La 
cholangiographie laparoscopique operatoire est indiquee quand l’anatomie demeure 
obscure ou que le canal biliaire parait dilate. Quand une choledocholithiase est 
confirmee, les options comprennent l’exploration ouverte ou laparoscopique du 
choledoque et la sphincterotomie endoscopique intra ou postoperatoire.
S ince the early reports of Dubois and associates,1 Perissat, Collet 
and Belliard2 and Reddick and Ols­
en,3 laparoscopic cholecystectomy 
has revolutionized the management 
of gallstones by shortening hospital 
stay to 2 days and allowing an 
earlier return to normal activity, in 
7 to 15 days. Laparoscopic chole­
cystectomy has become the proce­
dure of choice in managing symp­
tomatic gallstones.4-6
With the advent of laparoscopic 
cholecystectomy, there is an in­
creasing role for endoscopic retro­
grade cholangiopancreatography 
(ERCP) perioperatively.7’8 In this pa­
per, we review our experience with 
ERCP and endoscopic sphincteroto­
my (ES) in 12 patients who under­
went laparoscopic cholecystectomy, 
and we discuss the evolving role of 
ERCP.
Patients and Methods
Between January and September 
1991, 475 patients underwent lapa­
roscopic cholecystectomy at Univer­
sity Hospital, London, Ont., and 
three referral hospitals. Among this
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group of patients, ERCP was per­
formed pre- or postoperatively in 
the 12 patients (10 women, 2 men). 
The mean age of the patients was 
43 years (range from 28 to 86 
years). All patients were treated 
initially as outpatients. Seven were 
hospitalized for 24 hours after un­
dergoing ES. Two other patients 
were hospitalized for 4 days after 
undergoing percutaneous trans- 
hepatic cholangiography (PTC).
Findings
Among the 12 patients (2.5% of 
the study population) who needed 
ERCP at some point in their investi­
gation or treatment, ERCP dis­
closed a stone (9 patients) and a 
lesion (1 patient) in 83% of them 
(10 of 12) and was successful in 
clearing the bile duct of stones in 
78% of patients (7 of 9). By combin­
ing PTC with ERCP, the stone 
clearance rate was 100% (nine of 
nine). No complications related to 
ERCP or ES occurred. Eight of nine 
patients who had stones needed ES 
for their extraction. In the ninth 
patient a stone passed spontaneous­
ly.
Preoperative ERCP
The indications for ERCP preop- 
eratively were jaundice associated 
with biliary colic and increased liver 
enzymes (four), gallstone pancreati­
tis (two) and common bile duct 
(CBD) stones on ultrasonography 
(one) (Table I).
Preoperative ERCP revealed CBD 
stones in five patients and a normal 
bile duct in two (Table I). Among 
the five cases of choledocholithia- 
sis, one was diagnosed by ERCP, 
but cannulation with the sphinc- 
terotome was unsuccessful. PTC 
was performed 3 days later and was 
normal. The stone passed spontane­
ously during the delay. One patient
who had a normal ERCP underwent 
a liver biopsy that showed drug- 
related hepatitis. The second pa­
tient with a normal ERCP under­
went this investigation because of a 
gallstone pancreatitis.
Postoperative ERCP
The indications for ERCP postop­
eratively were jaundice with an in­
creased alkaline phosphatase level 
(three), cholangitis (one) and posi­
tive laparoscopic cholangiography 
(one) (Table I).
Postoperative ERCP revealed 
choledocholithiasis in four patients 
and CBD injury in one (Table I). In 
one patient with choledocholithia­
sis, cannulation with the sphinc- 
terotome was unsuccessful. PTC 
with insertion of a no. 8 French 
ring biliary catheter and ES by a 
combined approach as previously 
described9 were performed. The bile 
duct injury was caused by a hemo- 
clip misplaced while attempting to 
control intraoperative bleeding. A 
Roux-en-Y hepaticojejunostomy 
bile duct reconstruction was per­
formed 3 weeks later. Only one 
patient had a residual stone that 
was not identified from the clinical 
history and preoperative work-up, 
resulting in an incidence of 0.2% (1 
in 475). The patient presented 8 
months postoperatively and cholan­
gitis was diagnosed.
Discussion
At present, like many others, we 
favour a selective approach to the 
perioperative assessment of patients 
who undergo laparoscopic cholecys­
tectomy.5-10"13 All patients should 
undergo liver function testing (se­
rum aspartase transaminase [AST], 
serum alanine transaminase [ALT], 
serum bilirubin and serum alkaline 
phosphatase measurements) and ab­
dominal ultrasonography in addi­
tion to routine history-taking and 
physical examination.14 Patients 
with jaundice, cholangitis, gallstone 
pancreatitis, biochemical abnormali­
ties on liver function testing, a CBD 
greater than 8 mm or ultrasono­
graphic evidence of choledocholi-
Table I. Course of 12 Patients Who Underwent Laparoscopic 
Cholecystectomy and Endoscopic Retrograde 
Cholangiopancreatography (ERCP)
Patient
no.
Timing of 
ERCP
Indication 
tor ERCP Diagnosis Treatment
1 Preop Jaundice, 
high enzymes
Normal Liver biopsy
2 Preop CBD stone on 
ultrasonography
CBD stone ES
3 Preop Jaundice, 
high enzymes
CBD stone 
Failed ES
PTC normal
4 Preop Pancreatitis Normal
5 Preop Jaundice, 
high enzymes
CBD stone ES
6 Preop Jaundice, 
high enzymes
CBD stone ES
7 Preop Pancreatitis CBD stone ES
8 Postop Cholangitis CBD stone ES
9 Postop Jaundice,
fever
CBD stone 
Failed ES
PTC, ES
10 Postop Positive
cholangiogram
CBD stone ES
11 Postop Jaundice CBD stone ES
12 Postop Jaundice CBD injury Roux-en-Y
reconstruction
CBD =  common bile duct, ES =  endoscopic sphincterotomy, PTC =  percutaneous transhepatic 
cholangiography
82 JCC, VOL. 36, NO 1, FEVRIER 1993
CHOLEDOCHOLITHIASIS
thiasis should undergo ERCP pre- 
operatively (Table II).1415 If ERCP is 
unsuccessful, the CBD can usually 
be cannulated with the aid of PTC 
and insertion of a biliary catheter.9 
Intravenous cholangiography with 
computed tomography is used com­
monly for CBD assessment before 
laparoscopic cholecystectomy. We 
consider it neither routinely neces­
sary nor justified. In a recent report 
from Ireland,16 every patient who 
had a choledocholithiasis shown on 
a preoperative intravenous cholan- 
giogram also had abnormal liver 
function, justifying a preoperative 
ERCP.
ERCP with sphincterotomy pre- 
operatively is contrary to the find­
ings of Neoptolemos, Carr-Locke 
and Fossard17 and Neoptolemos, 
Shaw and Carr-Locke18 in their 
studies on CBD stones and standard 
open cholecystectomy. However, 
open CBD exploration would negate 
the advantage to the patient of 
laparoscopic over open cholecystec­
tomy. It is therefore advantageous 
to the patient to have ERCP preop- 
eratively with ES instead of an open 
bile duct exploration when there is 
a CBD stone. When a diagnostic 
ERCP is performed, a morbidity as 
low as 0.8% and a mortality as low 
as 0.05% can be attained. If ERCP 
with ES is executed for choledo­
cholithiasis, morbidity less than 5%
Table II. Indication for ERCP Related to 
Laparoscopic Cholecystectomy
Preoperative ERCP 
Jaundice
Gallstone pancreatitis 
Abnormal liver function test results 
(serum transaminases, bilirubin, 
alkaline phosphastasej 
Abdominal ultrasonography 
common bile duct > 8 mm 
common bile duct stone 
Postoperative ERCP 
Positive operative cholangiography 
Jaundice
Biliary fistula/biloma 
Abnormal liver function test results 
(serum transaminases, bilirubin, 
alkaline phosphatase)
and mortality less than 1% can be 
achieved. Bleeding (1.4%), infec­
tions (0.9%) and perforations (0.5%) 
are the most serious complica­
tions.19-20 Those numbers are com­
parable to, if not better than, the 
reported morbidity of 16% and mor­
tality of 3.8% associated with open 
CBD exploration.21
With selective preoperative 
ERCP, operative cholangiography 
through the gallbladder or cystic 
duct is necessary only when the 
dissection is complex, the anatomy 
is distorted by inflammation, there 
is a dilated bile duct or the preoper­
ative ERCP is unsuccessful.14 When 
an operative laparoscopic cholangi- 
ogram shows a CBD stone, a trans- 
cystic duct drain may be inserted 
for draining the bile duct of an 
impacted stone and for introducing 
a guide wire if postoperative ERCP 
and ES are not successful (10% to 
20% of cases).22 The other options 
are open or laparoscopic bile duct 
exploration and intraoperative 
ERCP.
With selective preoperative ERCP 
and intraoperative laparoscopic cho­
langiography, a 2% to 3% (0.9% to 
6.3%) incidence of residual bile duct 
stones is expected.7-23"25 Most re­
tained stones will never cause prob­
lems or will pass spontaneously into 
the gut.26 Only 0.2% to 0.5% of 
patients will eventually need treat­
ment for a symptomatic residual 
CBD stone.11-27-28
Routine laparoscopic cholangiog­
raphy can be performed, with a 
success rate of 70% to 95%.10 How­
ever, routine operative cholangiog­
raphy has never been proved to 
have a positive risk-benefit ratio. 
Disavantages include an increased 
cost (estimated $299 US), radiation 
exposure and problems related to 
false-positive diagnoses.18-27-29 A 
false-positive cholangiogram (10% 
to 25%),30 leading to an unneces­
sary negative CBD exploration 
would increase the morbidity and
mortality of the procedure. Opera­
tive cholangiography has not de­
creased the incidence of bile duct 
injury.31 Finally, it is difficult to 
justify a test that benefits only 
0.21% of the patients, those who 
will eventually present with a symp­
tomatic residual CBD stone.
Laparoscopic CBD exploration 
performed via the cystic duct or a 
choledochotomy has been reported 
but does not appear as a practical 
approach.5-28-32-33 It is a time-con­
suming (up to 6 hours), complicat­
ed, experimental procedure with a 
low success rate.34 It should be 
reserved for the experienced laparo- 
scopist. Most surgeons cannot hope 
to reach and maintain sufficient 
skill to match the low morbidity, 
the success rate and the efficacy of 
ERCP and ES.19
Intraoperative ERCP has recently 
emerged as a treatment for choledo­
cholithiasis. It has been used previ­
ously in the management of pancre­
atic trauma discovered intraopera- 
tively.35 It would be indicated when 
an unsuspected stone is demon­
strated intraoperatively. The safety 
of this approach is unknown; one 
case of pancreatitis with a pseudo­
cyst has been reported.36
The perioperative management of 
choledocholithiasis for patients un­
dergoing laparoscopic cholecystec­
tomy can now be added to the 
pre-existing roles of ERCP. Various 
indications for diagnostic as well as 
therapeutic ERCP exist with laparo­
scopic cholecystectomy as well as 
with standard open cholecystecto­
my (Table II).28-37
Conclusions
We consider that ERCP should 
be performed preoperatively when 
choledocholithiasis is suspected, 
based on the patient’s history and 
the findings on physical examina­
tion, abdominal ultrasonography
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and biochemical investigations. We 
do not advocate routine operative 
cholangiography or laparoscopic 
CBD exploration. Intraoperative 
ERCP may have a limited role for 
choledocholithiasis diagnosed by la­
paroscopic cholangiography when 
performed because of a dilated bile 
duct discovered during surgery. 
Prospective studies need to be done 
to establish the best possible ap­
proach to the management of pa­
tients who undergo laparoscopic 
cholecystectomy. It would have to 
define the role of ERCP and opera­
tive cholangiography as well as the 
best sequence of execution based 
on the morbidity and mortality of 
the procedures.
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Anterior Cervical Corpectomy 
for the Treatment of Complex 
Cervical Lesions
Richard Hu, MD, FRCSC;* R. Geoffrey Wilber, MDt
Instability and stenosis of the cervical spine have been treated by posterior 
decompression and anterior decompression with fusion. In this study the authors 
evaluate the results obtained in 31 patients who underwent anterior cervical 
corpectomy for compressive or unstable lesions of the cervical spine. Operative 
level, preoperative and postoperative symptoms and physical findings were assessed. 
Twenty-seven patients had preoperative neurologic symptoms and signs, including 
alterations in sensation, motor findings and reflexes. The average follow-up was 12 
months, average number of disc spaces excised was 2.5 and average number of 
vertebral bodies excised was 1.6. With respect to relief of pain, results were good or 
excellent in 27 patients. All patients but one had union of the bone graft. No 
neurologic deterioration occurred. The authors believe that patients with 
compressive lesions of the cervical spine can benefit from anterior cervical 
corpectomy with fusion and that complications are minimal.
La stenose et l’instabilite de la colonne cervicale ont, jusqu’a maintenant, ete traitees 
par decompression posterieure ou par decompression anterieure avec fusion. On a 
evalue dans la presente etude, les resultats obtenus par corpectomie cervicale 
anterieure chez 31 patients operes pour des lesions compressives ou instables de la 
colonne cervicale. Le niveau operatoire, les symptomes pre et postoperatoires, ainsi 
que les observations physiques ont ete evalues. Vingt-sept patients presentaient des 
symptomes et signes neurologiques preoperatoires comprenant l’emoussement des 
sensations et une diminution du tonus moteur et des reflexes. La surveillance 
moyenne des suites therapeutiques est de 12 mois; on a excise en moyenne 2,5 
espaces interdiscaux et 1,6 corps vertebral. En ce qui a trait au soulagement de la 
douleur, on a obtenu de bons ou d’excellents resultats chez 27 patients. Sauf pour 
un cas, il y a eu fusion du greffon osseux chez tous les malades. Aucune 
deterioration neurologique n'a ete observee. Les auteurs croient que les patients 
souffrant de lesions compressives de la colonne cervicale peuvent beneficier d’une 
corpectomie cervicale anterieure avec fusion, tout en eprouvant un minimum de 
complications.
S tenosis of the cervical spinal canal has been treated with a 
variety of techniques. Controversy 
exists as to whether an anterior or 
posterior approach should be used
Accepted for publication Apr. 13, 1992
and whether stabilization is re­
quired. Instability of the spine often 
occurs after posterior surgical inter­
vention,1-4 and as a result of degen­
erative or traumatic conditions.
Proponents of posterior decompres­
sive methods such as laminectomy 
and laminaplasty5’6 believe that mor­
bidity is minimal and recovery of 
neurologic function satisfactory. 
Postoperative instability is not con­
sidered serious provided the facet 
joints have not been damaged. Pro­
ponents of anterior decompression 
and fusion report good results for 
return of neurologic function and 
stability.7-11 The goal of this paper 
is to describe the technique and 
results of anterior vertebral corpec­
tomy for symptomatic cervical ste­
nosis and instability.
Patients and Methods
A consecutive series of 31 pa­
tients who underwent anterior cer­
vical corpectomy at MetroHealth 
Medical Centre, Cleveland, were re­
viewed retrospectively. All patients 
had surgery performed by one of 
the authors (R.G.W.). Follow-up in­
cluded a review of the outpatient 
clinic notes and radiographs. Indica­
tions for surgery included compres­
sive conditions with myelopathic or 
radicular symptoms, instability after 
posterior decompressive surgery 
and nonunion of segments previ­
ously operated on.
Patients were assessed preopera- 
tively by history taking and physical 
examination. Particular attention 
was paid to symptoms of pain in the 
cervical spine, to motor deficits and 
to signs of myelopathy, including 
abnormal reflexes and weakness. 
Radiologic assessment included an-
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teroposterior and lateral radio­
graphs of the cervical spine (Fig. 1). 
Magnetic resonance imaging (MRI) 
followed by computed tomography 
(CT) with intrathecal contrast medi­
um was performed to confirm the 
clinical diagnosis and help deter­
mine proposed levels of decompres­
sion and fusion (Fig. 2). The level 
of decompression used was based 
on the symptomatic radicular level 
with confirmatory motor deficit dis­
tal to the lesion and on the com­
pressive levels on MRI and CT as 
demonstrated by loss of subarach­
noid cerebrospinal fluid surround­
ing the spinal cord. Atrophy or 
deformation of the cord was consid­
ered a sign of substantial compres­
sion.
Surgical Procedure
Patients were positioned supine 
on the operating table with a small 
roll beneath the shoulders to allow 
slight extension of the cervical 
spine. Somatosensory-evoked po-
FIG. 1. Lateral radiograph of cervical 
spine demonstrating area of spondylo­
sis with disc-space narrowing and os­
teophytes.
tentials were used intraoperatively 
(Pathfinder; Nicolet, Inc.. Madison, 
Wis.). Shoulder traction was main­
tained with adhesive tape to allow 
satisfactory intraoperative radiolog­
ic visualization of the entire cervical 
spine. The head was turned to the 
contralateral side, allowing an an­
terolateral approach to the cervical 
spine. With the aid of self-retaining 
cervical retractors, the longus colli 
muscle was bluntly dissected from 
the anterolateral aspect of the verte­
bral bodies. Segmental vessels were 
coagulated with diathermy. A later­
al radiograph and a spinal needle in 
the disc spaces allowed identifica­
tion of upper and lower disc spaces 
for proposed decompression. Rou­
tine discectomies were then per­
formed and decompression to the 
posterior longitudinal ligament 
(PLL) was done. Further decom­
pression of vertebral bodies was 
carried to a depth corresponding 
with the disc space. A power burr 
was used to remove the rest of the 
vertebral body. Once the posterior 
cortical surface was reached, the 
burr was changed to a diamond- 
tipped one to allow more gentle
removal of the posterior cortex of 
the bodies. Angled and straight cu­
rettes were used to pull forward 
fragments that were adherent to the 
PLL. Adequate posterolateral de­
compression of the vertebral body 
must be done by undermining the 
vertebral body and the disc space 
with the diamond-tipped burr or the 
curettes.
Preparation of the end plates for 
acceptance of bone graft was then 
done with a keystone-type tech­
nique.12 The superficial margin of 
the trough for bone graft is narrow­
er than the deeper portions, thus 
allowing a shaped graft to lock into 
place once inserted (Fig. 3). Bone 
graft was obtained from the ipsilat- 
eral iliac crest if two or fewer 
vertebral bodies were removed. If 
more than two bodies were removed 
a fibular strut graft was used. The 
bone was harvested from the ipsilat- 
eral extremity. Post operatively, the 
patients were maintained in a rigid 
cervical thoracic orthosis if fewer 
than three levels were fused. If 
more than three levels were fused, 
patients were placed into a Halovest 
(Bremer Corp., Jacksonville, Fla.).
FIG. 2. Axial magnetic resonance image shows loss of cerebrospinal fluid anterior 
to spinal cord and cord compression.
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Patients with more than than 
three levels of decompression were 
kept in the intensive care unit with 
endotracheal intubation for approxi­
mately 36 to 48 hours because of 
the potential for obstruction of the 
airway secondary to edema in the 
neck.
Follow-up
Postoperative follow-up and as­
sessment were performed at 6 
weeks, 3 months, 6 months and 1 
year after surgery. Patients were 
assessed for pain, sensory and 
motor signs and myelopathic signs. 
Pain and neurologic findings were
assigned a numeric grade. Pain was 
graded from 0 to 3 as follows: 0, a 
poor result, showing continuous 
pain with no improvement from 
preoperative levels; 1, a fair result, 
some improvement; 2, a good re­
sult, marked improvement with 
minimal pain; and 3, excellent or no 
pain. Postoperative neurologic sta­
tus was graded similarly as follows: 
0, no improvement; 1, minimal im­
provement; 2, substantial improve­
ment in motor findings; and 3, 
normal motor strength.
Bony union was assessed from 
flexion and extension lateral radio­
graphs.
FIG. 3. Diagram demonstrating key­
stone shape of prepared trough with 
fitted graft in place. PLL = posterior 
longitudinal ligament.
FIG. 4. Nonunion of fibular graft treat­
ed with posterior multilevel wiring and 
fusion.
Results
Thirty-one patients were re­
viewed. The indications for surgery 
included cervical stenosis or cord 
compression (17 patients), non­
union from previous surgery (6 pa­
tients), an ossified PLL (5 patients) 
and cervical kyphosis after pre­
vious posterior decompression (3 
patients). There were 19 men and 
12 women in whom the average age 
was 52.9 years (range from 23 to 
77 years). Average time to follow­
up was 12 months (range from 10 
to 42 months). Preoperative neuro­
logic findings included sensory defi­
cit in 27 patients, motor weakness 
in 24 patients and myelopathy in 17 
patients. The average number of 
discs excised was 2.5 with a mode 
of 3. Four patients had one disc 
excised, 11 patients had 2 discs 
excised, 12 patients had 3 discs 
excised and 4 patients had four 
discs excised. An average of 1.6 
vertebral bodies were excised with 
the mode being one. Sixteen pa­
tients had one vertebral body ex­
cised, 11 patients had two vertebral 
bodies excised and 4 patients had 
three vertebral bodies excised.
An iliac-crest bone graft was used 
in 27 patients and a fibular strut
graft was used in 4 patients.
Twenty-seven patients had good 
or excellent (grades 2 and 3) results 
on assessment of pain relief. Four 
patients had poor or fair results. 
For patients with pre-existing neu­
rologic findings, 16 had good 
(grade 2) results and 11 had excel­
lent (grade 3) results. There was a 
slight negative correlation between 
number of vertebral bodies excised 
and neurologic result (r=  0.6).
All patients with iliac-crest grafts 
had bony union. One of four pa­
tients with a fibular strut graft had 
nonunion (Fig. 4).
Complications
Six patients had complications. 
One patient required re-exploration. 
After three-level anterior decom­
pression there was improvement 
from the preoperative levels, but 
neurologic recovery plateaued with 
continued weakness of the right 
arm. CT with intrathecal contrast 
medium demonstrated inadequate 
decompression of the right pos­
terolateral vertebral body. Re­
exploration resulted in neurologic 
improvement. One patient experi­
enced nonunion of a fibular graft 
and subsequently underwent pos­
terior fusion with wiring of the 
spinous process and bone grafting. 
One patient had a sterile seroma of 
the incision, and one had loosening 
of the halo pin. Two patients had 
persistent pain at the graft site. 
There were no neurologic complica­
tions and no other cases of nonun­
ion.
Discussion
Cervical corpectomy is useful in 
the treatment of complex compres­
sive diseases of the cervical spine. 
Alternatives include multilevel ante­
rior cervical discectomy with or
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without fusion,27’10' 15 cervical lami­
nectomy213 and cervical lamina- 
plasty.56
Multilevel discectomy has been 
shown to be useful; however, com­
pleteness of decompression and the 
limited visibility make this a more 
technically demanding procedure. A 
more complete decompression is 
possible with corpectomy, and os­
teophytes may be removed safely 
without potential damage to the 
spinal cord.8'9'12 With multilevel dis­
cectomy, the number of interfaces 
that are required for fusion in­
crease, and this will increase the 
incidence of nonunion. With cor­
pectomy, only two surfaces are pre­
sented for fusion with fewer 
chances for nonunion. Laminecto­
my as a treatment method for mul­
tilevel stenosis should be discour­
aged. Long-term results have prov­
en that neurologic progression is 
the rule rather than the exception 
and that instability will occur pro­
ducing cervical kyphosis.2-413 Bi­
omechanical testing confirms the 
instability of the spine after lami­
nectomy.16 Laminaplasty is com­
monly practised in the Far East 
where multilevel ossified PLL is 
common. It is considered that lami­
naplasty will maintain biomechani­
cal stability while enabling decom­
pression of the central canal. This 
approach may not be useful in 
patients who have radicular symp­
toms.
Postoperatively, 27 of the 31 
patients in our study showed satis­
factory neurologic improvement and 
27 had satisfactory pain relief. The 
number of vertebral bodies excised 
seems to have a negative correlation 
with neurologic results; that is, pa­
tients with greater numbers of ver­
tebral bodies excised will have the 
poorer neurologic scores postopera­
tively. This is not unexpected be­
cause patients requiring decompres­
sion of larger numbers of vertebral 
bodies have more severe symptoms
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and findings preoperatively. No pa­
tient in this series experienced neu­
rologic deterioration.
The choice of graft material de­
pends upon the number of levels 
being decompressed. Autogenous 
graft material is less prone to non­
union than xenograft or allograft 
material. With more than two verte­
bral bodies being removed, iliac- 
crest graft is not straight enough to 
provide a strong bicortical strut 
that will fit within the trough creat­
ed by corpectomy. Fibula will fit, 
but the rate of nonunion is higher 
with this type of grafting.17 One 
patient experienced nonunion of his 
fibular graft and required posterior 
fusion, which resolved his symp­
toms.17 Graft dislodgement did not 
occur in this series but is a compli­
cation of corpectomy.18 Patients 
with more than three bodies ex­
cised, with cervical lordosis or with 
posterior instability following lami­
nectomy are prone to dislodgement 
and require halo immobilization 
postoperatively.4 Airway obstruc­
tion is life threatening, and our 
patients with three-level corpectomy 
or high cervical corpectomies re­
main intubated in the intensive care 
unit for 36 to 48 hours postopera­
tively. Other complications in this 
series have not been serious and 
have been managed easily.
Conclusions
Cervical corpectomy is a safe and 
effective treatment for complex 
compressive lesions of the cervical 
spinal cord. With appropriate pre­
operative planning, intraoperative 
technique and postoperative care 
optimal results can be achieved.
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Carcinoma of the Prostate: Case Report
Padraig Warde, MB, MRCPI, FRCPC; Mary Gospodarowicz, MD, FRCPC
The authors report a case of carcinoma of the prostate with an unusual 
presentation. The patient, an 80-year-old man, had swelling of the right buttock and 
right side of the lower abdomen, diffuse bony pain and increasing weakness of both 
lower limbs. He responded well to therapy. Aggressive management of previously 
untreated carcinoma is warranted even in elderly patients with metastatic disease.
Les auteurs decrivent un cas de carcinome prostatique ayant presente un tableau 
clinique inhabituel. Le patient, un homme de 80 ans, montrait une enflure de la 
fesse droite et du cote droit de l’abdomen inferieur, une douleur osseuse diffuse et 
une faiblesse croissante des membres inferieurs. II repondit bien a la therapie. Un 
traitement agressif d’un cancer prealablement non traite est de mise, meme chez les 
patients ages qui montrent un envahissement metastatique.
A denocarcinoma of the prostate is the second commonest cause 
of cancer death in men in the 
United States. There, in 1991, it 
was estimated that 122 000 cases 
of the disease would be diagnosed, 
of which approximately 20% would 
be metastatic.1 We report on a 
patient with an unusual presenta­
tion of metastatic adenocarcinoma 
of the prostate and a gratifying 
response to therapy.
Case Report
An 80-year-old man was first 
seen in June 1986. He gave a 2-year 
history of swelling of the right 
buttock and right side of the lower 
abdomen, a 3-month history of dif­
fuse bony pain of increasing severi­
ty and a 2-week history of increas­
ing weakness of both lower limbs. 
He was admitted to a community 
hospital with acute urinary reten­
tion and paraplegia.
At the time of admission his 
performance status was estimated 
at 40% on the Karnofsky scale. He 
had a distended abdomen with a 
large nontender mass in the right 
iliac fossa, measuring 12 cm in 
diameter. A second mass in the 
right buttock measured approxi­
mately 15 cm in diameter, and a 
third mass in the medial left groin 
measured 10 cm in diameter. He 
had a urinary catheter in situ, and 
on rectal examination anal tone was 
normal. He had a moderately en­
larged hard prostate, which was 
clinically consistent with malignan­
cy.
Neurologic examination of his 
lower limbs showed virtually absent
power in all muscle groups. Muscle 
tone and sensation were decreased 
bilaterally, plantar responses were 
normal, but both ankle and knee 
jerks were absent bilaterally.
Biochemical screening revealed a 
10-fold elevation in the serum acid 
phosphatase level. Computed to­
mography (CT) of the pelvis and 
abdomen (Fig. 1) showed a large 
mass in the right side of the pelvis, 
with destruction of the right iliac 
bone. The mass, anterior to the iliac 
wing, measured 11 cm in diameter; 
the mass posteriorly measured 11.5 
cm in diameter. A left pelvic side- 
wall mass and a third palpable mass 
were present in the medial region of 
the left thigh, extending from the 
level of the mid-femur to the pubic 
ramus.
Initially, the patient refused to 
consent to any invasive investiga­
tions, but he agreed to a biopsy of 
the right buttock mass under local 
anesthesia. This showed a moder­
ately differentiated adenocarcinoma 
consistent with a primary carcinoma 
of the prostate (prostate-specific- 
antigen staining was positive). Bilat­
eral orchiectomy was recommended, 
but the patient refused and was 
started on stilbestrol, 1 mg three 
times daily. He returned to the 
referring hospital.
When seen again 6 weeks later 
the patient had no pain and was 
able to walk with some assistance. 
Repeat CT showed a marked de­
crease in the size of the previously 
noted masses; however, some dis­
ease was still present (Fig. 2). The
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FIG. 1. Computed tomography (CT) scan of pelvis at presenta- FIG. 2. CT scan of pelvis 6 weeks after start of stilbestrol 
tion. therapy, showing marked improvement.
serum acid phosphatase level had 
returned to the normal range. The 
urinary catheter was removed, and 
stilbestrol was discontinued because 
of concern regarding cardiovascular 
complications. The patient contin­
ued to refuse orchiectomy and was 
started on 1 mg leuprolide daily.
The patient has been followed up 
in the clinic at regular intervals for 
5 years since diagnosis. On the last 
follow-up examination he was fully 
ambulant and pain free with a Kar- 
nofsky performance status of 90%. 
Bladder control was normal. On 
physical examination he had no 
palpable masses, and digital rectal 
examination revealed a soft, some­
what enlarged prostate. Neurologi- 
cally his lower limbs were normal. A
recent CT scan of the pelvis showed 
an enlarged prostate but no other 
abnormality. His acid phosphatase 
level was normal, and his prostate- 
specific-antigen level was only mod­
erately elevated. He continues to 
have daily leuprolide injections and 
to refuse orchiectomy.
Discussion
Soft issue metastases as a pre­
senting feature of metastatic carci­
noma of the prostate are very un­
usual. When we first examined this 
patient it was our opinion that, 
although he likely had metastatic 
carcinoma of the prostate, he might 
have another malignant tumour,
perhaps a soft tissue sarcoma.
We emphasise that aggressive 
management of previously un­
treated carcinoma of the prostate is 
warranted, even in elderly patients 
with metastatic disease. The extent 
of disease does not accurately pre­
dict response to hormonal therapy; 
indeed there are no absolute predic­
tors of hormonal sensitivity.2
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EthiopiaT h e Spectrum of Surgery in
Antoine Loutfi, MD;* Joyce L. Pickering, MD, MSct
Ethiopia’s need for surgical services is assessed from on-site reviews of 
operating-room records in various hospitals and compared with data from other 
countries. Information on surgical manpower and total operations for the country 
were obtained from the Ministry of Health of Ethiopia. In Ethiopia the ratio of 
surgeons to population is very low (0.32 surgeons per 100 000 population) and 
inadequate numbers of essential operations (e.g., cesarean section and 
inguinal-hernia repair) are performed. The average age of the surgical patient is 
young (37 years), and men are operated on twice as frequently as women.
Of the 9422 operations performed during 6 months in the central, regional and 
rural hospitals surveyed, 7037 (75%) could be performed by a general practitioner or 
a paramedic specially trained for the procedure and would not require a fully trained 
general surgeon. The implications for surgical manpower training are discussed.
Les besoins ethiopiens en services chirurgicaux ont ete evalues par une etude sur 
place des dossiers chirurgicaux de divers hopitaux et une comparaison avec les 
donnees d’autres pays. L'information sur les effectifs chirurgicaux et sur le total des 
interventions chirurgicales pratiquees dans ce pays ont ete obtenus du ministere de 
la sante de l’Ethiopie. En Ethiopie, le rapport du nombre de chirurgiens a la 
population est tres faible (0,32 par 100 000 de population) et un nombre insuffisant 
d’operations essentielles (par exemple, cesarienne ou reparation de hernie 
inguinale) est pratique. L’age moyen des operes est bas (37 ans) et les hommes sont 
operes deux fois plus souvent que les femmes.
Des 9422 operations effectuees en 6 mois dans les hopitaux centraux, regionaux 
et ruraux ayant fait l’objet de l’enquete, 7037 (75 %) auraient pu etre pratiquees par 
un medecin generaliste ou par un infirmier paramedical forme specialement pour ces 
interventions, sans avoir a recourir a un chirurgien general. On commente les 
implications de ces resultats quant a la formation des effectifs chirurgicaux.
Published data on surgery in developing countries is scarce. 
From observation it appears that 
surgeons are few, that many people 
die of treatable surgical conditions
Accepted for publication Nov. 12, 1991
and that the quality of surgical 
service is often low.
To develop a rational approach to 
improve this situation, it is impor­
tant to have data on what surgery is
currently performed and on the cur­
rent state of surgical manpower. 
This study was undertaken to iden­
tify the number of surgeons and the 
type and complexity of surgical 
conditions commonly treated at the 
different levels of the health system 
in Ethiopia.
Methods
Information on the numbers of 
surgeons, surgical beds and opera­
tions performed throughout the 
country was obtained from the Ethi­
opian Comprehensive Health Ser­
vices Directories for 1983-1984 
and 1986-1987.12 Additional infor­
mation on specific types of opera­
tions (groin-hernia repair, cesarean 
section and appendectomy) was 
gathered from all the hospitals in 
Addis Ababa and from three region­
al hospitals (Jimma, Bahar Dar and 
Gondar) for the period September 
1988 to February 1989 inclusive. 
From this information, we calculat­
ed the annual rate of these opera­
tions per 100 000 population.
The spectrum of surgery was 
based on a review of the operating- 
room log books and outpatient re­
cords of minor operations for the 
6-month period September 1988 to 
February 1989 for the following 
institutions: two central teaching 
hospitals in Addis Ababa; the three 
regional hospitals already men­
tioned, all of which were located 
more than 350 km from Addis 
Ababa; two rural hospitals; and five 
health centres.
From the *Department o f Surgery, McGill University, Montreal. Que., and the Department o f  
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Project, Addis Ababa
Supported by the Canadian International Development Agency through the McGill Ethiopia 
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Although the rural and regional 
hospitals and the health centres 
were selected largely on the basis of 
accessibility, from personal experi­
ence they seem to be representative 
of these types of health institutions 
in Ethiopia. An important exception 
is health institutions in areas of 
active fighting due to the civil war. 
These areas were not accessible to 
the authors.
All operations were grouped into 
four categories (A, B, C and D) in 
ascending order of complexity, as 
recommended by Watters and Bay- 
ley.3 These categories are defined as 
follows.
•  Group A — operations that 
should be within the competence of 
any qualified doctor or suitably 
trained paramedic.
•  Group B — operations that 
could be performed by a doctor or 
paramedic specially trained for the 
procedure.
•  Group C — operations that 
normally could be performed by 
someone with higher qualifications 
and surgical training appropriate 
for developing countries.
•  Group D — operations that 
require subspecialty training beyond 
the scope of the average general 
surgeon.
Sex and age of the surgical pa­
tients were assessed for the two 
central teaching hospitals.
To assess seasonal variations, 
data were reviewed from one each 
of the central, regional and rural 
hospitals for an entire year, and 
compared with the 6-month find­
ings.
Findings
The population of Ethiopia was 
approximately 42 million according 
to the 1983-1984 census. With an 
estimated growth rate of 2.9% per 
year, the 1988-1989 population is 
estimated to be 49 million.
In 1986-1987 in Ethiopia there 
were 170 surgeons, including all 
general surgeons, orthopedic sur­
geons, urologists, otorhinoiaryn- 
gologists and obstetrician-gynecolo­
gists. Only 50 of these were Ethi­
opians. In total 67 982 operations 
were performed. The rate of opera­
tions was 148 per 100 000 popula­
tion, and there were nine surgical 
beds per 100 000 population.
Table I compares the rates of 
operations and surgeons per 
100 000 population in Ethiopia 
with those in other countries.4-6
In an attempt to contrast the 
need for surgery with the surgery 
performed in Ethiopia, population- 
based data on cesarean sections, 
groin-hernia repairs and appendec­
tomies were compared with the 
need for surgery in East African 
countries as estimated by Nordberg7 
(Table II5 78).
The seven hospitals and five 
health centres from which data
were drawn ranged in size from 30 
to 448 beds. The two central hospi­
tals accounted for 873 beds (27.5% 
of all beds in Addis Ababa), the 
three regional hospitals for 625 
beds (60.5% of all beds in the 
regions studied) and the two rural 
hospitals for 150 beds. All seven 
hospitals had qualified general sur­
geons, and all but one had a quali­
fied gynecologist during the period 
for which the operations were deter­
mined. Expatriate surgeons repre­
sented 50% of surgeons in teaching 
hospitals and 100% of the surgeons 
in the other hospitals.
Tables III to VI show the type 
and number of operations per­
formed at the three levels of hospi­
tals in the various groups (A to D). 
Table VII shows the number and 
percentage of the different catego­
ries of surgery performed in the 
three levels of hospitals. Overall, 
75% of the operations performed at 
all hospitals fell into groups A and
Table I. Rates of Operations and Surgeons per 100 000 Population in Various Countries
Country Operations Surgeons
Ethiopia, 1983 -  1984 163 0.32
Pakistan, 19834 124 0.36
England and Wales, 1976s* 1314 1.8
United States, 19786 9200 38
'Includes general surgeons and general surgery cases only
Table II. Number of Cesarean Sections, Groin-Hernia Repairs and Appendectomies Performed in 
Ethiopia and Other Countries Compared With the Need for These Operations in East Africa as 
Estimated by Nordberg7'
Area/country
Cesarean
section
Groin-hernia
repair Appendectomy
Addis Ababat 66 8.7 26
Regional
hospitals^ 9.2 2.5 3
England and Wales5 — 129.6 143.5
Canada (1977)8 184 219 163
Nordberg7§ 4 - 6 2 2 - 1 0 0 —
Need as estimated by 
Nordberg7 for East
African countries 225 175 —
'Numbers per 100 000 population 
tincludes all hospitals performing surgery
tJimma, Bahar Dar and Gondar. Although these are regional hospitals, the town population was 
used as the denominator to calculate the rates, because few patients actually come from outside 
the town. If the regional population was used as the denominator, the rates would, of course, be 
much lower.
§Data are from various East African countries, including Ethiopia.
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B, and these two groups accounted 
for 64% of all general surgery 
cases, 70% of urology cases, 59% of 
orthopedic cases and 89% of obstet­
ric and gynecologic cases. The 
three levels of hospitals had similar 
proportions of the different groups 
of surgery.
When the operations were 
grouped according to subspecialty, 
operative obstetrics and gynecology 
accounted for 44% of the total 
operations, general surgery ac­
counted for 34% of operations, or­
thopedics accounted for 15% of 
operations and urology accounted 
for 7% of operations.
The 10 most commonly per­
formed major operations were simi­
lar in the three levels of hospitals 
(Table VIII). A similar distribution 
was also found for the most com­
mon minor operations, with dilata­
tion and curettage being the most 
common.
General surgical emergencies ac­
Table III. Number of Operations of Group A* Performed at the Three Levels of Hospitals in
Ethiopia
Level of hospital
Procedure Central Regional Rural
Simple biopsy 367 12 —
Wound repair 224 169 91
Foreign-body removal 137 50 25
Incision and drainage
of abscess 87 79 27
Chest-tube insertion 33 25 8
Miscellaneous (cutdown,
catheterization, dressing) 47 — 2
Total 895 335 153
'Operations within the competence of any qualified doctor or suitably trained paramedic
Table IV. Number of Operations of Group B* Performed at the Three Levels of Hospitals in
Ethiopia
Level of hospital
Procedure Central Regional Rural
Skin grafting 109 24 1
Perianal surgery 74 51 27
Excision of lump 187 27 60
Groin-hernia repair 53 31 13
Appendectomy 111 40 14
Burr holes 10 1 —
Sigmoidoscopy 51 — —
Circumcision 91 6 61
Scrotal operations 85 27 9
Amputation
Debridement/
92 41 13
sequestrectomy 249 107 6
Bouginage 
Minor testicular
118 5
operations 20 14 1
Cystostomy 
Fracture: closed
9 11 1
reduction NAt 63 39
Dilatation and curettage 2654 314 90
Cesarean section 
Minor gynecologic
301 116 30
procedures 81 90 26
Total 4295 968 391
'Operations that could be performed by a doctor or paramedic specially trained for the procedure.
tNA =  not available
counted for 31%, 43% and 52% of 
all general surgical cases at the 
central, regional and rural hospitals 
respectively.
When sex was assessed, exclud­
ing obstetric and gynecologic cases, 
the male-to-female ratio was 2:1, 
and the average age, excluding pe­
diatric patients 12 years of age or 
younger, was 38 years for males 
and 34 years for females.
The average hospital stay on the 
surgical wards was 14 days for the 
two rural hospitals but over 20 days 
for all others, and up to 51 days for 
one of the regional hospitals.
Comparison of 6-month data ver­
sus 1-year data in the selected hos­
pitals showed no important differ­
ences.
Of the 1650 patients with surgi­
cal conditions who were seen at the 
five health centres in 6 months, 
90% had suffered trauma or had 
general surgical emergencies. The 
majority had lacerations, bites and 
closed fractures that were managed 
at the health centre. Patients with 
acute abdominal and obstetrical 
emergencies and elective conditions 
were advised to go to the closest 
hospital.
Discussion
A study such as this one, which 
merely records what is done, does 
not provide data on what operations 
should or should not have been 
performed. For this, population- 
based information is needed. Also 
we cannot comment on the out­
come of these operations, clearly a 
factor of major interest and worthy 
of future study.
It seems clear that the operations 
being performed in Ethiopia vary 
little between teaching and rural 
hospitals, with the exception of 
proportionally more general surgi­
cal emergencies (52% v. 31%) being 
done in rural as opposed to teach­
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ing hospitals. This difference may 
be a reflection of the more limited 
resources in peripheral hospitals, 
where beds and supplies are used 
for emergency conditions, and not 
enough are left for elective cases.
Like Watters and Bayley,3 we 
have found that the majority of 
cases (75%) were not complex.
Without information on the com­
plexity of individual cases, it is 
difficult to comment on the appro­
priateness of the relatively long av­
erage stay for surgical patients. 
However, personal experience in 
central hospitals suggests that 
much of it is unnecessary, and in a 
significant proportion of patients is 
due to long pre- and postoperative 
stays for elective procedures.
That the unmet surgical needs in 
most parts of East Africa are great 
is not disputed. Nordberg7 estimat­
ed that only 15% of needed opera­
tions are carried out, and for some 
areas this rate is much lower. We 
found that the regional hospitals 
performed only 4% of the needed 
cesarean sections and 1.4% of the 
needed hernia repairs. Many condi­
tions requiring surgery affect men 
and women during the most pro­
ductive years of their life, when 
they may be the primary breadwin­
ners. This finding is supported by 
the relatively young age of surgical 
patients (38 years for men, 34 years 
for women). The high ratio of men 
to women on the surgical wards 
suggests that women are probably 
underserved.
Although most surgeons (71%) in 
Ethiopia are expatriates and the aim 
is to replace them with nationals, it 
will take some time to replace them, 
because the only training program 
for surgeons in the country follows 
a standard 4-year curriculum.8 
Therefore, serious consideration 
should be given to assessing and 
improving the surgical skills of gen­
eral practitioners, especially those 
in rural areas. This could be done
through a short training program in 
which the practitioners can learn 
how to manage the commonly en­
countered surgical and obstetric 
conditions seen in the rural hospital 
or health centre. Specifically, they
Table V. Number of Operations of Group C ' Performed at the Three Levels of Hospitals in
Ethiopia
Level of hospital
Procedure Central Regional Rural
Elective laparotomy 46 18 5
Colorectal operations 41 7 3
Colostomy
Gastroduodenal
24 7 1
operations 77 8 _
Gallbladder operations 112 _ 1
Mastectomy 27 10 _
Thyroidectomy 50 17 1
Bronchoscopy 30 8 _
Tracheostomy 21 4 _
Incisional-hernia repair 
Operation for
25 18 5
intestinal obstruction 
Operation for
58 51 33
peritonitis 81 81 32
Intestinal fistula 10 8 _
Varicose-vein surgery 26 3 _
Prostatectomy 39 9 _
Kidney operations 30 2 1
Bladder operations 12 4 _
Cystoscopy 91 _ 1
Hypospadias repair 9 _ 1
Fracture fixation 
Hysterectomy and other 
major gynecologic
296 128 9
procedures 291 110 40
Total 1396 493 133
'Operations that normally could be performed by someone with higher qualifications and surgical 
training appropriate for developing countries.
Table VI. Number of Operations of Group D* Performed at the Three Levels of Hospitals in
Ethiopia
Level of hospital
Procedure Central Regional Rural
Plastic surgery 121 19 5
Orthopedicsf 122 13 12
General surgery): 51 19 1
Total 294 51 18
'Operations that require subspecialty training beyond the scope of the average general surgeon, 
tlncludes operations such as tendon transfers, hip replacement and laminectomy.
^Includes thoracic, vascular, head-and-neck tumour surgery and anal atresia surgery.
Table VII. Total Number (%) of the Four Groups of Operation Performed at the Three Levels of
Hospitals in Ethiopia
Level of hospital
Group Central Regional Rural Total
A 895 (13) 335 (18) 153 (22) 1383(15)
B 4295 (62) 968(52) 391 (56) 5654(60)
C 1396 (20) 493 (27) 133(19) 2022(21)
D 294 (4) 51 (3) 18(3) 363 (4)
Total 6880(100) 1847(100) 695(100) 9422(100)
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need to be able to perform all 
operations in groups A and B. 
These trained practitioners should 
be visited regularly by a fully 
trained surgeon to help maintain 
morale and quality control and to 
provide continuing medical educa­
tion.9
Ideally, these procedures should 
be in the repertoire of finishing 
interns. However, in Ethiopia the 
relatively high ratio of students, 
interns and residents to patients in 
teaching hospitals means that op­
portunities for students and interns 
to perform the operations are limit­
ed.
Three areas are of particular in­
terest for further research. The 
first, mentioned above, is the out­
come of the operations performed. 
The second is to know, before train­
ing general practitioners further in 
surgical skills, how many health 
centres and hospitals in Ethiopia 
actually have functioning equip­
ment and staff that would allow 
surgery to be performed. The third 
area for research is health centres. 
In Ethiopia in 1988 and 1989, there 
were 156 health centres and 88 
hospitals. Thus, more people have 
access to health centres than hospi­
tals. The referral system here is 
essentially nonfunctional and it is 
likely that, for reasons of logistics, 
many who present to health centres 
with acute surgical problems will 
never get to a hospital. Thus, it is 
important to know what surgical
services health centres can and 
should provide.
We thank the Ministry of Health of 
Ethiopia, the members of the Depart­
ment of Surgery, Addis Ababa Universi­
ty, and the many staff at various hospi­
tals whose cooperation helped us to 
prepare this report.
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Table VIII. T en  M o s t F re q u e n tly  P e rfo rm e d  M a jo r O p e ra tion s  b y  Leve l o f  H o sp ita l In E th io p ia
Level of hospital
Frequency Central Regional Rural
1 C esarean
se c tio n
F rac tu re
fix a tio n
H ys te re c to m y
2 F rac ture C esarean R e lie f o f
f ix a tio n se c tio n in te s tin a l
o b s tru c tio n
3 H y s te re c to m y H y s te re c to m y O p e ra tion  fo r  
p e r ito n itis
4 D e b r id e m e n t/ D e b r id e m e n t/ C esarean
se q u e s tre c to m y s e q u e s tre c to m y se c tio n
5 P la s tic  s u rg e ry O p e ra tion  fo r  
p e r ito n itis
P la s tic  su rge ry  
and te ndon  
tra n s fe rs
6 G a llb lad d e r R e lie f o f 
in te s tin a l 
o b s tru c tio n
A p p e n d e c to m y
7 A p p e n d e c to m y A m p u ta tio n A m p u ta tio n
8 A m p u ta tio n A p p e n d e c to m y G ro in -h e rn ia
repa ir
9 O p e ra tion  fo r G ro in -h e rn ia F rac tu re
p e rito n itis repa ir f ix a tio n
10 G a s tro du o d e n a l P la s tic D e b r id e m e n t/
o p e ra tio n s su rg e ry se q u e s tre c to m y
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NOUVELLES DES PARRAINS
Special Announcement
The Editorial Board of the Canadian Journal of 
Surgery was delighted to learn of the news, an­
nounced at the 78th Annual Clinical Congress of the 
American College of Surgeons in New Orleans in 
October 1992, that Dr. Lloyd D. MacLean has been 
elected to the office of president elect of the Ameri­
can College of Surgeons. Dr. MacLean will take 
office as president of the College in October 1993, 
during the Clinical Congress in San Francisco. This 
honour is richly deserved by Dr. MacLean who has 
served the American College of Surgeons throughout 
his illustrious surgical career. He has been an 
international representative of the Canadian surgical 
community and is held in highest regard by many 
national organizations, as recognized by election to 
this prestigious office.
Lloyd D. MacLean, OC, MD, PhD, 
FACS, FRCSC
The success of the Clinical Congress of the 
American College of Surgeons is due primarily to its 
highly organized and broadly ranging scientific pro­
gram. The chairman of the Program Committee is 
Dr. MacLean, in whose honour the 1991 Surgical 
Forum was dedicated. The Editorial Board and 
readers of the Journal applaud Dr. MacLean.
Canadian Association of General Surgeons
1992-1993 Executive
President: Dr. Marvin J. Wexler 
Past president: Dr. Frank W. Turner 
President elect: Dr. Frederic G. Inglis 
Secretary: Dr. Roger G. Keith 
Treasurer: Dr. Marshall C. Hunting
1993 Annual Meeting
The 1993 annual meeting of the Canadian Associa­
tion of General Surgeons (CAGS) will be held in 
conjunction with the annual meeting of the Royal 
College of Physicians and Surgeons of Canada in 
Vancouver, in September. The preliminary program 
under the chair of Dr. John Macfarlane is very 
exciting. The first postgraduate course will be held 
on the Thursday and will feature laparoscopic sur­
gery. A second postgraduate course to be held on the 
following Monday will be on surgical oncology with a 
focus on colorectal cancer. The CAGS Lecture will be 
presented by Mr. R.J. Heald from Basingstoke, 
England. He will speak on rectal cancer. The Ghent 
Lecture will be presented by Dr. Ernest Moore of 
Denver. The Langer Lecture will be presented by 
Professor Alfred Cuschieri from Dundee, Scotland, 
who will speak on the place of laparoscopic surgery. 
The 3 days of paper sessions will feature the CAGS 
CME Day on Saturday and a combined paper/poster 
session with the Canadian Association of Gastroen­
terology on Sunday.
Other Forthcoming Meetings
The CAGS Research Conference will be held in 
June 1993 in Banff, Alta. General surgery program 
directors are reminded to encourage submission of 
resident research abstracts in response to forthcom­
ing announcements.
The 1993 spring meeting of the American College 
of Surgeons will be held in Montreal from Apr. 25 to 
28. This meeting has become a focus for general
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surgery and will feature four postgraduate courses, 
on cancer management, ambulatory surgery, vascular 
surgery and trauma. Dr. Jonathan Meakins will 
present a named lecture entitled “Determinants of 
sepsis in surgical patients.”
Royal College Maintenance of Competence 
(MOCOMP) Program
Over 700 CAGS members have enrolled in the 
Royal College’s MOCOMP Pilot Program aimed at 
developing a comprehensive strategy for motivating 
specialists to continuously update their clinical prac­
tice. This pilot project will end in 1 year, and the 
formal program will be initiated by the Royal College 
thereafter.
Core Training Program in Surgery
The Royal College Specialty Committee in General 
Surgery has approved the 2-year program for core 
training in surgery and has developed guidelines to 
integrate this within the full 5 years of general 
surgery resident training. Most Canadian general 
surgery programs are integrating the combined pro­
grams with changes that have developed with the 
replacement of rotating internship by a basic clinical 
training year. Reduction in provincial funding for 
postgraduate training is concurrent with these 
changes in most provinces.
CAGS Coat of Arms
The CAGS has approved the preparation of a 
formal coat of arms for the Association. Gratitude is 
directed to Dr. Bob Thorlakson for his leadership and 
contributions to this project. The coat of arms will 
subsequently be displayed in the new Royal College 
headquarters and will be incorporated in the Associa­
tion’s stationery and materials.
Merck Frosst Awards
At the 1992 annual meeting, the CAGS Merck 
Frosst Awards for Teaching Excellence were present­
ed to the successful resident from each Canadian 
university, general surgery program. The following 
residents were honoured: University of British Co­
lumbia — Dr. Gary W. Kingston; University of 
Calgary — Dr. Doug Johnson; University of Alberta 
— Dr. Douglas May; University of Saskatchewan — 
Dr. Richard Bigsby; University of Manitoba — Dr. 
Donald Clark; University of Western Ontario — Dr. 
Edward Davis; McMaster University — Dr. Adrian 
Park; University of Toronto — Dr. George Azzie; 
Queen’s University — Dr. John Drover; University of 
Ottawa — Dr. Sully Garba; McGill University — Dr. 
Andrew Hill; Universite de Montreal — Dr. Lucie 
Bilodeau; Universite de Sherbrooke — Dr. Jean- 
Jacques Klopenstein; Universite Laval — Dr. Regent 
St. George; Dalhousie University — Dr. Russell 
Gowan; Memorial University — Dr. Barry Fleming.
General surgery program directors are reminded to 
submit nominations for the 1993 CAGS Merck 
Frosst Awards by the end of May 1993.
Canadian Orthopaedic Association
1992-1993 Executive
President: Dr. Maurice Duhaime 
Past president: Dr. Marvin Tile 
President elect: Dr. R. Mervyn Letts 
Secretary: Dr. Robert F. Martin 
Treasurer: Dr. Robert M. Hollinshead
Forthcoming Meetings
The Canadian Orthopaedic Association wishes to 
announce the following forthcoming meetings for the 
spring of 1993. Information on these programs may 
be obtained by contacting the Canadian Orthopaedic 
Association Secretariat in Montreal (phone: [514] 
874-9003):
Apr. 14 to 16, 1993. The 6th Sainte-Justine Pediatr­
ic-Orthopedic Review Course, Montreal, Que.
Apr. 23 and 24, 1993. The 24th Annual Meeting of 
the Quebec Scoliosis Society, Montreal, Que.
June 10 to 18, 1993. The University of British 
Columbia Orthopedic Update Course, Vancouver, BC.
Canadian Society for Vascular Surgery
1992-1993 Executive
President: Dr. Adrien Bouchard
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Past president: Dr. William G. Jamieson 
President elect: Dr. Neil V. McPhail 
Secretary: Dr. Kenneth A. Harris 
Treasurer: Dr. Kenneth C. Grant
1993 Annual Meeting
The 15th annual meeting of the Canadian Society 
for Vascular Surgery (CSVS) will be held in Vancou­
ver, Sept. 10 to 12, 1993, in conjunction with the 
annual meeting of the Royal College of Physicians 
and Surgeons of Canada. To accommodate those 
wishing to catch the Sunday flight “back east,” the 
format of the meeting has been changed. Seminars 
will begin Friday afternoon, concluding on Sunday 
morning. This year the CSVS Lecture will be deliv­
ered by Dr. Jonathan Towne from Milwaukee. The 
topic of the Saturday afternoon symposium is “Con­
troversies in the Management of Cerebral Vascular 
Disease.” This symposium will provide an update on 
many of the recently completed or ongoing trials and 
will include presentations by such distinguished 
speakers as Dr. Thomas Riles from New York.
Abstract forms were distributed in the December 
1992 issue of Annals o f the Royal College of 
Physicians and Surgeons o f Canada. They are also 
available from the Secretary of the Society. Surgeons 
are encouraged to submit papers or case reports. 
Cases should illustrate principles of vascular surgery 
or describe unusual conditions or abnormalities and 
include a review of the literature.
Dr. David Taylor and the local arrangement com­
mittees are promising an excellent social program to 
complement the scientific menu. We hope to have a 
record turnout in Vancouver.
Course on Venous Thromboembolism
McMaster University will be conducting a course 
entitled “Clinical Advances in Venous Thomboembol- 
ism — A Practical Approach” from May 14 to 16, 
1993, at Niagara-on-the-Lake, Ont. Further informa­
tion may be obtained from the Continuing Education 
Office, McMaster University, Hamilton, Ont.; phone: 
(416)521-7966 or (416) 389-4224.
Small Aneurysm Treatment Trial (SATT)
This study, randomizing patients with abdominal 
aortic aneurysms measuring 4.5 to 5.4 cm in greatest
diameter, continues to recruit patients from around 
the world. The study is funded by the Medical 
Research Council of Canada, with Dr. William Cole 
of Ottawa as the principal investigator. Many centres 
in Canada, the United States and Great Britain are 
participating in this study, and it is hoped that 
enrolment will reach over 400 patients in the next 2 
years. The study design compares operative treat­
ment and follow-up with ultrasonography of patients 
with appropriate sized aneurysms. Follow-up is over 
a 4-year period. The information gained should be 
useful to all vascular surgeons making decisions 
about treating infrarenal abdominal aortic aneu­
rysms.
Membership
The CSVS accepts membership applications on 
three different levels. Active members are surgeons 
with an interest in vascular surgery who hold a 
Certificate of Special Competence in Vascular Sur­
gery or its equivalent. Associate members are those 
with an interest in vascular surgery or vascular 
diseases. Associate (candidate) members are those 
enrolled in a vascular training program in Canada or 
the United States.
Application forms may be obtained from the Office 
of the Secretary of CSVS.
Luke Award
The Luke Award is given to the best paper 
presented at the CSVS annual meeting. The selection 
committee consists of the CSVS lecturer, the society 
president and the chairman of the program commit­
tee. The 1992 selection committee comprised Drs. T. 
O'Donnell, W. Jamieson and A. Salvian. The 1992 
prize was awarded to Dr. Joseph Sladen of Vancouver 
for his paper entitled “Superficial femoral vein: a 
useful alternative arterial conduit.”
Useful Addresses
The President of the CSVS is Dr. Adrien Bouchard 
who can be reached at the Ottawa General Hospital, 
501 Smyth Rd., Ottawa, ON K1H 8L6; phone: (613) 
737-8539. The Secretary, Dr. Kenneth A. Harris, 
can be reached at Victoria Hospital, 375 South St., 
London, ON N6A 4G5; phone: (519) 667-6780.
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SPONSORS’ NEWS
Canadian Society of Cardiovascular and 
Thoracic Surgeons
1992-1993 Executive
President: Dr. F. Neil McKenzie 
Vice president: Dr. Elliot T. Gelfand 
Secretary: Dr. W.R. Eric Jamieson 
Treasurer: Dr. Edward F. Busse
Meetings
The Canadian Society of Cardiovascular and Tho­
racic Surgeons (CSCTS) meets annually with the 
Royal College of Physicians and Surgeons of Canada. 
Highlights of the 1992 meeting were a symposium 
entitled “Further Directions in the Management of 
Myocardial Infarction — Modern Interventional Ther­
apies’’ and the Wilfred Bigelow Lecture, presented by 
Dr. Hermes Grillo of Harvard Medical School and 
entitled “Modern concepts in tracheal surgery.”
In 1993, the CSCTS will conduct joint symposia 
— one symposium on transplantation with the 
Canadian Thoracic Society and another symposium 
on thoracoscopic surgery with the Canadian Society 
of Endoscopic and Laparoscopic Surgery.
In July 1994, the Society will cosponsor, with the 
International Scientific Committee for the Advance­
ment of Cardiac Bioprostheses, the Vlth Internation­
al Symposium on Cardiac Bioprostheses in Vancou­
ver. The deadline for submission of abstracts for this 
meeting is Dec. 1, 1993. The Canadian organizing 
committee comprises Drs. Eric Jamieson (chairman), 
Tirone David, Conrad Pelletier and Lawrence Burr.
Royal College Task Force
The Royal College of Physicians and Surgeons of 
Canada is formulating a task force on training 
requirements in cardiothoracic and thoracic surgery. 
This task force will incorporate the nucleus members 
of the specialty committees in thoracic and cardio­
thoracic surgery. The CSCTS and membership will 
have an opportunity to participate in the process.
Canadian Society of Surgical Oncology
1992-1993 Executive
President: Dr. Walley J. Temple 
Past president: Dr. Henry R. Shibata 
Secretary/treasurer: Dr. David R. McCready
2nd Annual Scientific Meeting
The Canadian Society of Surgical Oncology 
(CSSO) will hold its 2nd annual scientific meeting on 
Saturday, Apr. 17, 1993 at the Queen Elizabeth 
Hotel, Montreal. The meeting will take place in 
conjunction with the National Cancer Institute of 
Canada (NCIC) spring meeting from Apr. 17 to 20, 
1993.
We encourage all interested members of the CAGS 
to attend.
Further details about the meeting may be obtained 
from: Dr. Walley J. Temple, President, CSSO, Tom 
Baker Cancer Centre, 1331 -  29th St. NW, Calgary 
AB T2N 4N2; phone: (403) 670-1914; fax: (403) 
283-1651.
Membership
The CSSO, a young and developing Canadian 
society, has joined the group of societies/associa- 
tions sponsoring the Canadian Journal o f Surgery. A 
mission of the Society is to stimulate the develop­
ment of surgical participation in regional and nation­
al clinical trials. There is a continuing need for 
increasing involvement of surgical oncologists with 
the programs of the NCIC. The Executive of the 
CSSO welcomes membership applications from en­
thusiastic surgeons with a dedicated interest in the 
fields of surgical oncology. We also invite all mem­
bers of the CAGS with a training in cancer and those 
with a practice of at least 50% oncology from all 
surgical disciplines to become members. For further 
information contact Dr. Walley Temple in Calgary 
(phone: (403) 670-1914).
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Instructions for Authors
The Canadian Journal o f Surgery will consider manuscripts of original articles, clinical research, surgical technique, 
clinical reviews, history of surgery, a limited number of case reports, editorials and letters. Four copies of manuscripts, in 
English or French, should be submitted to Dr. Roger G. Keith, Canadian Journal o f Surgery, Department of Surgery, Royal 
University Hospital, 103 Hospital Dr., Saskatoon, SK S7N 4J9.
A covering letter, signed by all the authors, should state that the manuscript has not been published previously and is not 
under consideration by any other journal. The authors should include a signed letter of permission from people identified in 
the acknowledgements or identifiable in illustrative material as well as from the copyright holder of previously published 
material (e.g., tables, illustrations and long quotations) that is being reproduced, with or without modification, in the 
submitted article. The authors must disclose the source of any financial or material support, any commercial interest they 
may have in the subject of the study and any affiliation or involvement with an organization that has a financial interest in 
the research materials used or the topic.
Manuscript Preparation
The style of the submission should be compatible with “Uniform requirements for manuscripts submitted to biomedical 
journals” (Can Med Assoc J  1992; 146: 861-868).
The authors’ names should appear on the title page and the back of each set of illustrations. All acknowledgements should 
be placed on a separate unnumbered page after the list of references.
To facilitate editing and electronic scanning, all pages (title page, abstract and key words [MeSH terms if possible], text, 
references and figure legends) must be double-spaced, in 10-cpi, letter-quality type, without right justification or proportional 
spacing.
For all manuscripts, authors should submit an original and three high-quality photocopies or additional printouts of the 
text and tables, and four camera-ready copies of the figures.
In writing a case report it is not necessary to give a detailed patient history and results of physical examination in the 
standard clinical format. Negative findings and normal results of laboratory tests need be included only if they are essential 
for ruling out a possible diagnosis. It is enough to establish the reasons for the diagnosis and the management. The clinical 
course should be described briefly and the significant observation or event described in sufficient detail to establish its 
credibility. Reference to the literature should be confined to supporting the principal point being made about the event or 
observation.
Abstracts are required for original, review and history articles and for case reports, but not for articles on surgical 
technique and editorials. A structured abstract should be provided for original and review articles (see October 1992 issue, 
pages 473 to 475). Abstracts for history articles and case reports should be brief, but detailed (from 60 to 150 words long).
References should be cited in numerical order of their appearance in the text. References cited in tables should be 
numbered according to where the table is first cited in the text. The style for references should be that used in this issue of 
the Journal.
Other Considerations
Colour figures can be reproduced only at the author’s expense. Authors should submit a positive transparency and three 
colour prints of each figure.
If the manuscript has been prepared on a computer-based word-processing system, authors must specify the software 
program used. We edit manuscripts with an IBM-compatible word-processing system and cannot edit from diskettes that are 
not IBM-compatible. Authors should indicate if they are willing to send us a diskette when their manuscript has been 
accepted.
The process of initial consideration, peer review and editorial decision making of the manuscript usually takes about 8 
weeks. The original copy of a rejected manuscript will be returned to the authors; all other copies will be destroyed.
Accepted manuscripts will be edited not only to conform with Canadian Journal o f Surgery style and for correctness of 
grammar, syntax and punctuation but also for clarity. The corresponding author will receive a copy of the edited manuscript 
or a galley proof before publication and is responsible for obtaining coauthors’ approval of the changes.
Authors will be expected to sign a document transferring copyright to the Canadian Journal o f Surgery. All accepted 
manuscripts become the permanent property of the Canadian Medical Association and may not be published elsewhere, in 
whole or in part, without written permission of the publisher. Reprints will be available for purchase and may be distributed 
as the author desires. ■
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Directives aux auteurs
Le Journal canadien de chirurgie etudiera les manuscrits d’articles originaux, de recherche clinique, de technique 
chirurgicale ou d’histoire de la chirurgie, un nombre restreint d’etudes de cas, des editoriaux et des lettres. Quatre 
exemplaires des manuscrits, en frangais ou en anglais, doivent etre adresses au Dr Roger G. Keith, Journal canadien de 
chirurgie, Departement de chirurgie, Hopital Royal University, 103 Hospital Dr, Saskatoon, SK S7N 4J9.
La lettre de presentation, signee par tous les auteurs, doit confirmer que le manuscrit n’a jamais ete publie et n ’a ete 
soumis a aucun autre journal. Les auteurs divent y joindre une autorisation signee par les personnes citees sous la rubrique 
des remerciements ou identifiable dans le materiel d’illustration ainsi que de tout detenteur de droits d'auteur de materiel deja 
publie (p.ex., tableaux, illustrations et longues citations) et qui est reproduit, avec ou sans modification, dans l’article soumis. 
Les auteurs doivent indiquer la source de toute aide financiere ou materielle, tout interet commercial qui les aurait motive en 
ce qui concerne le sujet a l’etude ainsi que toute affiliation ou travail avec un organisme qui a un interet financier dans le 
materiel de recherche utilise ou dans le sujet lui-meme.
Preparation du manuscrit
Le style doit se conformer aux «Exigences uniformes pour les manuscrits presentes aux revues biomedicales» (Can Med 
Assoc J  1992; 146 : 871-878).
Les noms des auteurs doivent paraitre sur la page titre, de meme qu’a l’endos de chaque jeu d’illustrations. Les 
remerciements doivent figurer sur un feuillet separe, non pagine, a la suite de la bibliographie.
Toutes les pages (page titre, resume et mots clefs [termes MeSH si possible], textes, references, tableaux et legendes de 
figures) doivent etre dactylographies a double interligne, a 10 caracteres au pouce, sans justification a droite ni espacement 
proportionnel, et imprime en «qualite lettre» afin de faciliter la revision et la lecture electronique.
Pour tout manuscrit, les auteurs doivent soumettre un original et trois photocopies de bonne qualite, ou trois impressions 
supp lem ental de texte et des tableaux, et quatre copies des figures pretes a la reproduction photographique.
Pour les etudes de cas, il n’est par necessaire de rapporter une anamnese detaillee avec les resultats de l’examen physique 
dans le format clinique normal. Les resultats negatifs ou normaux d’examens de laboratoire ne doivent etre mentionnes que 
s’ils sont essentiels a l’exclusion d’un diagnostic possible. II suffit d’etablir les raisons qui ont contribue au diagnostic ou au 
traitement. L’evolution clinique doit etre decrite succinctement et les observations ou evenements importants doivent etre 
rapportes avec suffisamment de details pour en etablir la credibilite. La bibliographie doit se limiter au soutien du point que 
Ton veut faire ressortir quant a l’evenement ou a l’observation.
Des resumes sont exiges pour les articles originaux, historique ou de revue ainsi que pour les etudes de cas; ils ne sont pas 
requis pour les articles sur les techniques chirurgicales ou pour les editoriaux. Un resume structure doit etre fourni pour les 
articles originaux et de revue (void le numero d’octobre 1992, pages 473 a 475). Les resumes pour les articles historiques et 
les etudes de cas doivent etre brefs mais, detailles (de 60 a 150 mots).
La bibliographie doit etre etablie numeriquement, selon l’ordre d'apparition dans le texte. Les references citees dans les 
tableaux doivent etre numerotees d’apres 1’ordre de la premiere mention du tableau dans le texte. Le style adopte pour la 
bibliographie est celui qui est utilise dans ce numero du Journal.
Autres considerations
Les figures en couleur sont a la charge de l’auteur. II lui faudra fournir une diapositive et trois epreuves en couleur pour 
chaque figure. Les auteurs sont pries de nous preciser, le cas echeant, le logiciel ayant servi a preparer le manuscrit. Nous 
revisons les manuscrits avec un systeme de traitement de texte compatible avec le systeme IBM. Nous ne pouvons pas reviser 
a partir de disquettes qui ne sont pas compatibles avec le systeme IBM. Les auteurs doivent nous indiquer s’ils sont disposes 
a nous faire parvenir une disquette quand leur texte est acceptee.
Le processus relatif a l’etude preliminaire de l’article, a la revue critique et a la prise de decision de la redaction peut durer 
a peu pres 8 semaines. La copie original de tout manuscrit refuse est retournee a ses auteurs et toutes les autres copies sont 
detruites.
Tout manuscrit accepte est revise non seulement pour le rendre conforme au style du Journal canadien de chirurgie et 
pour corriger les fautes de grammaire, de syntaxe et de ponctuation, mais aussi pour en assurer la clarte et la concision. 
L’auteur de l’article recevra une copie revisee ou les epreuves en placard avant la publication et doit obtenir l’approbation des 
coauteurs pour les changements apportes.
Avant la publication, tous les auteurs doivent signer un document par lequel les droits d’auteurs sont transferes au Journal 
canadien de chirurgie. Tout manuscrit accepte devient propriety permanente de l’Association des medecins du Canada et ne 
peut etre publie ailleurs, en entier ou en partie, sans la permission ecrite. Les tires a part sont disponibles sur demande et 
peuvent etre distribues selon les desirs de 1’auteur.B
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CLASSIFIED ADVERTISING 
ANNONCES CLASSEES
I he Canadian Journal o f  Surgery is pleased to accept classified advertisements. The deadline is 1 month before issue date. Classified rates: $58 
for the first 40 words or less, additional words 75? each (additional $23 for frame). Special Display under 100 words, 55 X 55 mm, $135. $17 
charge (first insertion only) for CJS reply box numbers. Display rates available on request. VISA, MASTERCARD AND AMERICAN 
EXPRESS ACCEPTED.
Copy should be mailed to: Beverley Kirkpatrick, Manager, Classified Advertising, Canadian Journal o f Surgery, PO Box 8650, Ottawa, ON 
K1G 0G8. Tel: (613) 731-9331. Fax: (613) 523-0824.
Send all box number replies to: Box . . . .  Canadian Journal o f Surgery, PO Box 8650, Ottawa, ON K1G 0G8.
Le Journal canadien de chirurgie  accepte volontiers les annonces classees. Celles-ci doivent etre recues au Journal au plus tard 1 mois avant la 
date de parution. Tarifs des annonces classees 58 $ jusqu’a 40 mots et 75 c par mot supplem ental (23 $ pour encadrement au trait). Encadre 
special jusqu’a 100 mots, 55 X 55 mm, 135 $. L’emploi d’une bolte-reponse au Journal donne lieu a la perception d’un supplement de 17 $ 
(pour la premiere insertion seulement). Tarifs des encadres grand format disponibles sur demande. VISA, MASTERCARD ET AMERICAN 
EXPRESS ACCEPTES.
La texte des annonces doit etre adresse a : Beverley Kirkpatrick, Gestionnaire des annonces classees, Journal canadien de chirurgie, CP 8650, 
Ottawa, ON K1G 0G8. T e l: (613) 731-9331. Fax : (613) 523-0824.
Veuillez faire parvenir les reponses aux numeros de boites a l’adresse suivante : Boite . . . , Journal canadien de chirurgie, CP 8650, Ottawa, 
ON K1G 0G8.
GFT -  GENERAL SURGEON: MB -  The
Department of Surgery, Faculty of Medicine, 
University of Manitoba and the Health Sci­
ences Centre are seeking a contingent geo­
graphical full-time general surgeon. Specific 
responsibilities in gastrointestinal surgery. 
Candidates must be eligible for registration 
with the College of Physicians and Surgeons 
of Manitoba. Certification in general surgery 
by the Royal College of Physicians and 
Surgeons of Canada is required. Additional 
specific requirements include the following: 
extensive clinical experience in gastrointes­
tinal surgery including major hepatic and 
pancreatic resections and laparoscopic sur­
gery; skills and extensive experience in en­
doscopic retrograde cholangiopancreatog­
raphy and other G.l. endoscopy; and train­
ing and experience in research with publica­
tion success. Salary and academic rank will 
be at the entry level in the department of 
surgery. The University of Manitoba encour­
ages applications from qualified women and 
men, including members of visible minori­
ties, aboriginal people, and persons with 
disabilities. The university provides a 
smoke-free environment, save for specially 
designated areas. In accordance with Cana­
dian immigration requirements, this adver­
tisement is directed to Canadian citizens 
and permanent residents. Closing date for 
receipt of applications is Feb. 28, 1993. 
Interested candidates should apply, enclos­
ing a curriculum vitae in writing, to: Dr. 
R.J.W. Blanchard, Professor and Head. 
Department of Surgery, Health Sciences 
Centre, GC 411 -820  Sherbrook St., W in­
nipeg, MB R3A 1 R9. -S93-137
SURGICAL ONCOLOGY FELLOWSHIP:
ON -  The Division of General Surgery at the 
University of Toronto is offering a 1-year 
clinical fellowship available July 1, 1993. 
The fellowship is intended for individuals 
who have completed an accredited North 
American university general surgical resi­
dency and are eligible for certification. Pref­
erence will be given to applicants eligible for 
Canadian licensure. Applicants should sub­
mit a current curriculum vitae with the 
names of three referees to: Lome E. Rot- 
stein, MD. Director, General Surgical On­
cology Postgraduate Education, Toronto 
General Hospital, Eaton Wing, 7th Floor, 
200 Elizabeth St., Toronto, ON Canada 
M5G2C4. -S92-131
SURGEONS-VASCULAR 
AND ORTHOPEDIC
MSI currently has 311 outstanding 
practice opportunities in solo, group, 
clinic and HMO settings throughout 
the U.S. These include coastal and 
southeastern areas. We want to pres­
ent these practices to you and be a 
problem solver. There is no charge to 
you for this service.
Call our
surgical specialists 
(404) 653-7360.
-S93-143
GENERAL SURGEON: ON -  Well-estab­
lished group practice is looking to replace a 
retiring partner/surgeon to serve a communi­
ty of 30 000 + located 25 minutes west of 
London. Town population 10 000+ . Fully 
computerized, modern clinic adjacent to a 
fully accredited, well-equipped hospital using 
116 acute care beds. Busy emergency de­
partment. Preference will be given to or- 
thopedics/gynecology. Essentials include la­
paroscopy skills and fellowship status. One- 
in-three on-call schedule for this pleasant 
community. Large referral base guaranteed. 
Associate to full partnership attainable. 
Please contact or send CV to: Steven Wong, 
c/o Strathroy Medical Clinic, 376 Carrie 
St., Strathroy, ON N7G 3E3; tel: (519) 
245-0430. -S92-128
FELLOWSHIP IN 
ENDOUROLOGY AND ESWL
This 1-year postgraduate fellowship offers a 
wide range of clinical experience in en- 
dourology including percutaneous surgery, 
ureteroscopy, ESWL and laparoscopic sur­
gery in urology. Aproximately 50% of the 
fellow's time will be spent in the laboratory 
participating in projects related to en- 
dourologic and shock wave lithotripsy re­
search. Salary will commensurate with the 
level of training.
Please reply with curriculum vitae to:
Dr. John Denstedt 
Chief of Urology 
St. Joseph's Health Centre 
268 Grosvenor St.
London, ON
N6A 4V2 -S92-130
CLASSIFIED ADVERTISING Unlike a tabloid or newspaper that is read today and discarded tomorrow, an adver­
tisement in the Classified Advertising section of CJS is read today and reread tomorrow.
CJS is the only Canadian publication exclusively for surgeons. No other Canadian surgical publication reaches over 6000 
subscribers every 2 months, giving wide coverage for your advertising dollar.
Average issue readership of CJS (81%) is among the highest of any medical journal in Canada, the latest reader- 
ship studies confirm the best and most cost efficient way to reach Canadian surgeons is through the pages of CJS.
LET CJS CLASSIFIED ADS WORK FOR YOU - cjs-i
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GENERAL PRACTITIONER/SURGEON: BC
— Souris Health District. Three physicians 
require a general practitioner/surgeon. Asso­
ciate would enter into active surgical/endo- 
scopic practice. The community o f 1700 
residents has a modern, 30-acute-bed facility, 
serving the district o f approximately 7000 
people. Located 30 minutes from  Brandon 
(population 40 000), a university centre. Con­
tact: Mr. J. Woodmass, Administrator, or 
Dr. D. Cram, Chief of Staff, PO Box 10, 
Souris, MB ROK 2C0; tel (204) 4 8 3 -2 1 2 1 .
-S93-145
B/C ORTHOPEDIC SURGEONS AND  
OTHER SPECIALTIES: NEW YORK, US -
Needed fo r a non-treatment disability evalua­
tion centre in Buffalo, New York. For further 
information please reply with CV to : Sam H. 
Stedman, 620  Erie Blvd. W , Ste. 208, 
Syracuse, NY, USA 13204: or tel (315) 
4 7 5 -3 9 2 6 . -S93-138
RESEARCH FELLOWSHIP SPINE SUR­
GERY -  Orthopaedic Hospital Spine Center in 
Los Angeles, California is offering a 1-year 
spine research fellowship starting July 1, 
1993. Fellowship training will include labora­
tory and clinical research with exposure to  
clinical orthopedic surgery and academic con­
ferences. Submit CV with references to: 
Santi Rao, M D , Director, Orthopaedic Hos­
pital Spine Center, 23 0 0  S Flower St., 
Ste. 2 0 0 , Los Angeles, CA 90007; tel 
(213) 741 -0800 , fax (213) 7 4 7 -17 16 .
-S93-144
GENERAL SURGEON
Second general surgeon required for the town 
of Milton in southern Ontario. This 103-bed 
hospital serves a population of 35 000 with a 
large catchment area; 16 general practitioners, 
an internist, radiologist, obstetrician and one 
other general surgeon comprise the active 
medical staff. Several other surgical subspecial­
ties available. State-of-the-art laparoscopic 
equipment available. Milton is located within 
easy access to two university medical centres 
and provides great recreational opportunities.
Applications to:
Dr. L. Robinson
Chair, Manpower Committee
Milton District Hospital
30 Derry Rd. E
Milton, ON L9T 2X5
Tel (416) 878-2383
Fax (416) 878-0498. —S93-146
CLINICAL FELLOWSHIP 
AVAILABLE
IN CARDIOVASCULAR SURGERY  
BEGINNING JULY 1, 1 9 9 3
There is an opportunity fo r considerable 
surgical experience w ith  a busy adult cardi­
ac surgical team (650 pumps/year). Ideal 
fo r surgeon awaiting a position or between 
residencies. Eligibility fo r Ontario general or 
educational licence necessary. Salary ac­
cording to  experience or fee fo r service if 
applicable.
Replies to:
Dr. Bernard S. Goldman
Head, Cardiovascular Surgery
Sunnybrook Health Science Centre
2 0 7 5  Bayview Ave., S te. H 410
Toronto, ON
M 4N  3 M 5
Tel (416) 4 8 0 -6 0 7 0
Fax (41 6) 4 8 0 -6 0 7 2  -S93-136
CLINICAL FELLOWSHIP 
IN KNEE AND 
SHOULDER SURGERY 
IN
SPORT MEDICINE
Applications are now being accepted fo r a 6-month sport medicine fellowship 
starting July 1, 1993 emphasizing arthroscopic and open treatment o f  knee and 
shoulder injury and disease.
Applicants must be eligible for licensure in the province o f  Alberta and 
preferably will have completed their FRCSC in orthopedic surgery.
Address enquiries to:
Caroline Eagles, Program Secretary 
Department o f  Surgery, Room D6-012 
Calgary General Hospital, BVC 
841 Centre Avenue East 
Calgary, Alberta
T2E 0A1 —S93-140
University of Ottawa • Faculty of Medicine
Chair of Surgery
The University of Ottawa invites applications for the position of chairperson 
of the university department of surgery.
Applicants must be eligible to practise in Ontario and hold certification of the 
Royal College of Physicians and Surgeons of Canada in surgery. The faculty 
is seeking an individual with a track record of clinical and academic 
excellence, leadership skills and potential to develop a strong research 
program in surgery.
The department is responsible for directing both undergraduate teaching and 
postgraduate programs in surgery in the Ottawa Civic Hospital and Ottawa 
General Hospital and Children’s Hospital of Eastern Ontario. The successful 
candidate will hold a joint appointment as chair of the university department 
of surgery and head at one of the affiliated teaching hospitals.
The faculty is seeking an individual who will hold a full-time university 
appointment. Salary and fringe benefits are commensurate with qualifica­
tions and experience, and are in accordance with existing scales at the 
University of Ottawa.
Priority will be given to Canadian citizens and permanent residents of Canada 
in accordance with Canadian immigration requirements. Employment equity 
is university policy.
A working knowledge of both English and French is desirable and a 
commitment to support bilingualism within the faculty is essential.
Applicants are requested to forward their curriculum vitae and the names of 
three referees prior to Apr. 15, 1993.
John F. Seely, MD 
Dean, Faculty of Medicine 
University of Ottawa 
451 Smyth Rd. 
Ottawa, ON 
K1H 8M5
Universite d ’Ottawa •  Faculte de medecine
Chaire de chirurgie
L’Universitd d’Ottawa accueille les candidatures k la direction de sa chaire 
de chirurgie.
Les candidats et candidates doivent etre admissibles k exercer la profession 
en Ontario et possbder I'agrdment k titre de specialiste du College royal des 
medecins et chirurgiens du Canada, tout en faisant preuve de realisations 
et d’experience en chirurgie Clinique et universitaire. Le poste comporte un 
role de direction dans les milieux universitaire, hospitalier et communautaire 
et la preference sera accordde a une personne competente qui s’est 
engagde dans la voie de I'excellence universitaire en enseignement et en 
recherche.
Le departement a la responsabilite de fournir un enseignement de qualite 
au niveau prddiplome et postdoctoral dans les hopitaux affilies offrant une 
formation en chirurgie soit I'Hopital Civic d’Ottawa, I’Hopital General 
d’Ottawa et I'Hopital pour enfants de I’Est de I’Ontario. La personne retenue 
assumera une double affectation k la direction de la chaire de chirurgie de 
I’universitb et a la direction de chirurgie dans un des hopitaux d’enseignement 
mentionnes.
La faculte est a la recherche d ’une personne pour combler un poste a temps 
complet. Le traitement et les avantages sont fonction de la formation et de 
I'expbrience, conformement k I'dchelle en vigueur k  I’Universite d'Ottawa.
En vertu des exigences canadiennes relatives a I’immigration, la priority est 
accoutee aux personnes de citoyennete canadienne et de residence per- 
manente au Canada. L'universitd a une politique d ’bgalite en matiere d'emploi.
Une connaissance de I’anglais et du francais est desirable. Un engagement 
a promouvoir le bilinguisme au sein de la faculte est essentiel.
Priere d'envoyer les demandes, accompagnees d’un curriculum vitae et du 
nom de trois repondants, a I'adresse ci-dessous avant le 15 avr. 1993.
John F. Seely, MD 
Doyen, Faculte de medecine 
Universite d’Ottawa 
451, chemin Smyth 
Ottawa, ON
K1H 8M5 S93-139
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THE MONTREAL GENERAL HOSPITAL 
DIVISION OF PLASTIC SURGERY
A Search Committee has been 
formed to
appoint a Plastic Surgeon-in-Chief at 
The Montreal General Hospital
Candidates should possess a Quebec 
medical licence,
certification by the Royal College of 
Physicians and Surgeons of Canada 
and demonstrated leadership 
abilities as a
university plastic surgeon.
Interested candidates should contact:
Dr. David S. Mulder 
Surgeon-in-Chief 
The Montreal General Hospital 
1650 Cedar Avenue, Room D6-136 
Montreal, PQ 
H3G 1A4
—S93-141
York-Finch General is a 
303 bed community hospital 
located at Highway 400 and 
Finch Ave. West.
Orthopaedic
Surgeon
We are a fully accredited acute care facility 
committed to a rapidly expanding community. 
We are seeking an Orthopaedic Surgeon to 
complement our Orthopaedic services.
Inquiries should be directed to Dr. M. Heller, 
Chief of Surgery at (416) 748-7443.
York-Finch General Hospital 
2111 Finch Ave. West 
Downs view, Ontario 
M3N INI
—S93-142
York-Finch General is a smoke free environment.
York-Finch General Hospital
For prescribing information see page 44 —104
NOT RECOMMENDED DURING PREGNANCY
BEFORE PRESCRIBING, PLEASE SEE PRESCRIBING INFORMATION
Trademark Merck & Co., Inc./Merck Frosst Canada Inc.. R.U. IP A A B I 
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M  MERCK FROSST
FROSST
DIV. OF MERCK FROSST CANADA INC 
KIRKLAND, QUEBEC
Gradual blood pressure reduction
• Prompt onset of action (usually within 15 minutes)
• Duration of action in most patients approximately 6 hours
Can be used to treat hypertension in many patients 
with coexisting disorders including diabetes, asthma, 
heart failure and angina
Favourable hemodynamic profile
Favourable tolerability profile
... as with VASOTEC (enalapril maleate, 
Frosst Std.) tablets
Easy to convert from I.V to oral and oral to I.V
Convenient to administer
VASOTEC
■ M f l
(enalaprilat)
For Many Patients With Elevated 
Blood Pressure When Oral 
Therapy Is Not Practical
The Only 
Injectable 
ACE 
Inhibitor
The benefits continue 
long after Valtrac 
has disappeared.
Introducing the Valtrac* 
biofragmentable anastomosis ring, 
a major breakthrough in bowel 
anastomosis technology that’s both 
surgeon friendly and patient friendly.
Already surgeons have proved Valtrac’s 
procedural superiority over sutures and 
staples in thousands o f patients. Valtrac 
provides uniform application 
regardless o f location and 
disparate bowel end sizes. It 
also performs consistently in 
end-to-end, end-to-side and 
VALlTtAC side-to-side procedures.
And, finally, Valtrac closes under direct 
visualization. So you know it’s closed.
Valtrac is patient friendly because it 
biofragments and passes harmlessly and 
painlessly out o f the body, leaving no foreign 
matter to hinder postoperative imaging. It 
provides the added benefit during healing 
o f supplying intraluminal support, which 
reduces the incidence o f stricture, stenosis 
or obstruction1.
To attend a Valtrac clinic and get the full 
Valtrac story, please call: (416)470-3600 
and ask for the Valtrac line.
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